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Krüppel-like factor 5 (KLF5) encodes a zinc finger transcription factor involved in growth, 
differentiation and apoptosis of a number of different tissues, and it has previously been 
implicated as either a tumour suppressor or oncogene in various solid tumours. Expression of 
Klf5 is up-regulated during granulocyte-macrophage differentiation of the murine myeloid 
cell line FDB1 in response to expression of a constitutively active mutant form of the human 
GM-CSF/IL-3/IL-5 receptor common E subunit (FI' mutant)
1. The aim of this work was thus 
to characterise the role of KLF5 in the myeloid lineage and to determine whether deregulation 
of this gene may contribute to Acute Myeloid Leukaemia (AML). We show that KLF5
mRNA expression is increased during granulocyte-macrophage differentiation of both cell 
lines and primary haemopoietic cells. KLF5 expression levels increase to the greatest extent 
during granulocyte differentiation, and accordingly we demonstrate that knock-down of Klf5
in the 32D cell line model attenuates granulocyte differentiation. Enforced expression of 
KLF5 in the FDB1 cell line model and in primary murine bone marrow progenitors functions
to induce terminal myeloid differentiation, coupled with cell cycle arrest and cell death. 
Consistent with a potential role as a promoter of differentiation and tumour suppressor, we 
show that mean KLF5 mRNA expression is significantly reduced in AML samples compared 
to normal controls (mononuclear cells and bone marrow CD34
+ samples). KLF5 expression is 
selectively decreased in French-American-British (FAB) subtypes M1, M3 and M4, and in 
samples positive for the FLT3-ITD mutation, relative to primitive bone marrow CD34
+
controls. We identify methylation of the KLF5 5’ proximal promoter and intron 1 as potential 
mechanisms for down-regulation in AML, and accordingly demonstrate that treatment of 
leukaemia cell lines with demethylating agents re-activates KLF5 expression in cells 
displaying hypermethylation of KLF5. Aberrant methylation of the KLF5 proximal promoter 
Abstract – Page 13 Abstract – Page 14 
is associated with samples displaying monosomy 7 or deletions in chromosome 7q, and 
methylation of KLF5 intron 1 is significantly higher in samples with normal karyotype than in 
those displaying abnormal cytogenetics. We demonstrate expression and splicing of an 
alternative exon within KLF5 intron 1, which is encompassed by the region shown to be 
hypermethylated in a subset of AML samples. It is likely that this exon represents an 
alternative transcription start site which is regulated by an alternative promoter associated 
with a high level of interspecies conservation. Translation of this alternative KLF5 isoform is 
predicted to code for an N-terminal-truncated KLF5 protein, and further research is now 
required to determine the regulation and functional significance of this isoform in normal 
haemopoiesis and in AML. Finally, we demonstrate that enforced expression of KLF5 in the 
leukaemia cell line U937 induces changes associated with myeloid differentiation, and 
enhances differentiation in response to differentiation-inducing reagents. Collectively, these 
data are consistent with KLF5 acting as a tumour suppressor in the myeloid lineage. Declaration – Page 15 
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1.1 Acute Myeloid Leukaemia 
Leukaemia is a malignancy of the blood system characterised by the continued proliferation 
and suppressed differentiation of haemopoietic progenitor cells. Pathologically, leukaemias 
result in a high proportion of progenitor cells in the blood system, causing a variety of clinical 
symptoms such as fatigue, weakness and recurrent infections. Approximately 2500 
Australians are diagnosed with leukaemia each year, and myeloid leukaemia in particular 
accounts for more than half of these cases (Australian Institute of Health and Welfare and 
Australian Associated Cancer Registry, 2005). Although therapy for myeloid leukaemia is 
available the success rates are usually low and the treatment involved is associated with 
significant morbidity and mortality
2. Current treatment regimes for Acute Myeloid Leukaemia 
(AML) have an average of 40-50% 5 year survival, although this can be as low as 10-20% in 
some subtypes
2,3. A significant proportion of patients experience relapse of disease following 
induction chemotherapy (33-78% depending on subtype
4-6), and approximately 1000 deaths 
result from AML per year in Australia alone (Australian Bureau of Statistics, 2008). 
Conventional chemotherapy is not specific for targeting haemopoietic cells, and can result in 
life-threatening toxic side-effects by destroying healthy tissue. Consequently there is a need 
for improved treatments, and in order to develop these a clear understanding of the molecular 
mechanisms involved in normal haemopoiesis and leukaemia is essential. 
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During haemopoiesis, multipotent haemopoietic stem cells (HSCs) maintain the adult blood 
system through reciprocal processes of self-renewal and progressive cell maturation. These 
stem cells respond to a variety of intrinsic and extrinsic factors which control the formation of 
lymphoid, myeloid, erythroid and megakaryocytic cell types. In particular, a complex 
interplay of growth factors and transcriptional regulators is required for directing 
haemopoietic cell fate (Figure 1.1)
7-14.  The early stages of haemopoiesis require transcription 
factors such as TAL1 and RUNX1 (also known as AML1), which are necessary for the 
derivation of adult HSCs
15. HSCs are transcriptionally primed for multi-lineage 
differentiation, expressing low levels of lineage-specific genes and transcription factors which 
fluctuate in response to external cues
7,16. Developmental morphogens such as the WNT 
proteins or members of the BMP family can influence the decision for HSC to either maintain 
self-renewal or to differentiate to more committed progenitor types
17,18. In response to such 
extrinsic signals the balance of transcription factor expression is shifted and lineage 
commitment initiated. Progression through subsequent developmental stages in which 
committed progenitor cells differentiate to mature cell types is coordinated by a range of 
haemopoietic cytokines, for example EPO, GM-CSF, and IL-7
19,20, and through cooperation 
of a number of lineage-specific transcription factors, for example KLF1 (erythroid), C/EBPİ
(granulocytic), and PAX5 (B-cell lineage)
21-23 (see Figure 1.1). Differentiation is coupled with 
reduced lineage potential and proliferative capacity, with mature haemopoietic cells retaining 
only a very limited ability for proliferation and self-renewal. These highly-coordinated 
mechanisms sustain the adult blood and immune system, however genetic disturbances which 
interfere with these processes can contribute to the development of haemopoietic disorders 
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Figure 1.1: Haemopoiesis. Multipotent haemopoietic stem cells (HSC) maintain a balance of self-renewal 
and differentiation to a series of committed progenitor types then to mature cell types of myeloid and 
lymphoid lineages. Examples of growth factors influencing this process at various stages of development 
are shown in green text, whereas transcription factors are shown in red. CMP = common myeloid 
progenitor, CLP = common lymphoid progenitor, MEP = megakaryocyte-erythrocyte progenitor, GMP = 
granulocyte-macrophage progenitor, NK cell = natural killer cell.
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leukaemia. 
1.1.2 Molecular genetics of myeloid leukaemia 
Myeloid leukaemias are a group of diseases displaying heterogeneity in clinical presentation, 
cellular morphology, and causative genetic lesions. Despite this variability, each case is 
characterised by acquired mutations conferring deregulated proliferation, survival advantages, 
and impaired differentiation of haemopoietic cells. It has been proposed that mutational 
events in AML can be broadly separated into two complementation groups or classes
24,25. The 
first class of mutations result in enhanced proliferation and/or increased survival capacity of 
haemopoietic cells. These primarily include activating mutations in signalling molecules such 
as FLT3, RAS, and KIT, which give rise to autonomous cell proliferation
26,27. However, a 
number of other lesions may also be categorised as Class I mutations, such as inactivating 
mutations in, or deletion of, key regulators of the cell cycle (e.g. TP53 and RB1
28-31), or 
genetic lesions which promote cell survival through inhibition of apoptosis (e.g. over-
expression of BCL2
32-35).
The second class of lesions are those which primarily impair differentiation of haemopoietic 
cells. These mutations often involve deregulation of transcription factors important for the 
control of myeloid differentiation; for example, point mutations have been described which 
alter the activity of the myeloid regulators PU.1 and C/EBPĮ
36,37. Haemopoietic transcription 
factors are frequently disturbed in AML by chromosomal translocations or inversions, giving 
rise to chimeric transcription factors with altered properties. For example, common 
chromosomal abnormalities involving RUNX1 (AML1), such as the t(8;21) translocation, or 
Chapter 1: Literature review and research proposal – Page 21 RARA, such as the t(15;17) translocation, result in expression of the fusion proteins AML1-
ETO and PML-RARĮ respectively, which act as dominant negative forms of the original 
transcription factor and contribute to the leukaemic differentiation block
38. Abnormal 
activation of key haemopoietic transcription factors involved in the self-renewal and 
maintenance of progenitor populations may also be categorised as Class II lesions. For 
example, members of the HOX family are commonly over-expressed or activated by 
translocation in AML, where they contribute to aberrant differentiation and enhanced self-
renewal
39-42.
Identification of lesions contributing to the pathogenesis of myeloid leukaemia has led to the 
development of targeted therapies which have significantly improved survival in selected 
subtypes. For example, the tyrosine kinase inhibitor Imatinib (Gleevec) inhibits the 
constitutively active BCR-ABL fusion protein in treatment of Chronic Myeloid Leukaemia 
(CML)
43, and All-trans retinoic acid (ATRA) acts to restore expression of differentiation-
inducing genes blocked by the PML-RARĮ fusion protein in treatment of Acute 
Promyelocytic Leukaemia (APL)
44. Therefore, it is clear that a more thorough understanding 
of the particular pathways and genetic lesions involved in AML will be necessary to aid in the 
development of more effective and less toxic targeted therapies for this disease. 
1.1.3 Cooperation of mutations in AML 
Like other cancers, AML requires the accumulation of multiple genetic lesions. This has been 
demonstrated in a number of murine models where expression of a single aberrant gene or 
fusion protein is not sufficient to induce leukaemia. For example, expression of the Class I-
acting ETV6-ABL fusion protein (complex t(9;12) translocation), or the FLT3 internal 
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mouse bone marrow transplantation studies, resulting in a phenotype similar to that of human 
MPN
45,46. Accordingly, Class I mutations are commonly found in patients with MPN, for 
example the BCR-ABL fusion protein generated by the t(9;22) translocation in CML
47, or the 
JAK2 V617F mutation prevalent in Polycythemia Vera (PV)
48. Alternatively, over-expression 
of Class II-acting fusion proteins involving components of the Core binding factor (CBF) 
complex, such as AML1-ETO (t(8;21)) or CBFȕ-MYH11 (inv(16)), impairs haemopoietic 
differentiation in mice and results in a myelodysplastic-like phenotype
49,50. However, 
transplantation of haemopoietic progenitor cells expressing both FLT3-ITD and CBFȕ-
MYH11 induces an aggressive AML phenotype in mice
51, demonstrating the importance of 
cooperation between these two classes of lesions in the biology of AML. Class II mutations 
contribute to the transformation of MPN to AML in human disease, for example, individuals 
displaying chronic phase CML associated with the BCR-ABL translocation may develop blast 
crisis with subsequent acquisition of the NUP98-HOXA9 t(7;11) translocation
52. Recent 
studies have demonstrated that point mutations in RUNX1, which inhibit differentiation of 
haematopoietic stem cells, are often acquired in the transformation of MPN to leukaemia
53,54.
The observation that more than one genetic abnormality is detected in most individuals with 
AML further supports the idea of cooperating mutations in the pathogenesis of this disease. 
For example, studies have shown a strong association of Class I mutations in FLT3, RAS, or 
KIT with translocations involving elements of the CBF complex
25,55,56. Mutations in FLT3 can 
also occur in conjunction with Class II acting mutations in NPM1 and CEBPA
55,56. Further 
insights have been obtained from studies of familial myeloid disorders, where it has been 
noted that germline mutations in RUNX1 and CEBPA predispose individuals to AML
57.
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1.1.4.1 Methylation 
Although genetic events such as mutation or chromosomal translocation play an important 
role in the development of AML, an expanding number of studies have also implicated 
epigenetic regulation in leukaemogenic processes
58,59. Chromatin state is affected by a 
combination of DNA methylation, histone modification and nucleosome remodelling, which 
lead to large-scale, heritable gene silencing
60,61. DNA methylation involves the addition of a 
methyl group to the 5 position of a cytosine pyrimidine ring within a DNA sequence, typically 
in a CpG dinucleotide context. Methylation of CpG dinucleotides within gene promoter 
sequences can repress expression by disrupting the ability of transcription factors to bind to 
their target sites
62,63, or by enhancing the ability of methylation-dependent transcriptional 
repressors to bind to these regions
64,65. A hallmark of cancer is aberrant methylation of CpG 
islands in gene promoter regions, particularly those associated with tumour suppressor genes, 
which are normally hypomethylated in healthy tissues
66.
The importance of aberrant DNA methylation as an initiating event in the development of 
leukaemia has not yet been fully elucidated. In some tumour types, such as colon cancer, it 
has been suggested that epigenetic changes are accumulated subsequent to primary mutations 
which initiate the cancerous phenotype
67. However, large-scale methylation profiling studies 
such as that conducted by Figueroa, et al., have demonstrated that hypermethylation is a wide-
spread phenomenom in AML
68. A number of tumour suppressors are frequently found to be 
silenced by methylation in AML, such as the cell cycle regulators CDKN2B (p15) and TP73,
and the growth suppressors HIC1 and RARB
69-74. Methylation-induced silencing of the 
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subgroup of AML
75. Studies have shown that overall CpG methylation increases during 
progression of MDS to AML, suggesting that methylation may be a key event in the early 
stages of acute transformation
76,77.
The mechanisms associated with aberrant methylation in AML have not yet been 
comprehensively determined. Studies have shown that the de novo DNA methyltransferases 
DNMT3A and DNMT3B are over-expressed in AML, and in the case of DNMT3B this 
correlated with hypermethylation of the tumour suppressor gene CDKN2B
78.  A recent study 
by Ley, et al., identified mutations predicted to affect translation of DNMT3A in 22% of AML 
patients
79. Although it is not yet clear how these mutations may contribute to aberrant 
methylation in leukaemia, it was observed that mutations in DNMT3A were associated with 
poor patient outcome. Gain-of-function mutations in the metabolic proteins IDH1 and IDH2 
have been recently linked to specific hypermethylated epigenetic subgroups in AML
80.
Functional studies demonstrated that these mutant IDH proteins interfere with the activity of 
the hydroxymethylase enzyme TET2, which normally plays a role in DNA demethylation. 
Interestingly, mutations in TET2 are also found in AML, and the authors demonstrated that 
patients with TET2 mutations display a similar hypermethylated epigenetic profile to patients 
with IDH1/2 mutations
80. Aberrant methylation in AML can also be induced through the 
actions of common leukaemic fusion proteins such as AML1-ETO and PML-RARĮ via 
recruitment of DNA methyltransferases
81,82. It is likely that tumour suppressor gene silencing 
by DNA methylation cooperates with other genetic mechanisms in the development of AML.
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Histone proteins are the core component of nucleosomes, which act as a scaffold to package 
DNA into a higher order chromatin structure. Post-translational modification of key amino 
acids in histone proteins can effect structural changes in chromatin, either remodelling the 
chromatin structure to allow transcriptional activation (euchromatin), or resulting in a 
condensed chromatin formation associated with transcriptional repression 
(heterochromatin)
83,84. Histone modifications also act to recruit protein complexes which 
further modify chromatin state, such as the Nucleosome remodelling factor (NURF) 
complex
85-88, or which can influence methylation of DNA, such as complexes involving the 
CBX family of heterochromatin proteins (HP1 proteins) and DNA methyltransferases
89-91.
Most histone modifications occur on the N-terminal tails of Histones H3 and H4, generating a 
complex pattern of modifications referred to as the Histone Code
92.
The most extensively studied histone modification is acetylation of lysine residues, which is 
associated with an open chromatin state and gene activation
93,94. Lysine methylation can be a 
mark of open or condensed chromatin depending on the amino acid position being modified 
and the extent of methylation, for example, di- or tri-methylation of lysines 9 and 27 in 
Histone H3 are associated with transcriptional repression, whereas mono-methylation of 
lysine 4 in Histone H3 is associated with transcriptional activation
95. A number of other 
modifications have also been reported such as phosphorylation, glycosylation, SUMOylation 
(addition of Small ubiquitin-like modifier (SUMO) proteins), Adenosine diphosphate (ADP) 
ribosylation, and ubiquitination, and the specific contribution of these to the chromatin state is 
the subject of ongoing investigation
84.
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The common fusion proteins PML-RARĮ and AML1-ETO directly recruit histone 
deacetylases (HDACs) which result in inactivation of genes important for haemopoietic 
differentiation
96-98. The MLL gene is translocated to a number of different partners in AML, 
such as AF4/AF9/AF10 which contain intrinsic histone methyltransferase activity, and CBP, a 
known histone acetyltransferase, which results in deregulated modification of histones and 
aberrant target gene activation or repression in AML
99,100. An increasing number of point 
mutations have been recently discovered in members of the Polycomb-group protein family, 
such as UTX, ASXL1, and EZH2
101-103. The Polycomb-group of proteins are involved in 
methylation of histone residues, and are key regulators of Homeobox gene expression
104.
Although the mechanisms involved have not yet been fully elucidated, it is clear that histone 
modifications and DNA methylation cooperate to induce stable silencing of tumour 
suppressor genes in cancer pathogenesis
61,105.
1.1.5 Methods for identification of novel leukaemic lesions and pathways 
Many genetic lesions contributing to AML have been identified by cytogenetic techniques. 
Genes located at chromosomal breakpoints are often involved in the leukaemic process, and 
can be involved in the creation of fusion proteins with altered activity as discussed previously 
in Section 1.1.2. However in up to 50% of myeloid leukaemias the key aberrations involved 
cannot be identified from chromosomal abnormalities as these are lacking or apparently 
random
2,106,107.
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Advances in genomics-based methods have allowed development of large-scale screening 
techniques for identification of genes with roles in leukaemogenesis. Comprehensive 
microarray analyses to study gene expression changes in primary AML patient samples have 
been used to identify biologically relevant pathways in specific subtypes of leukaemias. For 
example, Wouters, et al. demonstrated that the subgroup of AML samples with silenced 
CEBPA were associated with aberrant NOTCH1 signalling
108. A gene expression profiling 
study of APL patients with a t(11;17) translocation identified the retinoic acid binding protein 
CRABP1 as a downstream target of the RARĮ-PLZF fusion protein, which was subsequently 
shown to contribute to retinoid-resistance in these patients
109,110.
Large-scale analyses of methylation patterns have been successfully used to identify potential 
tumour suppressor candidates in AML. For example, Gebhard, et al. developed a novel 
approach for genome-wide assessment of methylation using a methyl-binding protein 
chromatin immunoprecipitation (ChIP) technique
111. They identified a number of 
transcription factors whose promoters were hypermethylated in leukaemia cell lines and in 
primary patient samples, which correlated with reduced gene expression (e.g. MAFB, KLF11).
Methylation profiling of 344 AML patients using the HpaII tiny fragment enrichment by 
ligation-mediated PCR (HELP) approach identified a set of 45 genes which were consistently 
methylated in the majority of AML samples assessed, suggesting that down-regulation of 
these genes may be a common factor necessary for leukaemic transformation
68,112.
Genome-wide approaches have also been utilised to identify novel mutations contributing to 
the development of AML. Screening for copy number alteration in patient samples using 
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amplifications, and mutations, providing a host of candidate genes to be further investigated 
in the pathogenesis of AML
113,114. The application of this technology has led to identification 
of novel mutations in genes such as CBL and TET2 in a range of myeloid disorders
115-117.
Whole-genome sequencing of AML patient samples has been utilised to detect mutations in 
genes previously not associated with AML, for example, recurrent heterozygous mutations 
were identified in the gene encoding the metabolic protein IDH1, and further screening 
revealed that these mutations occur in approximately 9% of de novo French-American-British 
(FAB) M1 subtype AMLs, as well as in other myeloid neoplasms
118-120.
1.1.5.2 Functional screens 
Genomics-based screens have provided valuable insight into potential mechanisms underlying 
leukaemogenesis, especially in recent years with improved capacity and sensitivity of 
screening methods such as next-generation sequencing
121. For any changes identified by these 
approaches, further research is required to validate the functional role of candidate genes and 
to determine the biological consequences of their deregulation. Functional screens are an 
alternative approach to identify novel genes involved in haemopoiesis and in AML. One 
example is gene dysregulation by retroviral insertion mutagenesis giving rise to leukaemia in 
animal models. This approach has revealed oncogenes such as MYB and REL
122,123. The 
Retroviral Tagged Cancer Gene Database (RTCGD) is an extensive compilation of genes 
associated with these insertions, allowing scientists to rapidly screen potential oncogenes for 
association with a leukaemic phenotype
124. Functional expression cloning screens have 
identified genes involved in leukaemic processes based on their ability to confer a specific 
phenotype in a target cell system. This approach has been successfully used to isolate both 
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novel oncogenes, such as SOCS1and the RAS-related protein RASGRP4, and putative tumour 
suppressors such as  the protein phosphatase PP4
125-127.
1.2 Identification of novel oncogenes and tumour suppressors using the 
FDB1 murine myeloid cell line 
1.2.1 The FDB1 cell line model 
In order to study the regulation of growth and differentiation in the granulocyte-macrophage 
lineage and the mechanisms underlying the pathogenesis of AML, our laboratory has made 
use of the unique murine myeloid cell line FDB1. The FDB1 cell line arose spontaneously in 
murine foetal liver cell cultures following retroviral infection with the human GM-CSF/IL-
3/IL-5 receptor common beta chain ( hȕc)
128. FDB1 cells are completely growth factor-
dependent; when maintained in IL-3 they proliferate continuously with an immature 
promyelocytic morphology, whereas in GM-CSF they differentiate to produce approximately 
equal proportions of granulocytes and macrophages over 5 days (Figure 1.2). Interestingly, 
factor-independent growth of FDB1 cells can be achieved with enforced expression of 
activated mutants of hEc. Expression of the leukaemogenic V449E mutant allows cells to 
proliferate with a similar morphological appearance to cells in IL-3 in media without factor, 
whereas with expression of the FI' extracellular mutant cells differentiate to granulocytes and 
macrophages (see Figure 1.2)
128. These properties make the FDB1 cell line a useful model for 
studying aspects of normal and malignant myelopoiesis, as the growth, survival and 
differentiation of these cells can be manipulated through the use of cytokines or by expression 
of constitutively activated cytokine receptors.FDB1 IL-3 FDB1 GM-CSF (Day 5)
FDB1+V449E No factor FDB1+FI' No factor (Day 5)
Figure 1.2: FDB1 model system of myeloid differentiation. FDB1 parental cells 
cultured in IL-3 proliferate continuously and display an immature myeloblastic 
morphology. When cultured in GM-CSF for 5 days they differentiate to produce 
approximately equal proportions of granulocytes and macrophages128. FDB1 cells 
expressing activated mutants of hȕc display factor-independent growth. Expression of the 
V449E mutant leads to continuous proliferation with a morphology similar to that of 
parental cells in IL-3, whereas expression of the FI' mutant results in differentiation to 
macrophages and granulocytes similar to parental cells in GM-CSF129. Gran = 
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To identify potential myeloid tumour suppressors or oncogenes, an extensive series of 
microarray analyses were previously performed using FDB1 cell populations to detect gene 
expression signatures associated with the switch from continuous cell proliferation to 
granulocyte-macrophage differentiation. Gene expression profiles were generated using 
FDB1 cells undergoing continuous proliferation (either with addition of IL-3 or expression of 
the hEc mutant V449E) or granulocyte-macrophage differentiation (either with addition of 
GM-CSF or expression of the hEc mutant FI')
1. Although expression of the hEc mutants 
produces similar cellular outcomes to cytokine stimulation, the signalling redundancy is 
greatly reduced allowing for better dissection of the pathways and genes involved in these 
processes
130. We hypothesised that gene expression signatures associated with continued 
proliferation of FDB1 cells, particularly those activated by the leukaemogenic V449E mutant, 
would be consistent with a potential oncogenic role for these genes in the development of 
leukaemia. Alternatively, gene expression signatures associated with differentiation of FDB1 
cells (i.e. repressed by V449E and/or activated by FI'/GM-CSF) would represent potential 
tumour suppressor function. These studies highlighted a number of transcription factors with 
potential for playing a critical role in governing the process of myeloid differentiation
1.
1.2.3 Identification of Krüppel-like factor 5 as a differentiation-associated 
gene in the myeloid system 
Krüppel-like factor 5 (Klf5) was identified as a transcription factor whose messenger RNA 
(mRNA) expression increased in FDB1 cells undergoing granulocyte-macrophage 
differentiation induced by expression of FI' (Figure 1.3A)
1. In contrast, proliferating cells 
Chapter 1: Literature review and research proposal – Page 32 Figure 1.3: Klf5 expression during FDB1 differentiation. A. Klf5 mRNA expression increases during   
factor-independent granulocyte-macrophage differentiation of FDB1 cells expressing the hEc FI' mutant, but 
not during factor-independent culture of cells expressing the V449E mutant (continuous proliferation). Data 
was extracted from microarray analyses performed by Brown, et al.1, and Klf5 fluorescence plotted relative to 
Day 0 (cells in IL-3). The morphology of cells on Day 5 of culture is shown. n=4. B. Klf5 mRNA expression 
increases during factor-independent granulocyte-macrophage differentiation of FDB1 cells expressing the hEc
FI' mutant, but not during factor-independent macrophage-only differentiation of cells expressing the 
FI'Y577F mutant. Data was extracted from Q-PCR analyses performed by D. Salerno (unpublished data), and 
Klf5 fluorescence plotted relative to Day 0 (cells in IL-3). The morphology of cells on Day 5 of culture is 
shown. n=3. Gran = granulocyte, Mac = macrophage. No factor  =  media not supplemented with growth 
factors.































































































































































































Chapter 1: Literature review and research proposal – Page 33expressing V449E showed no change in Klf5 expression under similar conditions. 
Unsupervised hierarchical cluster analysis performed using the gene expression profiling data 
grouped Klf5 with a number of genes known to induce growth arrest and/or terminal myeloid 
differentiation, such as Egr1 and Egr3, and the homeobox-related Hlx gene
1, suggesting that 
KLF5 may have a similar functional role in the haemopoietic system. 
1.2.3.1 Klf5 expression is associated with the granulocyte lineage 

Further microarray analyses were utilised to identify gene expression signatures associated 
specifically with granulocyte or macrophage differentiation (A. Brown and C. Wilkinson, 
unpublished data). Lineage-specific manipulation of the FDB1 cell line was achieved using 
enforced expression of additional mutant forms of hȕc. As described above, expression of the 
FI' mutant drives factor-independent differentiation of FDB1 cells to both granulocytes and 
macrophages. A second-site tyrosine to phenylalanine mutation in FI' (Y577F) reduces 
granulocyte differentiation, thus driving factor-independent differentiation of FDB1 cells 
predominantly to macrophages
129. By comparing gene expression profiles from cells 
expressing the FI' or FI' Y577F mutant, we were able to identify gene-sets associated with 
macrophage or granulocyte differentiation (A. Brown, unpublished data). In particular, Klf5
expression increased significantly during FI'-induced granulocyte-macrophage 
differentiation, but not during FI' Y577F-induced macrophage differentiation, consistent 
with selective increased expression in the granulocyte lineage. These results were validated 
using quantitative reverse-transcription PCR (Q-PCR) analysis, as shown in Figure 1.3B (D. 
Salerno, unpublished data). 
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granulocyte-specific gene-set (A. Brown, unpublished data). CEBPA encodes a transcription 
factor expressed early during myeloid differentiation, and in vivo studies have demonstrated 
an essential role for this protein in development of the granulocyte lineage
131. Within the 
granulocyte-specific gene-set, the expression profile of Klf5 was associated with that of a 
number of C/EBPĮ target genes, suggesting that it too may be regulated downstream of 
C/EBPĮ during FDB1 myeloid differentiation. This is consistent with a study by Cammenga, 
et al., who identified KLF5 as a target of C/EBPĮ in human CD34
+ haemopoietic progenitor 
cells
132. Regulation of KLF5 by C/EBPĮ further supports a role for KLF5 in granulocyte 
differentiation. From these observations we have hypothesised that KLF5 may function as a 
transcription factor regulating differentiation in the myeloid lineage, particularly along the 
granulocytic pathway. This function would also be consistent with a potential role for KLF5 
as a tumour suppressor in the myeloid system. 
1.3 Krüppel-like factor 5 
1.3.1 The Krüppel-like family of transcription factors 
KLF5 belongs to the family of Krüppel-like transcription factors. Members of this family 
have been implicated in an extensive array of biological processes including embryonic 
development, control of cellular proliferation and differentiation, stress response, and many 
others (Table 1.1)
133,134. The KLF family of proteins all share a common zinc finger motif 
displaying homology to the Drosophila melanogaster ‘ Krüppel’ gene, deletion of which 
results in the loss of central segments to give the ‘crippled’ phenotype
135,136. KLF family 
members are closely related to the Sp family of transcription factors but are distinguished by a 
































































































































































































































































































 unique pattern of three cysteine-2/histidine-2 zinc finger motifs separated by 7 conserved 
amino acids at the carboxy terminal of the proteins
195,196. These zinc fingers comprise the 
DNA-binding domain of the KLF transcription factors, which all bind to similar elements 
within GC-rich promoter sequences of target genes. Outside of the DNA-binding domain, the 
KLF family members display relatively low conservation, although phylogenetic analysis has 
identified distinct subgroups within the KLF family (Figure 1.4). Members of these subgroups 
share similar features such as specific activation or repression domains, or domains used for 
protein interaction with other transcriptional coregulators. Specificity of action for members 
of the KLF family is determined in part by differences in the amino-terminal transactivation 
domains of these proteins and also by their tissue-specific expression
195.
1.3.2 Krüppel-like factor 5 
KLF5 was originally cloned as the Basic transcription element binding protein 2 (BTEB2)
gene
197. It was independently identified as a member of the KLF family of transcription 
factors by its homology with KLF2
198. Prior to the reclassification of KLF family 
nomenclature KLF5 was known as Intestinal krüppel-like factor (IKLF) due to high levels of 
protein expression in intestinal epithelial cells
198. Interest in this gene has greatly expanded in 
recent years as studies have revealed emerging functions in a variety of cell types and 
biological systems, with homologues identified in numerous vertebrate species. KLF5 has 
known functions in different aspects of cellular regulation (proliferation, self-renewal, 
survival and differentiation), as well as in embryonic development, cardiovascular 
remodelling, stress and immune response, and many other systems
199. KLF5 plays a number 
of diverse roles, and has been reported to act as a transcriptional activator or repressor, a 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 1: Literature review and research proposal – Page 38promoter or inhibitor of cell growth, and has been implicated as either a tumour promoter or 
suppressor depending on the cellular and genetic context in which it is being studied
199.
1.3.3 Gene structure and transcriptional regulation 
The KLF5 gene is located on human chromosome 13q21-22 (Figure 1.5A). The primary 
transcript comprises 4 exons generating a 3350 nt mRNA, however a smaller 1.5 kb transcript 
has been detected in the testes
201. KLF5 is expressed in a variety of epithelial cell types as 
well as vascular smooth muscle cells (VSMCs), neural cells and lymphoid cells
202-204. It is 
highly expressed in the digestive system, with lower levels found in the reproductive organs, 
pancreas, prostate, skeletal muscle, lung and bladder
197,198,201,202.
The KLF5 promoter is high in GC content and does not have a canonical TATA box 
consensus sequence
205. A number of functional regulatory elements have been identified for 
transcription factors activating KLF5 gene expression (see Figure 1.5A). These include the 
common transcription factors Sp1, EGR1 and EVI1, all of which bind to the KLF5 promoter 
to up-regulate transcription
205-207. Klf5 expression is also directly activated by the embryonic 
stem cell (ESC) transcription factor Nanog in mouse cells, and by two members of the C/EBP 
family in a murine pre-adipocyte cell line (C/EBPE/G)
156,208. Deletion mapping of the KLF5
promoter region has identified a 6 bp element (nucleotides -454 to -448 where +1 denotes the 
first nucleotide of the ATG start codon) which is necessary for transcriptional activity in 
human epithelial cells
206. In the rat Klf5 promoter this element corresponds to a functional 
CCAAT box, which binds the RUNX family of transcriptional regulators as shown by gel 
mobility shift assays (GMSA)
209. In addition, the rat Klf5 promoter contains a functional NF1 
binding element
209. Deletion of a 1.5 kb region of the human KLF5 promoter (nucleotides 
Chapter 1: Literature review and research proposal – Page 39 Figure 1.5: KLF5 gene and protein (Homo sapiens). A. The human KLF5 gene contains four exons spanning 
approximately 18.5 kb on chromosome 13q21-22 (exon 1 - 585 bp, exon 2 - 874 bp, exon 3 - 60 bp, and exon 
4 - 1831 bp). 5`- and 3`- untranslated regions are indicated in green. The KLF5 promoter region and regulatory 
transcription factor binding elements spanning the proximal promoter and exons 1-2 are shown. Note that 
lower case transcription factor names indicate that regulation by these transcription factors has been shown in 
rat or mouse and remains to be validated for the human promoter. B. The human KLF5 protein is 457 amino 
acids in length and contains two main functional domains – a transactivation domain (TAD) and a DNA-
binding domain (DBD) consisting of 3 zinc finger motifs (ZnF). Other regions or motifs shown are: The region 
required for ubiquitin-independent degradation (Deg), a nuclear export signal (NES), and the region required 
for KLF5 homo-dimerisation. KLF5 can be modified post-translationally by phosphorylation on S153,  S303, 
T234 and T323 (P), SUMOylation on K162 and K209 (Su), acetylation on K369 (Ac) and ubiquitination on 
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Homo-dimerisation TAD DBD  -1959 to -454) results in increased promoter activity suggesting that this sequence may 
contain elements for binding repressor proteins
206, and in fact a recent study performed by 
Tetreault and colleagues in mouse primary esophageal keratinocytes demonstrated that 
another member of the KLF family, KLF4, can bind to the Klf5 promoter within this region 
(at approximately -600 bp) to repress transcription
210. KLF5 in turn can bind to the Klf4
promoter and repress expression, which highlights the antagonistic activities of these two 
related transcription factors
211. The muscle-specific MEF2 protein can also bind to the KLF5
promoter to activate transcription
212. Interestingly, a single nucleotide polymorphism 
(rs3812852) within the MEF2 binding site can alter the binding affinity of MEF2 and 
subsequent KLF5 expression
212. The G>A polymorphism at -1606 from the ATG codon 
(positive strand) enhances MEF2 binding and KLF5 expression, and is associated with 
increased risk of hypertension in human disease
212. An A>G change at this position has been 
linked to decreased KLF5 expression associated with schizophrenia
203. Transcription of KLF5
can also be directly modulated by enhancer elements located outside of the proximal 
promoter. ChIP analysis and deletion mapping demonstrated binding of the Androgen 
receptor (AR) protein to intron 1 of the KLF5 gene which up-regulates expression in prostate 
cancer cells
213.
Recent studies have shown that KLF5 mRNA expression may also be regulated through the 
action of selected microRNAs. In rat VSMCs, Klf5 is targeted by microRNA-145 which plays 
a functional role in phenotypic modulation of vascular development
214. Klf5 mRNA is also 
regulated through the actions of microRNAs 143 and 448, which have important roles in 
adipogenesis
215,216.
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The human KLF5 protein (Figure 1.5B) is 457 amino acids in length and consists of the 
common Krüppel-like factor DNA-binding domain (three zinc finger motifs), a 
transactivation domain (TAD), and a nuclear export signal (NES). As a transcription factor it 
is primarily present in the nucleus
201. However an active NES domain can promote 
cytoplasmic localisation of KLF5 which effectively inhibits function
217.
It has been shown that various post-translational modifications are crucial in determining the 
transactivation function of KLF5. Phosphorylation of KLF5 can lead to activation or 
repression of downstream target genes, through recruitment of various cofactor proteins such 
as CBP or JUN
218-220. Acetylation can also switch the transactivation function of KLF5 with 
respect to regulation of selected target genes. For example, it has been shown that the non-
acetylated KLF5 protein acts as a repressor of CDKN2B transcription via recruitment of MYC 
and other transcriptional coregulators. However, upon TGFȕ signalling KLF5 is acetylated by 
the coactivator p300 and instead becomes an activator of expression through altered binding 
to the promoter and subsequent recruitment of coactivators including SMADS2/3/4 and 
FOXO3
221,222.
SUMOylation of KLF5 near the NES domain promotes nuclear localisation, where it can act 
as a repressor of genes (e.g. for the lipid oxidation genes CPT1B and UCP2/3)
217,223. This 
occurs through formation of a corepressor complex which involves the nuclear receptor 
corepressors NCoR1 and NCoR2 together with the unliganded metabolic protein PPARį.
Treatment with a PPARį agonist deSUMOylates KLF5 which binds liganded PPARį
together with the coactivator CBP and results in transcriptional activation of lipid oxidation 
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223. Thus SUMOylation can act as a switch for KLF5 activity from activator to 
repressor, and the levels of this modification may explain the different functional roles seen in 
various sytems. 
Finally, KLF5 can also be ubiquitinated and targeted for proteasomal degradation via protein-
protein interaction with the E3 ubiquitin ligases WWP1 and FBW7
224-226. FBW7 regulates 
ubiquitination of the KLF5 protein through binding to phosphorylated CDC4 phosphodegron 
(CPD) motifs
225. Interestingly, it appears that KLF5 can also be degraded by the proteasome 
in a ubiquitin-independent manner via its N-terminal 19 amino acids; Chen, et al. generated a 
lysine-less mutant which could still be degraded without ubiquitination, however deletion of 
the N-terminal 19 amino acids protected against this degradation
227. While such a mechanism 
does not affect the transactivation function of KLF5, it serves to control the level of KLF5 
protein and may be important in modulating activity in many systems. 
1.3.5 Target genes 
KLF5 preferentially binds to GC-boxes and CAAT/GT-boxes within promoters of target 
genes
197,201. These elements mainly lie in GC-rich areas of proximal promoter regions. A 
number of direct target genes of KLF5 have been identified with roles in cell proliferation, 
renewal, survival, and differentiation (Table 1.2). Although in most cases KLF5 has been 
shown to increase expression of target genes, there have been a growing number of examples 
where it acts to repress transcription
199. As discussed above, the transactivation function of 
KLF5 can be reversed in different conditions via post-translational modification and alternate 
recruitment of coactivators or corepressors (see Section 1.3.4).   
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ABCG2  ATP-binding cassette, sub-family G (WHITE), member 2  Repressed  Membrane transporter  228 
CCNB1  Cyclin B1  Activated  Cell cycle progression  229-231 
CCND1  Cyclin D1  Activated  Cell cycle progression  219, 229-231 
CDK1 (CDC2)  Cyclin-dependent kinase 1  Activated  Cell cycle progression  229-231 
CDKN1A (p21)  Cyclin-dependent kinase inhibitor 1A  Repressed  Cell cycle control  220 
CDKN2B (p15)  Cyclin-dependent kinase inhibitor 2B  Both  Cell cycle progression  229-231 
CPT1B  Carnitine palmitoyltransferase 1B  Both  Lipid synthesis  156 
DAF  Decay accelerating factor  Activated  Survival (complement system protection)  232 
EGFR  Epidermal growth factor receptor  Activated  Proliferation  233 
EGR1  Early growth response 1  Activated  Proliferation/migration/prevents differentiation  234 
FASN  Fatty acid synthase  Activated  Lipid metabolism  156, 223 
FGFBP1  Fibroblast growth factor binding protein 1  Activated  Proliferation/survival  235, 236 
HBG1  Hemoglobin, gamma A  Activated  Haemoglobin protein  237 
IGF1  Insulin-like growth factor 1  Activated  Growth factor  158 
ILK Integrin-linked  kinase  Activated  Migration  238 
KLF4  Krüppel-like factor 4  Repressed  Differentiation  211 
LAMA1  Laminin alpha 1  Activated  Differentiation/tumour cell proliferation  239 
LTF Lactotransferrin  Activated  Differentiation  marker  201 
MAOB  Monoamine oxidase B  Repressed  Amine degradation  240 
MIR146A MicroRNA-146a  Activated  Proliferation  241 
MMP9 Matrix  metalloprotease  9  Activated  Migration  242 
MYC  V-myc myelocytomatosis viral oncogene  Both  Proliferation  243 
MYH10  MYH10 myosin, heavy chain 10, non-muscle  Activated  Proliferation/migration/prevents differentiation  202, 244 
NANOG Nanog  homeobox  Activated  Self-renewal  208,  245 
OCT3 Octamer  3  Activated  Self-renewal  208,  245 
OCT4 Octamer  4  Activated  Self-renewal  208,  245 
SERPINE1  Serpin peptidase inhibitor, clade E, member 1  Activated  Proliferation/migration/prevents differentiation  234 
PDGFA  Platelet-derived growth factor A  Activated  Proliferation/migration  157, 246 
PDGFB  Platelet-derived growth factor B  Activated  Proliferation/migration  247 
PIM1 Pim-1  oncogene  Activated  Survival  248 
PPARG  Peroxisome proliferator-activated receptor gamma  Activated  Differentiation  156 
TAGLN Transgelin  Activated  Proliferation/migration/prevents  differentiation  249 
SURVIVIN Survivin  Activated  Survival  250 
TCL1  T-cell leukemia/lymphoma 1  Activated  Self-renewal  208, 245 
TRB  T cell receptor beta chain locus  Activated  T-cell receptor component  204 
UCP2  Uncoupling protein 2  Both  Lipid synthesis  156 
UCP3  Uncoupling protein 3  Both  Lipid synthesis  156 
VEGFA  Vascular endothelial growth factor A  Activated  Proliferation/migration  159 
Table 1.2: Direct KLF5 target genes and their transcriptional regulation by KLF5. 
Adapted from Dong and Chen199.
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There have been several microarray studies performed to date to study gene expression 
changes associated with KLF5 activity. Chen et al. showed that over-expression of KLF5 in 
the TSU-Pr1 bladder cancer cell line induces proliferation, and in this system they used 
microarray analysis to identify 58 genes which were differentially regulated in KLF5-
expressing clones versus controls
251. Putative target genes were known to have roles in 
proliferation, cell cycle, differentiation and apoptosis, as well as in cell 
migration/angiogenesis and metabolic pathways. Genes involved in the MEK/ERK and 
retinoic acid pathways were also affected by KLF5 expression. Interestingly, almost three 
quarters of the regulated genes were activated on KLF5 over-expression, and only one quarter 
were repressed. Wan, et al. developed a mouse model with conditional ablation of Klf5 in the 
lung
159. Deletion of Klf5 inhibited lung maturation, and genome-wide microarray analyses 
were utilised to identify genes which were differentially expressed in this system compared to 
wild-type littermates. These included genes involved with lung morphogenesis 
(vasculogenesis, smooth muscle cell differentiation, paracrine interactions) and those with 
roles in cancer and the cell cycle. Many members of the TGFȕ, BMP and MEK/ERK 
signalling pathways were also regulated by KLF5 expression. Although the microarray 
studies performed by Chen, et al. and Wan, et al. have identified many putative target genes 
of KLF5, the authors did not attempt to confirm that these are directly regulated by KLF5 
using ChIP analysis. Two independent studies have utilised microarray gene expression 
profiling combined with ChIP analyses to identify direct targets of KLF5 in murine 
ESCs
208,245. Reduced Klf5 expression by siRNA knock-down or gene targeting induces ESC 
differentiation, and accordingly these studies have demonstrated that KLF5 activates 
expression of genes involved in  the  maintenance of  ESC self-renewal, such as Oct4, Nanog,
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differentiation
160,208,252. Interestingly, Parisi and colleagues demonstrated that a subset of 
KLF5 target genes were oppositely regulated in ESCs and keratinocytes on Klf5 knock-down, 
which is consistent with KLF5 having different target gene specificity in distinct tissue 
types
208.
1.3.6 Interacting proteins 
KLF5 has been shown to homo-dimerise when binding to a KLF5 target sequence probe in
vitro, with deletion assays identifying amino acids 251-353 as the region necessary for homo-
dimerisation (see Figure 1.5B)
253. Whether KLF5 forms complexes with other KLF proteins is 
not yet known.
Direct interaction of KLF5 with other proteins has been shown by coimmunoprecipitation, 
yeast two-hybrid screening and mass spectrometry. These interacting proteins include post-
translational modifiers and coactivators or corepressors (Table 1.3). KLF5 has been shown to 
recruit various coactivators or repressors to target gene promoters through direct interaction, 
as discussed in Section 1.3.4. Interaction of KLF5 with histone modifiers such as HDAC1 and 
the histone chaperone ANP32B can directly inhibit KLF5 binding to target gene 
promoters
254,255. KLF5 has been shown to recruit ANP32B to the promoter of the PDGFA
target gene where it inhibits histone acetylation and down-regulates transactivation of the 
promoter
255. These observations suggest that KLF5 may have an important role in modulating 
histone modification.  
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HIF1D Hypoxia inducible factor 1 alpha  Transcription factor  262 
TFIIB  General transcription factor 2B  Basal transcriptional component  256 
TFIIEE General transcription factor IIE 2  Basal transcriptional component  256 
TFIIFE General transcription factor IIF 2  Basal transcriptional component  256 
KLF5  Krüppel-like factor 5    253 
PARP1  Poly (ADP-ribose) polymerase 1  Activator of apoptosis  263 
TBP  TATA box binding protein  Basal transcriptional component  256 
PROTEIN SYMBOL  PROTEIN NAME  FUNCTION  REFERENCES 
Effectors of KLF5 function      
ANP32B  Acidic (leucine-rich) nuclear phosphoprotein 32 family B  Inhibition of KLF5 binding to target genes  255 
CBP  CREB binding protein  Transactivation of KLF5  218 
FBW7  F-box and WD repeat domain containing 7  Ubiquitin-dependent KLF5 protein degradation  225 
HDAC1  Histone deacetylase 1  Deacetylation and inhibition of KLF5  254, 257 
p300  E1A binding protein p300  Acetylation of KLF5 and transactivation  221, 257 
PIAS1  Protein inhibitor of activated STAT 1  Transactivation of KLF5 (SUMOylation?)  258 
PKC  Protein kinase C  Phosphorylation and transactivation of KLF5  218 
SET  SET nuclear oncogene  Deacetylation and inhibition of KLF5  257 
WWP1  WW domain containing E3 ubiquitin protein ligase 1  Ubiquitin-dependent KLF5 protein degradation  224 
Transcriptional coregulators      
C/EBPE CCAAT/enhancer binding protein beta  Coactivator  156 
C/EBPG CCAAT/enhancer binding protein delta  Coactivator  156 
JUN Jun  oncogene  Coactivator/Corepressor  219,  220 
NCoR1  Nuclear receptor corepressor 1  Corepressor  223 
NCoR2  Nuclear receptor corepressor 2  Corepressor  223 
NF-țB  Nuclear factor kappa-light-chain-enhancer of activated B cells   Coactivator  246, 253 
p53  Tumour protein p53  Coactivator  250 
PPARG Peroxisome proliferator-activated receptor delta  Coactivator/Corepressor  223 
RAR/RXR  Retinoic acid receptor/Retinoid X receptor  Coactivator  157 
SREBP1  Sterol regulatory element binding protein-1  Coactivator  259 
Other      
E-catenin  Beta-catenin Transcription  factor  260 
Table 1.3: KLF5 interacting proteins. 
Adapted from Dong and Chen199.
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as the transcription factors TFIIȕ, TFIIEȕ, TFIIFȕ, and the TATA box-binding protein 
TBP)
256. It has also been reported to interact with a variety of other transcriptional 
coregulators to control expression of downstream targets. For example, the KLF5 protein 
forms a heterodimer with unliganded RAR to activate expression of PDGFA
264, and interacts 
with NF-țB p65 to synergistically activate a NF-țB reporter construct
253. It associates with 
C/EBPȕ and C/EBPį, p53 and SREBP1 to activate gene expression
156,250,259.
KLF5 binding can also directly inhibit protein function, for example binding to the ERĮ
protein inhibits ERĮ transcriptional activity in the presence of estrogen, thereby preventing 
induction of downstream ERĮ target genes
261. KLF5 interacts with the pro-apoptotic PARP1 
protein, which results in inhibition of apoptosis
263.
1.3.7 Function in cell growth, differentiation and survival 
1.3.7.1 KLF5 as a positive regulator of proliferation 
Spatial and temporal expression patterns of KLF5 suggest a role in proliferation in many 
systems. Expression levels of KLF5 are high in actively dividing cell types such as ESCs or 
proliferating cells of the intestinal epithelium, and expression decreases on differentiation to 
terminally mature cells
152,245. In murine tooth development KLF5 is expressed early in 
proliferating cells but expression is decreased on differentiation into mature tooth 
structures
265. KLF5 is also highly expressed in rapidly proliferating keratinocytes of the hair 
matrix, and expression is further increased on treatment with the pro-proliferative agent 
phorbol  12-myristate  13-acetate  (PMA)
253.   Serum   stimulation  of  fibroblasts and  smooth  
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198,266. KLF5 
expression is induced in rodent models of biological stress caused by physical injury, 
irradiation or bacterial pathogens, which may suggest a proliferative role in the body’s 
inflammatory or immune response systems
202,205,267-269.
Ectopic expression of KLF5 in a variety of cell types also provides supporting evidence for 
the role of KLF5 as a positive regulator of cell proliferation. Over-expression of KLF5 
increases growth rates of intestinal and esophageal epithelial cells, keratinocytes and NIH-
3T3 fibroblasts
229,270-273. RNA interference (RNAi) knock-down of Klf5 shows the expected 
opposite effect with reduced cellular proliferation of keratinocytes, VSMCs, and normal 
mammary epithelial cell lines
233,236,266. In vivo studies support a growth-promoting role for 
KLF5 in the intestine, with heterozygous knock-out mice displaying shorter intestinal crypts 
and villi and decreased thickening of arterial walls, consistent with a reduction in cell 
growth
157. A number of rat and mouse models have shown that KLF5 contributes to 
vasculogenesis and angiogenesis through modulating smooth muscle cell phenoytpe. KLF5 
up-regulates expression of genes which increase VSMC proliferation and migration, and 
prevent differentiation, such as Vegfa, Myh10, Tagln, Serpine1, and Egr1
159,202,234,244,249. A rat 
model of cardiovascular injury has shown that over-expression of KLF5 leads to a higher 
frequency of neointima formation due to increased proliferation and migration of VSMCs
274,
and heterozygous ablation of Klf5 in a mouse model of colitis results in significantly 
increased disease severity due to reduced epithelial proliferation and migration in the colon
275.
A key role in promoting proliferation is consistent with studies indicating an oncogenic role 
for KLF5 in some tissues such as intestinal epithelium (discussed further in Section 1.3.8.1). 
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There is considerable evidence that the function of KLF5 as a positive regulator of cell 
growth is intimately linked with activation of the pro-proliferative MEK/ERK pathway 
(Figure 1.6). The MEK/ERK pathway can be stimulated by a variety of mitogenic factors 
such as growth factors and small molecule agonists. A number of studies have shown that 
treatment of epithelial cells with various stimuli (e.g. Lipopolysaccharide, PMA, Basic 
fibroblast growth factor, Angiotensin II, Sphingosine 1-phosphate, dextran sulphate sodium) 
activates the MEK/ERK pathway which in turn stimulates KLF5 expression primarily through 
the transcription factor EGR1
205,246,247,269,275,276. The MEK/ERK pathway can be activated to 
promote expression of KLF5 via the RAS pathway (e.g. downstream of the EGF receptor) and 
also via up-regulation of PKC (downstream of Lisophosphatidic acid and non-canonical WNT 
signalling) in epithelial cell types
233,277-279. The functional activity of KLF5 may also be 
altered through MEK/ERK induced serine phosphorylation downstream of Angiotensin II 
signalling
219,220 (see Figure 1.5B). Following induction via the MEK/ERK pathway, KLF5 
can bind to proteins such as NF-țB or RARĮ to form complexes which directly activate 
expression of PDGFA and PDGFB, which contribute to increased proliferation and cell 
migration
157,246,264,266. KLF5 also promotes proliferation via up-regulation of the cell cycle-
promoting proteins CCND1, CCNB1 and CDK1 (CDC2), and down-regulation of the cell 
cycle regulator CDKN1A ( p21), which act to increase the G1-S phase transition of 
cells
219,220,229,230,277. Although in many systems KLF5 is activated by the MEK/ERK pathway, 
there is evidence to suggest that KLF5 expression and function may also be mediated by 
additional signalling pathways. For example, the p38 MAPK pathway has been shown to 
influence KLF5 expression in both pancreatic cancer cells and in VSMCs
212,219,262, and in 
ESCs Klf5  transcription   is  induced   by  the   STAT3  pathway
252.   The   KLF5  protein  is
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Figure 1.6: The MEK/ERK pathway and KLF5 in proliferation. The MEK/ERK pathway is a central 
component for activation of KLF5 in proliferative signalling pathways. MEK/ERK components can be 
stimulated by a variety of growth factors and other mitogens, via RAS or PKC signalling, or other pathways 
which are yet to be identified. KLF5 is up-regulated downstream of MEK/ERK via EGR1, where it then 
activates genes to promote cellular proliferation. In particular, KLF5 up-regulates expression of PDGFA/B
(through formation of complexes with NF-țB and RAR/RXR), and various cell cycle proteins. RTK = 
receptor tyrosine kinases, LPA = Lisophosphatidic acid, S1P = Sphingosine 1-phosphate, DSS = Dextran 
sulfate sodium, PMA = Phorbol 12-myristate 13-acetate, LPS = Lipopolysaccharide. Dotted arrows 























Chapter 1: Literature review and research proposal – Page 51phosphorylated downstream of the PI3K/AKT and GSK3ȕ signalling pathways, which can 
alter protein function or stability
225,280.
1.3.7.3 Function in embryonic stem cells and development 
In the mouse embryo, Klf5 expression is increased during development and gastrulation, 
reaching maximum levels at e8.5-10.5
281. Accordingly, a homozygous null mutation in Klf5
results in early embryonic lethality (before e8.5) in mice
160. Studies have demonstrated that 
ablation of Klf5 results in a developmental block at the blastocyst stage, as KLF5 is required 
for differentiation of the inner cell mass and trophectoderm, and for suppression of the 
primitive endoderm lineage
160,161.  KLF5 also contributes to the proliferation and self-renewal 
of ESCs. Knock-down of Klf5 by RNAi or complete knock-out by gene targeting have shown 
that loss of KLF5 expression leads to an increase in expression of differentiation markers, 
particularly in the mesoderm/trophoblast lineages
160,208,252. Klf5 knock-out ESCs also show 
reduced proliferation due to G1 cell cycle arrest. Correspondingly, over-expression of KLF5 
increases proliferation of ESCs and prevents their differentiation in response to removal of 
LIF
160. KLF5 promotes these effects in ESCs by directly regulating expression of a number of 
genes which are necessary for maintenance of the ESC pluripotent state
162,163,208,245. The key 
ESC transcription factors, Oct4 and Nanog, are activated by KLF5 and two other members of 
the KLF family, KLF2 and KLF4
162,163,208,245. Concurrent knock-down of these three Klf
members induces differentiation of ESC to a greater extent than that of Klf2, Klf4, or Klf5
alone, suggesting that cooperation of these transcription factors is essential for complete 
maintenance of ESC self-renewal
162,208,245. An independent study demonstrated that Klf5
expression is repressed in ESCs by the homeobox transcription factor HOXA1, which inhibits 
proliferation during retinoic acid-mediated differentiation of ESCs
231. Together these studies 
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maintenance of blocked differentiation. 
1.3.7.4 The role of KLF5 in apoptosis 
As well as promoting proliferation and self-renewal in certain cell types, some studies suggest 
that KLF5 also contributes to cell survival through inhibition of apoptotic pathways. In 
VSMCs and Acute Lymphocytic Leukaemia (ALL) cell lines, KLF5 up-regulates expression 
of the anti-apoptotic Survivin gene
250,282. This process forms a positive regulatory loop as 
Survivin subsequently increases KLF5 expression
282. Correspondingly, small interfering RNA 
(siRNA) knockdown of KLF5 in ALL cell lines with high KLF5 expression sensitises the 
cells to apoptosis induced by chemotherapeutic drugs
250. In vivo studies have shown that 
Klf5
+/- mice have increased apoptosis in vascular lesions, and this may be due to reduced 
KLF5 interaction with the PARP1 protein in VSMCs to inhibit its pro-apoptotic effect
263. A 
recent study utilising a rat model has shown that VSMCs over-expressing KLF5 have 
decreased apoptosis on cardiovascular injury associated with reduced cleavage of Caspase-
3
274. In intestinal epithelial cell lines, RNAi knock-down of KLF5 increases sensitivity to 
Fluorouracil (5-FU) induced apoptosis
248. Interestingly, it was found that this effect is 
independent of p53. Knock-down of KLF5 in this system reduces expression of PIM1 kinase 
which usually acts to phosphorylate the pro-apoptotic protein BAD. Non-phosphorylated 
BAD sequesters inhibitors of apoptosis, and hence reduced phosphorylation promotes 
apoptosis. In breast cancer cell lines siRNA knock-down of KLF5 induces apoptosis through 
reduced expression of the FGF binding protein and subsequent inhibition of the pro-survival 
protein MKP1
235,236.
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protein. KLF5 expression increases in cardiac myocytes treated with Endothelin-1, a peptide 
which causes cells to undergo apoptosis through cardiac hypertrophy
283. Over-expression of 
KLF5 in the TE2 esophageal cancer cell line induces apoptosis through activation of the pro-
apoptotic protein BAX
284.
1.3.7.5 Growth inhibition and differentiation 
In contrast to the growth-promoting and pro-survival role KLF5 plays in a number of different 
cell types, there are relatively few examples where KLF5 acts to decrease cell proliferation 
and induce differentiation. A well-characterised example of this is in differentiation of 
adipose tissue. Klf5 expression is induced in the early stages of differentiation of pre-
adipocyte cell lines. In the 3T3-L1 cell line, over-expression of KLF5 stimulates 
differentiation to adipocytes even without the addition of relevant hormones, whereas 
expression of a dominant-negative form of KLF5 inhibits insulin-induced differentiation
156. In 
vivo studies support this observation, with heterozygous knock-out mice exhibiting decreased 
formation of mature adipose tissue due to reduced differentiation
156. In 3T3-L1 cells it has 
been shown that members of the C/EBP family are key factors in inducing adipocyte 
differentiation. C/EBPȕ and C/EBPį up-regulate expression of KLF5, and these three proteins 
then form complexes to activate expression of Pparg which promotes differentiation. Cebpa
expression is also induced downstream of KLF5 during differentiation of adipose tissue
156.
Although most evidence supports a growth-promoting role for KLF5 in keratinocytes (see 
Section 1.3.7.1 above), epidermal-specific KLF5 over-expression in a transgenic mouse 
model resulted in loss of the epidermal stem cell population and consequently a reduction of 
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285. Mechanistic studies have shown that KLF5 normally 
promotes proliferation in the HaCaT keratinocyte cell line by repressing CDKN2B and 
activating MYC
221,222,243. However, on TGFȕ treatment KLF5 is acetylated and its function 
reversed, resulting in activation of CDKN2B and repression of MYC to inhibit cell growth. 
These studies highlight that the function of KLF5 will depend not only on tissue type, but also 
on the presence of various stimuli which may lead to modifications that alter activity. 
1.3.8 KLF5 in human tumourigenesis 
1.3.8.1 KLF5 as an oncogene 
Consistent with a role for KLF5 as a promoter of proliferation and survival, a number of 
studies have suggested that KLF5 may act as an oncogene in various epithelial tumours 
(Table 1.4). For example, in human cancers of the salivary gland, comparative genome 
hybridisation (CGH) analysis identified amplification of the KLF5 chromosomal region in 
45% of tumours examined
271, and in bladder cancer, enforced expression of KLF5 was shown 
to enhance tumour formation of Tsu-Pr1 bladder cancer cells when injected into severe 
combined immunodeficiency (SCID) mice
251. However, the strongest evidence for KLF5 
acting as an oncogene is in transformation of intestinal epithelial cells leading to colon cancer. 
In primary intestinal cancers with KRAS mutations, KLF5 expression was found to be 
elevated in comparison to normal tissues
286. In support of this observation, functional studies 
showed that knock-down of KLF5 in a KRAS-transformed intestinal epithelial cell line 
reduced cell growth. Enhanced nuclear localisation of KLF5 due to SUMOylation was shown 
to increase anchorage-independent growth of the HCT116 (KRAS D13
+/-) colon cancer cell 
line
217. Interestingly, although KLF5 has a pro-proliferative role in KRAS-transformed 
286

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 1: Literature review and research proposal – Page 56tumours, over-expression of KLF5 in a HRAS-transformed epithelial cell line was reported to 
inhibit colony formation
229. These observations suggest that the status of RAS may alter the 
function of KLF5 in intestinal tumourigenesis, and is consistent with studies which have 
identified KLF5 as a downstream effector of the RAS pathway
233,277,292.
In vivo murine models have provided further evidence supporting an oncogenic role for KLF5 
in intestinal epithelium. Reduced KLF5 levels were detected in a mouse model of colitis-
associated colon cancer; Lysophosphatidic acid receptor 2 (Lpar2) knock-out mice displayed 
lower tumour incidence due to inhibition of intestinal epithelial cell proliferation
287,293.
Although one study by Bateman, et al., showed that Klf5 expression is decreased in Apc
min/+
mice
229, McConnell, et al., demonstrated that haploinsufficiency of Klf5 can rescue the 
intestinal adenoma phenotype seen in these mice
260. Interestingly, it was shown that this effect 
is even greater in mice harbouring combined Apc
min/+ and Kras-V12 mutations, as Klf5
haploinsufficiency reduced tumour formation by 92% in these mice compared with 75% in 
mice transgenic for  Apc
min/+ alone
288. Evidence from these mouse models suggests that 
reduced KLF5 expression acts to decrease tumour formation through down-regulation of 
Ccnd1, Mki67, and also by reducing nuclear Beta-catenin levels
260,288.
In order to target the proliferative effects of KLF5 in colon cancer, studies have been aimed at 
identification of chemical inhibitors of KLF5 expression. ATRA was shown to decrease KLF5
expression in selected colon cancer cell lines and subsequently reduce proliferation
272. More 
recently a screen of almost 1300 small molecule compounds identified 8 inhibitors of KLF5
expression using a reporter construct containing approximately 2 kb of the KLF5 promoter 
upstream of the ATG
294. These included selected PI3K inhibitors and receptor tyrosine kinase 
Chapter 1: Literature review and research proposal – Page 57 inhibitors, and application of 3 of these (Wortmannin, AG17 and AG879) to colorectal cancer 
cell lines decreased KLF5 expression and inhibited proliferation.
1.3.8.2 KLF5 as a tumour suppressor 
Although in most tissues KLF5 is thought to have a pro-proliferative function consistent with 
the evidence for an oncogenic role in colorectal cancer (see Sections 1.3.7.1 and 1.3.8.1), 
there is increasing evidence to suggest that KLF5 may alternatively act as a tumour 
suppressor in selected epithelial malignancies (Table 1.5). The strongest evidence for KLF5 
acting as a tumour suppressor gene is in epithelial tumours from prostate cancer patients and 
in prostate cancer cell lines. KLF5 is commonly deleted or down-regulated in prostate cancer, 
consistent with tumour suppressor function in this tissue
295,296. Deletion mapping using 
primary tumour samples identified a 3 Mb common region of deletion on chromosome 
13q21
296. This region was further narrowed to a 142 kb region using human tumour samples 
(xenografts) and prostate cancer cell lines, with KLF5 being the only complete gene to lie 
within this region
295. Approximately 90% of total samples tested showed decreased KLF5
expression, with hemi- or homozygous deletions in 13q accounting for one third of these
295.
No mutations were found in the coding region of the KLF5 gene. Other studies have shown 
down-regulation of KLF5 expression or activity by excess protein ubiquitination and 
degradation, increased cytoplasmic localisation, and possibly methylation, as global 
demethylation of prostate cancer cell lines led to increased expression of KLF5
206,224,297,298.
Enforced expression of KLF5 in the PC3 prostate cancer cell line, where the KLF5 protein is 
actively degraded, overcame the differentiation block in response to TGFȕ signalling
221.
Duhagon and colleagues recently demonstrated that KLF5 mRNA expression was further 
reduced in  cancer-stem cells of  prostate cell lines and primary prostate tumour samples when  











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 1: Literature review and research proposal – Page 59compared with the remaining blast population, suggesting that decreased KLF5 expression is 
an important event in the initiation of prostate cancer
299.
Although these studies collectively point to tumour suppressor function in the prostate 
epithelium, an independent study has suggested that KLF5 may alternatively have a role in 
promoting metastasis
213. KLF5 was shown to up-regulate expression of the cell-surface 
chemokine receptor CXCR4, enabling migration of cancer cells to areas with high levels of 
the chemoattractant CXCL12 such as that found in the bone microenvironment. KLF5 may 
also play a pro-migratory role in other epithelial tissues such as in esophageal keratinocyte 
cells, where it stimulates expression of the pro-migratory protein ILK
238, or in skeletal muscle 
cells, where it up-regulates expression of MMP9, resulting in degradation of gelatine in 
skeletal muscle cell systems and enhanced migratory activity
242. These conflicting 
observations suggest that KLF5 may have alternate functions in different stages of tumour 
formation, potentially acting as a tumour suppressor which is down-regulated in initiation of 
tumourigenesis but later acting as an oncogene in metastatic transformation.  
There is also substantial evidence for KLF5 acting as a tumour suppressor in breast cancer, 
with 70% of breast cancer cell lines tested showing reduced KLF5 mRNA levels compared to 
the BRF-97T non-neoplastic breast epithelial cell line
301. Mechanisms for this down-
regulation included hemizygous deletion in 43% of cell lines and frequent copy number 
neutral loss of heterozygosity (LOH), but did not include homozygous deletion or promoter 
methylation. One cell line tested also showed a point mutation in the coding sequence of 
KLF5 (resulting in a methionine to valine amino acid change at codon 294) in addition to 
hemizygous deletion. An independent study demonstrated that KLF5 may also be down-
regulated in breast cancer cell lines by excessive protein degradation due to amplification of 
Chapter 1: Literature review and research proposal – Page 60 the ubiquitin ligase WWP1 gene
297. Loss of the 13q21-q22 genomic region, which includes 
KLF5 and 7 other known genes, has been linked to hereditary breast cancer in families with 
BRCA1 and BRCA2-negative breast cancer
300. Functional evidence for KLF5 acting as a 
tumour suppressor in breast cancer was initially provided by Chen, at. al., who demonstrated 
that re-expression of KLF5 in the T47d breast cancer cell line significantly inhibited colony 
formation of these cells
301. More recently, it has been reported that KLF5 can inhibit 
proliferation of ERĮ-positive breast cancer cell lines in response to Estrogen. KLF5 binds to 
ERĮ and reduces its transcriptional activity, providing a potential mechanism for the tumour 
suppressor activity of KLF5 in ERĮ-positive breast cancer
261. Although the majority of 
evidence supports a tumour suppressor role for KLF5 in breast cancer, recent studies have 
demonstrated that it may also have oncogenic potential in this tissue (see Table 1.4). The 
reason for these conflicting observations has not yet been fully elucidated, although it is 
interesting to speculate that expression of ERĮ may influence the function of KLF5 in breast 
cancer, as KLF5 was not able to inhibit proliferation of an ERĮ-negative breast cancer cell 
line in the study mentioned above
261.
1.4 Research proposal 
1.4.1 Retroviral expression cloning using the FDB1 target cell line 
We propose to use retroviral expression cloning to identify novel oncogenes which confer 
factor-independent growth or a block in differentiation of myeloid progenitor cells. The 
properties of the FDB1 cell line make it an ideal target to screen for oncogenes which confer 
the two major types of abnormalities found in myeloid leukaemias, i.e. (i) improved 
proliferation and/or survival (through reduced dependence on growth factors) and (ii) 
suppression of differentiation (see Section 1.2.1). Specific aims are as follows: 
Chapter 1: Literature review and research proposal – Page 61 1. Optimise construction of high quality retroviral complementary DNA (cDNA) 
libraries.
2. Construct and screen a library from a leukaemic source to identify genes which 
effectively suppress differentiation or improve proliferation/survival of the FDB1 cell 
line.
The identification of putative oncogenes based on function will provide valuable insights into 
the normal process of haemopoiesis, and how this may be deregulated in the development of 
AML.
1.4.2 Characterisation of the putative tumour suppressor KLF5 in normal 
myelopoiesis and in AML 
We previously identified Klf5 as a gene whose expression is associated with granulocyte-
macrophage differentiation of the FDB1 cell line model (see Section 1.2). The expression 
profile of Klf5 in this system was similar to that of other genes known to regulate myeloid 
differentiation, and our hypothesis is thus that KLF5 may have a related role as an inducer of 
granulocyte-macrophage differentiation. As a potential novel regulator of myelopoiesis, we 
also hypothesised that KLF5 may be deregulated in AML and hence contribute to disease 
pathogenesis. Thus we propose to characterise the role of KLF5 in normal haemopoiesis and 
in the development of AML. Specific aims are as follows: 
1. Determine KLF5 expression profiles during myeloid differentiation in selected cell 
lines and primary cell systems. 
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a. Characterise KLF5 mRNA expression during granulocyte-macrophage 
differentiation.
b. Assess whether KLF5 expression is associated specifically with the 
granulocyte or monocyte lineages. 
2. Analyse KLF5 function in normal haemopoiesis. This will be achieved by: 
a. Retroviral over-expression of KLF5 in haemopoietic systems. 
b. Knock-down of KLF5 in systems where its expression is shown to increase 
during differentiation. 
3. Assess KLF5 expression in leukaemia cell lines and in primary AML patient samples. 
a. Compare KLF5 mRNA expression in a panel of leukaemia cell lines, primary 
AML samples, and normal bone marrow controls. 
b. Compare these findings with results of bioinformatic analysis of published 
microarray data using larger patient cohorts. 
4. Examine methylation of the KLF5 gene as a mechanism for deregulation in AML. 
a. Perform quantitative methylation analysis of the KLF5 gene using samples 
described in 3a above. 
b. Determine whether demethylation of the KLF5 gene is associated with 
reactivation of expression. 
5. Determine if re-expression of KLF5 in selected leukaemia cell lines is sufficient to 
overcome the leukaemic differentiation block. 
Collectively these studies will define KLF5 as a regulator of myeloid growth and 
differentiation and will establish the potential for KLF5 to act as a tumour suppressor in 
AML.Chapter 2 - Materials and methods 
2.1 Materials 
Supplier Reagent
American Tissue Culture 
Collection - USA 
32D cell line 
FDC-P1 cell line 
 HEK-293T  cell  line 
 HL-60  cell  line 
  K562 cell line 
  M1 cell line 
  MCF7 cell line 
 MOLM-13  cell  line 
  MV4;11 cell line 
  U937 cell line 
Applied Biosystems - USA  BigDye Terminator v3.1 sequencing reagent 
BDH Chemicals - USA  DEPEX mounting medium 
  Formaldehyde 40% solution 
Beckman Coulter - USA  Anti-CD14-PE antibody (human) 
  Matched isotype control antibody 
Biolegend - USA  Anti-CD15-PE antibody (human) 
  Anti-CD34-PE antibody (human) 
  Matched isotype control antibodies 
Biotium - USA  EvaGreen fluorescent nucleic acid dye 
eBioscience - USA  1x RBC lysis buffer (red blood cell lysis buffer) 
  Anti-CD11b(Mac-1)-PE antibody (human/murine) 
 Anti-CD115(c-Fms)-PE  antibody  (murine) 
  Anti-CD117(c-Kit)-PE antibody (murine) 
  Anti-Ly6G(Gr-1)-PE antibody (murine) 
  Matched isotype control antibodies 
GE Healthcare Life Sciences 
- USA 
Ficoll-Paque PLUS 
Chapter 2: Materials and methods – Page 64 Geneworks - Australia  Oligonucleotide primers 
German Collection of 
Microorganisms and Cell 
Cultures - Germany 
KG-1 cell line 
THP-1 cell line 
Invitrogen - USA  0.5-10 Kb RNA ladder 
  1 Kb Plus DNA ladder 
 Opti-MEM 
  T4 DNA Ligase kit 
 Trizol  solution 
  Trypan Blue solution 
Kirin Pharmaceuticals - Japan  SCF (human) 
Merck Australia - Australia  Ethanol, absolute 
 Isopropanol 
Miltenyi Biotec - Germany  MACS Human CD34 MicroBead kit 
New England Biolabs - USA  EcoRI restriction endonuclease 
  Sfi1 restriction endonuclease 
  XhoI restriction endonuclease 
 Restriction  endonuclease  buffers 
Open Biosystems - USA  I.M.A.G.E. Consortium clones 
  pSM2c shRNAmir constructs 
Peprotech G-CSF  (human) 
 IL-6  (human) 
 M-CSF  (human) 
Qiagen - USA  HiSpeed Plasmid Midi kit  
  QIAamp DNA Blood and Cell Culture Mini kit  
  QIAprep Spin Miniprep kit 
  QIAquick Gel Extraction kit  
  QIAquick PCR Purification kit  
  QuantiTect Rev. Transcription kit 
  RNeasy Micro kit  
Roche - Australia  FastStart Taq reagents 
SAFC Biosciences - USA  1x Trypsin-EDTA solution (0.25% Trypsin, 0.2% EDTA) 
Sigma-Aldrich - USA  1x Phosphate buffered saline (PBS) 
  1x TAE buffer (tris-acetate-EDTA) 
 5-aza-2-deoxycytidine 
 5-azacytidine 
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 Agarose 
  Amphotericin B (Fungizone) 
 Ampicillin 
 ATRA  (All-trans retinoic acid) 
  Bovine serum albumin 
 Chloramphenicol 
 Dimethyl  sulfoxide 
  DMEM (Dulbecco’s Modified Eagle’s Medium with L-
glutamine, NaHCO3, 1000 mg/L glucose and pyridoxine) 
 Ethidium  bromide 
  Foetal calf serum (FCS) lot #3A0561 
 Fluorouracil 
 Glucose 
  IMDM (Iscove’s Modified Dulbecco’s Medium with L-
glutamine and 25 mM HEPES) 
  L-glutamine-penicillin-streptomycin solution for cell 
culture 
  Leukocyte peroxidase (Myeloperoxidase) kit 
 Luria  Broth 
  MEM (Eagle’s Minimum Essential Medium with L-
glutamine and NaHCO3)
  MOPS buffer (3-(N-morpholino)propanesulfonic acid) 
 PMA  (12-O-Tetradecanoylphorbol-13-acetate) 
 Polybrene 
 Propidium  iodide 
 Puromycin 
 Ribonuclease  A 
  RPMI (Roswell Park Memorial Institute medium with L-
glutamine and NaHCO3)
 Sodium  acetate 
 Sodium  azide 
 Triton  X-100 
StemCell Technologies - 
Canada
Methocult incomplete medium for murine cells (M3231) 
Veterinary Services of 
Australia - Australia 
Isofluorane inhalation anaesthetic 
Chapter 2: Materials and methods – Page 66 2.2 Nucleic acid protocols 
2.2.1 Production, isolation and analysis of DNA samples 
Plasmid DNA - Chemically competent JM109 Escherichia coli cells were prepared by D. 
Salerno according to the method described by Hanahan, et al.
310. For transformation, 5 Pl of 
ligation product or 10 ng of plasmid was added to 200 Pl of cells and mixed gently. The cells 
were incubated on ice for 30 mins then heat shocked at 42qC for 1 min and returned to ice 
briefly. Transformed cells were then plated onto Luria Broth/agar plates containing 
appropriate antibiotics and left at 37qC overnight
311. Potential clones were selected using 
ampicillin resistance (100 Pg/ml) or chloramphenicol resistance (25 Pg/ml). Overnight 
bacterial cultures of 2 mls and 50 mls Luria Broth (with appropriate antibiotics) were 
prepared from single colonies and DNA isolated according to the Qiagen Miniprep and 
Midiprep protocols respectively. Gel extraction and DNA purification were performed 
according to protocols contained in the Qiagen QIAquick Gel Extraction or PCR Purification 
kits. Where necessary, ethanol precipitation of DNA was undertaken following addition of 
sodium acetate (adapted from Sambrook, et al.
311). Plasmid DNA was stored at -20qC.
Genomic DNA - Genomic DNA was isolated using either the Qiagen Blood and Cell Culture 
Mini kit or the Invitrogen Trizol protocol according to the manufacturer’s instructions and 
stored at 4qC.
Chapter 2: Materials and methods – Page 67 DNA Analysis - DNA samples were analysed by electrophoresis using 0.5-2% agarose in 1x 
TAE buffer according to the protocol outlined by Sambrook, et al.
311. The Invitrogen 1 Kb 
Plus DNA ladder was used in determining DNA size. Agarose gels were stained for 1 min in 
2.5 Pg/ml ethidium bromide solution, then destained for 1 min in reverse osmosis quality 
water. Stained gels were visualised and photographed using an Integrated Sciences UVItec 
gel documentation system and UVIPhotoMW1 software. An Integrated Sciences UVP 
transilluminator was utilised for gel excision. Quantitation of DNA was performed using a 
NanoDrop Spectrophotometer. Sequencing of DNA was performed by the Institute of 
Medical and Veterinary Sciences (IMVS) Molecular Pathology Sequencing Division (SA 
Pathology). Sequencing reactions were set up according to protocols specified by the 
Sequencing Division using BigDye Terminator v3.1 sequencing reagents. 
2.2.2 RNA isolation and analysis, and cDNA production 
Total RNA was isolated using either the Qiagen RNEasy Micro kit or the Invitrogen Trizol 
protocol according to the manufacturer’s instructions. Quantitation of RNA was performed 
using a NanoDrop Spectrophotometer. RNA was analysed by electrophoresis on a denaturing 
agarose-formaldehyde gel according to the protocol outlined in Fritsch, et al. (MOPS buffer 
method)
312. The Invitrogen 0.5-10 Kb RNA ladder was used for RNA size determination. 
RNA gels were visualised on a gel documentation system as described above for DNA. RNA 
was stored in aliquots at -80qC. For production of cDNA, between 200-1000 ng of RNA was 
DNAse treated and reverse-transcribed using the Qiagen QuantiTect Rev. Transcription kit as 
per the manufacturer’s protocol. cDNA samples were stored at -20qC.
Chapter 2: Materials and methods – Page 68 2.2.3 Polymerase chain reactions 
Polymerase chain reaction (PCR) detection of KLF5 isoforms from cDNA - PCR was 
performed using the Roche FastStart Taq PCR kit according the manufacturer’s protocols 
with the following parameters: 2.5 Pl cDNA template, primer annealing temperature of 50qC,
and 40 amplification cycles. PCR was performed on a Corbett Gradient Palm-Cycler. 5 Pl of 
each PCR reaction was separated and visualised using gel electrophoresis. Oligonucleotide 
primer sequences are shown in Table 2.1. 
Quantitative reverse transcription PCR (Q-PCR) - Q-PCR reactions were carried out using 
the following conditions per reaction: 1.25 U/Pl Roche FastStart Taq, 1x Taq Buffer (without 
magnesium), 2.5 mM magnesium chloride, 200 PM each dNTP, 1x EvaGreen fluorescent 
nucleic acid dye, 450 nM each forward and reverse PCR primers, and 1 Pl cDNA template. 
Q-PCR was performed on a Corbett RotorGene 6000 instrument with the following cycling 
conditions: 95qC for 10 mins (1 cycle), 95qC for 25 secs - 60qC for 25 secs - 72qC for 30 secs 
(40 cycles – acquiring to green), 72qC for 1 min (1 cycle). Products of Q-PCR were analysed 
by melt curve analysis as follows: Increments of 1qC for 5 secs each from 72qC-99qC,
acquiring to green. For each sample duplicate reactions were performed for detection of the 
gene of interest and a control gene (Beta-actin, ACTB). QGene software was used for analysis 
of relative mRNA expression levels
313. Oligonucleotide primer sequences are shown in Table 
2.1.

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 2: Materials and methods – Page 702.2.4 Plasmids and expression constructs 
Constitutive retroviral expression constructs - cDNAs were cloned into the bicistronic 
MSCV-IRES-eGFP (MIG) vector
320 (kind gift of Dr. Elio Vanin, St Jude Childrens Research 
Hopsital, Memphis USA). Murine Klf5 had previously been cloned into this vector. Human 
KLF5 cDNA was purchased as an I.M.A.G.E. Consortium clone in the pOTB7 vector (clone 
ID 5454169). Both the MIG vector and pOTB7-KLF5 plasmid were digested using EcoRI and 
XhoI restriction endonucleases according to the manufacturer’s instructions. The products of 
digestion were separated on a 1% agarose gel, then MIG and KLF5 DNA bands were excised 
and isolated using the Qiagen QIAquick Gel Extraction kit. Ligations were undertaken in 
accordance with the Invitrogen T4 DNA Ligase protocol and products were transformed into 
chemically competent JM109 Escherichia coli cells. A selection of ampicillin-resistant clones 
were amplified and sequenced to ensure correct generation of the MIG-KLF5 construct. 
Sequencing oligonucleotide primers for the MIG construct are shown in Table 2.1. cDNA 
sequences for the MIG-Klf5 (murine) and MIG-KLF5 (human) constructs aligned with the 
nucleotide sequences NM_009769 and NM_001730 respectively (National Center for 
Biotechnology Information (NCBI) database
321).
RNAi knock-down – Small hairpin RNA (shRNA) cassettes were expressed constitutively 
using the retroviral constructs pMSCV-'LTR-H1 (pM'H) or p-SHAG MAGIC 2 (pSM2c). 
pM'H is based on the pRETRO-SUPER vector
322, and shRNA cassettes had previously been 
designed and cloned into this plasmid. These included 6 sequences predicted to target murine 
Klf5 (pM'H K1-K6) and 2 control shRNAs (1 non-targeting (NT) sequence and 1 targeting 
eGFP). pSM2c constructs were purchased from Open Biosystems’ shRNAmir library 
collection (microRNA-based shRNA design)
323. These included 3 sequences predicted to 
Chapter 2: Materials and methods – Page 71 target murine Klf5 (pSM2c K1-K3) and 2 control shRNAs (1 non-targeting (NT) sequence 
and 1 eGFP-targeting sequence). Details of all shRNA constructs are shown in Table 2.2. 
Both pM'H and pSM2c constructs contained the Pac gene sequence for selection using 
puromycin.
Retroviral cDNA expression libraries - The construction of retroviral cDNA expression 
libraries is described in Chapter 3, Section 3.2.1. cDNA for human CD4 had previously been 
cloned into the MIG-Sfi1 vector (MIG-Sfi1-CD4).
Other constructs – The BG717510 expressed sequence tage (EST) clone was purchased as an 
I.M.A.G.E. consortium clone in the pBluescriptR vector (clone ID 4821765). T3 and T7 
oligonucleotide primers were used for sequencing (see Table 2.1). 
2.3 Cell culture protocols 
2.3.1 Culture medium and supplements 
All cells were cultured in medium supplemented with 2 mM L-glutamine, 100 U/ml penicillin 
and 100 Pg/ml streptomycin. Cultures were maintained in a Sanyo humidified incubator with 
5% CO2 at 37qC. Recombinant murine IL-3 and murine GM-CSF were produced from 
baculoviral vectors supplied by Dr Andrew Hapel (John Curtin School of Medical Research, 
Canberra, Australia). Recombinant human SCF was a kind gift of Dr Ian Lewis. All other 
recombinant cytokines were purchased in lyophilised form and stocks prepared using 0.2 PM
sterile  filtered 0.5% bovine  serum albumin solution.  Cytokines were aliquoted and stored at 
-80qC.













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 2: Materials and methods – Page 732.3.2 Cell lines 
Murine cell lines - FDB1 cells
128 and FDB1-ITD cells
326 were maintained in IMDM 
supplemented with 10% foetal calf serum (FCS) and 500 bone marrow units (BMU)/ml 
murine IL-3. FDC-P1 cells were culture in DMEM supplemented with 7.5% FCS and 80 
BMU/ml murine GM-CSF. 32D cells were maintained in RPMI medium with 10% FCS and 
500 BMU/ml murine IL-3, and cells were passaged using sterile cell scrapers. Leukaemic M1 
cells were maintained in RPMI supplemented with 10% FCS.  
Human cell lines - The leukaemia cell lines HL-60, KG-1, MOLM-13, MV4;11, THP-1 and 
U937 were cultured in RPMI supplemented with 10% FCS. The CML cell line K562 was 
maintained in IMDM supplemented with 10% FCS. The breast cancer cell line MCF7 was 
cultured in MEM supplemented with 10% FCS, and was passaged using a 1x Trypsin-EDTA 
solution. Fibroblastic HEK-293T cells were cultured in DMEM supplemented with 7.5% 
FCS, and were passaged as for MCF7 cells above.
Cell line methods - For centrifugation, cells were spun at 1200 rpm for 5 mins in an Eppindorf 
5810R Centrifuge. Cells were frozen at densities of up to 5x10
6/ml in FCS supplemented with 
10% dimethyl sulfoxide using an isopropanol cycler. Cell line stocks were stored in liquid 
nitrogen. Aliquots of cells were thawed in a 37qC water bath then added to complete medium 
in a 1 in 10 dilution.  Cells were centrifuged then resuspended in complete medium for 
culture. For selection and maintenance of cells expressing the Pac gene, puromycin was 
added to culture medium at 1 Pg/ml. 
Chapter 2: Materials and methods – Page 74 2.3.3 Murine bone marrow cells 
C57BL/6 female mice (8-12 weeks) were purchased through and housed in the IMVS 
Veterinary Services Division (SA Pathology) in a conventional holding type. Mice were 
treated with 150 mg/kg fluorouracil by intraperitoneal injection to enrich for haemopoietic 
progenitors. After 4 days mice were humanely killed using a lethal dose of isofluorane 
inhalation anaesthetic followed by cervical dislocation. Bone marrow cells were harvested 
then cultured in IMDM supplemented with 15% FCS and 50 ng/ml human SCF, 10 ng/ml 
human IL-6 and 500 BMU/ml murine IL-3 unless otherwise stated. For centrifugation, cells 
were spun at 1500 rpm for 10 mins in an Eppindorf 5810R Centrifuge. 
2.3.4 Cell differentiation assays 
FDB1 - Cells were washed 3 times in 1x phosphate buffered saline (PBS) to remove IL-3, 
then seeded at 1x10
5/ml in culture medium containing 500 BMU/ml murine GM-CSF for 
differentiation to granulocytes and macrophages over 5 days. 
32D - Cells were washed 3 times in 1x PBS to remove IL-3, then seeded at 1x10
5/ml in 
culture medium containing 50 ng/ml human G-CSF for differentiation to granulocytes over 7 
days.
U937 - Cells were seeded at 1x10
5/ml in complete culture medium. For differentiation to 
neutrophils, cultures were treated with 0.3 PM ATRA for 4 days; and for differentiation to 
monocytes, cultures were treated with 5 nM PMA for 4 days. ATRA was dissolved in ethanol 
Chapter 2: Materials and methods – Page 75 to form a stock solution of 10 mM which was stored at -80qC for up to 1 month. PMA was 
dissolved in ethanol to form a stock solution of 150 PM which was stored at -20qC.
Mouse bone marrow - Bone marrow was harvested from fluorouracil treated C57BL/6 female 
mice then treated with 1x RBC lysis buffer according to manufacturer’s instructions. Cells 
were seeded at 3x10
5/ml in medium containing 100 ng/ml human M-CSF for differentiation 
to macrophages over 7 days. 
2.3.5 Demethylation of leukaemia cell lines 
Selected human leukaemia cell lines were seeded at 5x10
5 cells/ml in complete culture 
medium and treated with 4 PM 5-azacytidine or 5 PM 5-aza-2-deoxycytidine for 48 hrs. Cells 
were then harvested for isolation of RNA and production of cDNA. Q-PCR was performed 
for detection of KLF5 reactivation. Solutions of 5-azacytidine and 5-aza-2-deoxycytidine 
were made up fresh on the day of use in 1x PBS and were 0.2 Pm sterile filtered prior to use 
in assays.
2.3.6 Viral transduction of cells 
Production of viral supernatant - The pEQ-Eco packaging vector was used for production of 
murine retrovirus, and the pEQ-PAM3 vector was used for production of human retrovirus
327
(kind gift of Dr. Elio Vanin, St Jude Childrens Research Hopsital, Memphis USA). Viral 
supernatant was generated using HEK-293T cells. Cells were seeded at 1x10
6 cells total in 5 
mls of medium in a 25cm
2 flask. 24 hrs after seeding cells were transfected with constructs of 
interest using Invitrogen’s Lipofectamine 2000 according to the manufacturer’s protocol. 
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added to 500 Pl of Opti-MEM medium. 20 Pl of Lipofectamine 2000 reagent was added to 
500 Pl of Opti-MEM medium and the mixtures were incubated separately for 10-15 mins at 
room temperature. The mixtures were combined and incubated for a further 1 hr at room 
temperature before adding to cells. 24 hrs post-transfection the medium was replaced with 5 
mls complete culture medium for the intended target cells. Viral supernatant was collected 
after 24 hrs, and 5 mls of fresh culture medium was added for collection of a second volume 
of viral supernatant at 48 hrs. The supernatants were combined and stored at -80qC.
Transduction - Viral supernatant was thawed in a water bath at 37qC prior to use. Cells were 
transduced at a maximum cell density of 1x10
6/ml of supernatant for cell lines and 1x10
8/ml 
for mouse bone marrow. Cells were suspended in neat viral supernatant supplemented with 1 
Pg/ml polybrene and 2.5 Pg/ml amphotericin B (Fungizone) then aliquoted into 6-well plates 
(2-5 mls total per well). Plates were spun at 1800 rpm for 1 hr at 37qC in an Eppindorf 5810R 
Centrifuge then transferred to an incubator for 5 hrs. Following transduction fresh culture 
medium was added to the wells as needed and cells were incubated for at least a further 18 hrs 
prior to use in assays.
2.3.7 Cellular assays 
Cell and viability counts - Cells were mixed with Trypan Blue solution in a 1:1 ratio then 
counted using a haemocytometer (at least 100 total live and dead cells per sample). 
Morphology - Up to 30,000 cells were centrifuged onto slides using a Thermo Shandon 
Cytospin 4 cytocentrifuge at 500 rpm for 5 mins. Slides were air-dried then Wright-Giemsa 
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DEPEX mounting medium and cover-slipped for analysis. Photographs were taken using an 
Olympus BX51 microscope and DP70 camera system at 200x or 400x original 
magnifications. Morphology was scored by counting a minimum of 200 cells per slide. 
Surface marker expression analysis - For staining, at least 5,000 cells per sample were 
suspended in 50 Pl Fluorescence-activated cell sorting (FACS) wash solution (5% FCS and 
0.1% sodium azide in 1x PBS) containing antibody (at the manufacturer’s recommended 
concentration) then incubated for 30 mins on ice without exposure to light. Cells were washed 
once in FACS wash then fixed in FACS fix solution (2% glucose, 1% formaldehyde and 
0.02% sodium azide in 1x PBS) and stored at 4qC prior to flow cytometric analysis.  
Myeloperoxidase enzyme activity - Up to 30,000 cells were centrifuged onto slides using a 
Thermo Shandon Cytospin 4 cytocentrifuge at 500 rpm for 5 mins. Slides were treated using 
the Sigma-Aldrich Leukocyte peroxidase (Myeloperoxidase) kit according to the 
manufacturer’s instructions (Hanker-Yates method
328). Slides were mounted using DEPEX 
mounting medium and cover-slipped for analysis. Photographs were taken using an Olympus 
BX51 microscope and DP70 camera system at 200x original magnifications. 
Myeloperoxidase activity was scored by counting a minimum of 200 cells per slide. 
Cell cycle analysis - A minimum of 10,000 cells were suspended in 300 Pl cold 1x PBS. Ice 
cold ethanol was then added drop-wise while vortexing. Cells were fixed overnight at 4qC.
For staining, cells were suspended in 500 Pl propidium iodide staining solution (40 Pg/ml 
propidium iodide, 100 Pg/ml Ribonuclease A and 0.1% Triton X-100 in 1x PBS) and 
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4 hrs of staining for propidium iodide fluorescence. 
Colony formation - Methylcellulose colony forming assays were performed using Methocult 
incomplete medium for murine cells according to the manufacturer’s protocol. Cells were 
seeded at densities as stated in results chapters in triplicate plates for each condition. Colonies 
greater than 40 cells in size were counted at Day 7 post-seeding. Representative photographs 
for colony morphology were taken using an Olympus CK2 microscope and DP11 camera 
system at an original magnification of 100x. 
2.3.8 Flow cytometry and Fluorescence-activated cell sorting 
Flow cytometric analyses were performed using the Beckman Coulter analysers FC500 and 
XL-MCS. For FACS, cells expressing the construct of interest were centrifuged then 
resuspended in complete medium diluted 1 in 4 with medium containing no supplements. 
FACS was performed by the IMVS Flow Cytometry Division using a Beckman Coulter 
ALTRA or Becton-Dickinson ARIA cell sorter. Cells were resuspended in complete medium 
immediately following sorting. 
2.4 Analysis of patient samples 
2.4.1 AML panel 
AML samples - A panel of 30 de novo AML patient samples was assembled using bone 
marrow mononuclear cell (BMMNC) samples taken at diagnosis from the Queen Elizabeth 
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thawed at 37qC then diluted 1 in 10 with IMDM + 10% FCS (drop-wise addition with regular 
mixing). Previous studies have shown that this freeze-thaw process results in AML samples 
containing 80-100% blasts regardless of initial blast count at diagnosis
329. Following dilution, 
thawed samples were left at room temperature for 10-15 mins before resuspension in IMDM 
+ 10% FCS. Samples were then analysed using various cellular assays or lysed in Trizol for 
production of genomic DNA and total RNA. Genomic DNA was stored at 4qC, RNA was 
stored in aliquots at -80qC, and excess vials of cells were stored in liquid nitrogen. Clinical 
information relevant to the AML cohort was compiled through the use of the South Australian 
Open Architecture Clinical Information System (OACIS). Samples were screened for 
mutations in CEBPA, FLT3, and NPM1 by the Therapeutic Product Facility, IMVS, Adelaide 
AUSTRALIA. 
Normal controls - Normal bone marrow samples were obtained using an approved collection 
process through the Royal Adelaide Hospital, Adelaide AUSTRALIA. Samples were 
processed on the day of collection. Bone marrow was diluted 1 in 2 with 1x PBS then 
mononuclear cells were extracted using Ficoll density gradient centrifugation (according to 
manufacturer’s instructions). For total BMMNC samples, cells were lysed in Trizol at this 
stage for collection of RNA and DNA. Excess cells were frozen and stored in liquid nitrogen. 
For isolation of CD34
+ progenitor cells, BMMNC were sorted using the Miltenyi Biotec 
MACS Human CD34 MicroBead kit according to the manufacturer’s protocol. Isolated cells 
were stained for purity using anti-CD34-PE and matched isotype control antibodies, and 
CD34
+ and CD34
- fractions were then lysed in Trizol for RNA and DNA extraction. A total of 
4 normal BMMNC and 5 normal bone marrow CD34
+ samples were collected for use as 
controls.
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Genomic DNA samples were analysed for methylation by the Australian Genome Research 
Facility (AGRF), Brisbane AUSTRALIA. The genomic region investigated encompassed the 
KLF5 proximal promoter, exon 1, intron 1 and exon 2 (genomic coordinates chr13:72521648-
72526071 of the Mar.2006 (NCBI36/hg18) assembly – International Human Genome 
Sequencing Consortium). The design of amplicons for methylation analysis (and relevant 
oligonucleotide primer pairs) was accomplished with the aid of Sequenom EpiDesigner 
Software (see Table 2.3 for details). Between 0.2-1.0 Pg of genomic DNA was sent to the 
AGRF for quantitative methylation analysis using a matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry-based system 
(Sequenom EpiTYPER using the MassARRAY system)
330. The standard deviation of 
quantitation using EpiTYPER is 5%
331. MultiExperiment Viewer v4.5.1 was utilised for 
generation of heat maps and hierarchical cluster analysis
332. The University of California, 
Santa Cruz (UCSC) Genome Browser was utilised for bioinformatic analysis of the KLF5 
region assessed for methylation
333,334.
2.5 General 
2.5.1 Ethical approval 
All laboratory work was carried out in PC2 approved facilities with approval from the Office 
of the Gene Technology Regulator, AUSTRALIA (certificate numbers PC2NLRD30/2007 
and NLRD1144/2003). Studies involving mice were conducted using existing ethical 
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approval from the Central Northern Adelaide Health Service Animal Ethics Committee, 
Adelaide AUSTRALIA (approval number 103/07). For compilation and use of the panel of 
human AML tissue samples, ethical approval was sought and obtained from the following 
institutes and committees in Adelaide AUSTRALIA: Central Northern Adelaide Health 
Service Human Ethics Committee (approval number 2007072), Royal Adelaide Hospital 
Research Ethics Committee (approval number 070604), and the Children, Women’s and 
Youth Health Service Women’s and Children’s Hospital Human Research Ethics Committee 
(approval number REC1927/2/2010). Approval was granted for use of archived AML 
samples, freshly collected AML samples with appropriate consent, and for use of normal bone 
marrow samples obtained with consent. Approval to access clinical information for patient 
samples through the OACIS Healthcare System was obtained for each of the institutes listed 
above.
2.5.2 Statistical analysis 
Unless otherwise stated, all error bars in figures indicate standard error of the mean of 
independent experiments. Probability and statistical significance were analysed using the two-
tailed student t-test.Chapter 3 – Retroviral expression cloning for 
detection of leukaemic oncogenes. 
3.1 Introduction 
Retroviral expression cloning is a powerful strategy developed in the mid-1990s for the 
identification of genes based on their ability to confer a specific phenotype in a target cell 
line
335-338. The approach is similar to other plasmid-based expression cloning methods as it 
involves the cloning of expressed cDNAs in an experimental cell-based system of interest and 
subsequent selection of clones displaying a specific phenotype. Briefly, the retroviral 
expression cloning approach (Figure 3.1) involves cloning of expressed cDNAs from a source 
cell population (e.g. a leukaemia cell line) into retroviral expression vectors. These vectors 
produce viruses which are unable to replicate themselves due to deletion of the Gag-Pol and 
Env gene sequences. The library is introduced into packaging cell lines, which provide the 
required retroviral proteins to generate infections retroviruses
339,340. The viral stock generated 
is used to transduce a target cell population, where the cDNA of interest is integrated into the 
host genome and expressed from retroviral promoter sequences. Infected target cells are 
subsequently selected for a specific phenotype, and the integrated gene is recovered for 
analysis. Retroviral expression cloning displays several advantages over conventional 
plasmid-based functional screening methods. The most important is delivery of cDNA 
constucts into a wide variety of biologically relevant target cell lines (e.g. haemopoietic cells). 
The limited number of proviral integrations per cell facilitates identification of the causative 
gene of interest, and stable expression of cDNAs following viral integration enables the use of 
a wide variety of functional assays for detection of relevant genes
341.




















Figure 3.1: Retroviral expression cloning method. cDNA is produced from a ‘source’ population then 
cloned into retroviral vectors which lack the necessary Gag-Pol and Env viral protein sequences for 
replication. The resulting plasmids are cotransfected with a packaging plasmid into an intermediate cell line 
which is used to create live retroviruses. The viral supernatant is then used to infect the ‘target’ cell 
population, and the construct is integrated into the host genome and expressed. Infected cells are selected for 
the desired functional phenotype, and the cDNA expressed in the particular clonal population of interest is 
recovered for further characteristion. LTR = long terminal repeat (for retroviral integration and expression).
Chapter 3: Retroviral expression cloning for detection of leukaemic oncogenes – Page 85Early studies in which libraries generated from haemopoietic cell lines were screened 
demonstrated the feasibility of the retroviral expression cloning method, with isolation of both 
known oncogenes (RAF1, ETS2,  and LCK), as well as novel genes with oncogenic potential 
(Rho-related guanine nucleotide exchange factors), based on their ability to transform 
fibroblastic NIH-3T3 cells
337. More relevant haemopoietic target cell lines have also been 
successfully used for detection of genes involved in leukaemogenesis. For example, the 
murine haemopoietic cell line, FDC-P1, has been utilised to detect genes conferring factor 
independent growth
335, and the leukaemic M1 cell line has been utilised to detect genes which 
suppress differentiation in response to IL-6
125,342. Mourtada-Maarabouni, et al. performed a 
screen utilising mouse thymoma W7.2 cells treated with dexamethasone and Ȗ-irradiation,
which allowed identification of genes involved in apoptosis
127,343.
Over the last two decades, cDNA library construction methods have advanced considerably, 
allowing for the generation of high-quality, normalised libraries containing a high proportion 
of full-length cDNAs
344. These newer methods may now aid in the discovery of novel 
oncogenes which were previously difficult to detect using expression cloning approaches due 
to low transcript frequency or long transcript length. We sought to utilise improved methods 
for cDNA library construction to generate high-quality retroviral cDNA libraries from 
leukaemic sources. 
In previous studies, oncogenes have been successfully isolated by screening cDNA libraries 
from both non-tumourigenic haemopoietic cell lines such as the murine B6SUta and FDC-P1 
cell lines
125,337,343, and also from leukaemia cell lines such as the T-cell leukaemia Jurkat and 
the myeloid leukaemia HL-60 cell lines
345,346. We selected the M1 murine leukaemia cell line 
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independent cell line with an immature myeloblast-like morphology. It was established in
vitro from a spontaneous myeloid leukaemia of SL strain mice
347, and can be induced to 
undergo terminal macrophage differentiation through addition of cytokines such as LIF, IL-6 
and Oncostatin M
348-350. Interestingly, these particular properties of M1 have led to its use as a 
target cell line in the identification of oncogenes such as the differentiation suppressor 
SOCS1
125, although thus far there have been no reports of its use as a source of library 
material. The karyotype of M1 is atypical, with the majority of clones examined exhibiting a 
hypodiploid karyotype
351. However the particular genetic lesions responsible for either the 
factor-independence or suppressed differentiation of the cell line remain unknown. In 
selecting a target cell line in which to screen the M1 library we considered that a cell line 
which is normally factor-dependent, and also capable of differentiation, would be required. 
The properties of the FDB1 cell line (see Chapter 1, Section 1.2.1) make it an ideal target cell 
population for detection of oncogenes present in the M1 leukaemia library which confer 
factor-independence or a block in differentiation.  
This chapter describes the construction of a retroviral cDNA library from murine M1 
leukaemia cells, assessment of the FDB1 cell line system as a target population for detection 
of oncogenes using expression cloning methods, and functional screening of the M1 library 
for genes which confer factor-independent growth of myeloid cells. 
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3.2.1 M1 library construction 
3.2.1.1 Outline 
For cDNA library construction, we chose to utilise the Clontech SMART Library 
Construction kit in combination with a size fractionation protocol (Figure 3.2). The SMART 
protocol optimises production of full-length cDNA at the 3` end using a modified oligo(dT) 
primer (CDSIII) for first strand reverse transcription. Powerscript reverse transcriptase adds 
several additional ‘C’ nucleotides when reaching the end of a transcript. A modified 
oligonucleotide (SMART IV) is designed to hybridise to the poly-C tail for second strand 
cDNA extension, thereby enhancing the production of full-length cDNA at the 5` end of 
mRNA transcripts
352,353. We have incorporated a size fractionation protocol following this 
step to prevent bias towards amplification and cloning of small cDNA
354. Double-stranded 
cDNA is separated into different size fractions using gel electrophoresis, and these fractions 
are handled independently in subsequent steps. Each cDNA fraction is amplified by PCR 
using the SMART oligonucleotide primers, which produce non-identical Sfi1A and Sfi1B 
sites on either end of the resulting cDNA for directional cloning. We used a modified form of 
the bicistronic MSCV-IRES-eGFP retroviral expression construct
320 adapted to incorporate 
two non-identical Sfi1 restriction sequences in the multiple cloning site (MIG-Sfi1, D. 
Salerno, Figure 3.3). Following Sfi1 digestion, cDNA from each size fraction is ligated to the 
Sfi1-modified vector then transformed into bacteria for production of the cDNA library.
Chapter 3: Retroviral expression cloning for detection of leukaemic oncogenes – Page 88 Figure 3.2: Library construction method. cDNAs are produced using the SMART SfiI-modified 
oligonucleotide primers. Reverse transcription of messenger RNAs produces a poly-C tail at the 3` end of the 
first strand. The second strand primer is specific to this poly-C tail enabling production of full-length cDNAs. 
This is followed with size fractionation using gel electrophoresis, then amplification of each fraction using 
PCR. cDNA products are digested with Sfi1 and ligated to an appropriate SfiI-modified vector prior to 
bacterial transformation for production of the cDNA library. The aim is for a library complexity of >1x106
independent clones. Figure is modified from the Clontech SMART cDNA Library Construction kit manual.
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                                          NOTE:   
   This figure is included on page 89 of the print copy of  
     the thesis held in the University of Adelaide Library.Figure 3.3: Vector map of the Sfi1-modified MSCV-IRES-eGFP retroviral expression 
construct (MIG-Sfi1). The cDNA of interest is cloned using non-identical Sfi1 restriction sites. 
Mouse stem cell virus (MSCV) long terminal repeat (LTR) sequences promote integration into 
the host genome and expression of the transcript. Enhanced green fluorescence protein (eGFP) is 
coexpressed with the cDNA of interest from a single transcript via an internal ribosome entry site 
(IRES) allowing selection of transduced cells. Unique restriction sites are shown. Note that the 
MIG-Sfi1 construct was initially cloned to contain an eGFP cassette sequence between the Sfi1 
restriction sites. AmpR = ampicillin resistance for plasmid production in bacteria. Note that sizes 
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For construction of the M1 library, first strand cDNA synthesis was performed on 1 Pg of M1 
total RNA using Powerscript reverse transcriptase as described in the SMART Library kit 
protocol. Double-stranded cDNA synthesis by primer extension was also performed as 
described using Advantage 2 DNA polymerase. cDNA was separated on a 1% agarose gel, 
and different sized fractions were excised and isolated using the Qiagen QIAquick Gel 
Extraction kit.  
The cDNA fractions were subsequently amplified by PCR using the Clontech Advantage 2 
Polymerase kit according to the manufacturer’s protocols. For this amplification step the 
SMART Library kit 5` PCR primer and CDSIII primer were utilised. The Advantage 2 
polymerase mix is designed for efficient amplification of PCR products up to 18 kb in length 
and contains a proof-reading polymerase for high-fidelity amplification. This PCR step was 
required to produce a sufficient quantity of cDNA in each size fraction for subsequent 
digestion and ligation to the MIG-Sfi1 vector, however it was necessary to optimise the 
number of cycles as excessive amplification can bias towards a greater representation of 
smaller or more abundant transcripts. We observed that the smaller sized fractions contained a 
larger amount of cDNA and hence required fewer PCR amplification cycles, whereas the 
opposite was true of larger sized fractions. The optimum number of PCR cycles was as 
follows: Fraction 1 (0.2-1.7 kb) = 5 cycles, Fraction 2 (1.7-3 kb) = 15 cycles, Fractions 3 (3-5 
kb) and 4 (>5 kb) = 20 cycles. Following amplification, PCR products were separated on an 
agarose gel and isolated with the Qiagen QIAquick Gel Extraction kit.  
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The four amplified cDNA fractions were digested with Sfi1 restriction endonuclease 
according to the manufacturer’s protocol. These were purified using the Qiagen QIAquick 
PCR Purification kit then precipitated overnight. The MIG-Sfi1 retroviral expression 
construct was prepared for cloning by Sfi1 digestion according to the manufacturer’s 
protocol. The digested MIG-Sfi1 vector was isolated by gel electrophoresis and purified using 
the Qiagen QIAquick Gel Extraction kit. This isolation step was performed twice to ensure 
purity of the digested construct. Ligations of Sfi1-digested MIG-Sfi1 vector with each of the 
four M1 cDNA fractions were undertaken in accordance with the Invitrogen T4 DNA Ligase 
protocol. Each ligation was transformed into Lucigen’s electrocompetent E. Cloni 10G cells 
using the manufacturer’s recommended protocol, and plated on Luria Broth/Agar plates 
containing 100 Pg/ml ampicillin. A small proportion of transformed cells were plated 
separately at a known dilution for estimation of the number of colonies formed in each 
fraction. Plates were incubated overnight then scraped twice following addition of 10 ml 
Luria Broth for collection of transformed clones. DNA from each fraction was isolated using 
the Qiagen HiSpeed Maxiprep kit, and retroviral cDNA library fractions were stored at -20qC
until further use. 
3.2.2 Composition of the M1 retroviral cDNA library 
The composition of the M1 library was assessed using a selection of clones from each of the 
four size fractions. Twelve bacterial colonies were selected from each fraction and plasmid 
DNA prepared for analysis. DNA was digested using Sfi1 according to the manufacturer’s 
protocol then separated by gel electrophoresis to visualise cloned cDNA inserts (Figure 3.4). 
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Figure 3.4: Analysis of selected clones from each fraction of the M1 library. 12 representative clones 
from each fraction of the M1 cDNA library were cultured overnight and plasmid DNA extracted. Clones were 
then digested using Sfi1and separated on a 1% agarose gel. Note that one clone in Fraction 3 (#2) did not 
grow when cultured overnight. M = DNA size marker (1 Kb Plus ladder). The size of selected marker bands 
is indicated to the left of each agarose gel photograph, and the expected size for inserts in each fraction is 
indicated with red dotted lines on each gel photograph. The band showing linearised MIG-Sfi1 vector 
backbone is indicated with a blue arrow for each photograph (MIG-Sfi1 = 6.5 kb). Note that clones #3 and #4 
in Fraction 4 contain large inserts which are not visible as they are a similar size to the vector backbone 
(determined by sequencing, see Appendix A).
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in each fraction of the M1 cDNA library are summarised in Table 3.1. 
Between 75% and 92% of clones in each fraction contained a single cDNA insert in the MIG-
Sfi1 vector. The remaining clones consisted of the original MIG-Sfi1 vector which had not 
taken up a cDNA insert, clones which had taken up multiple cDNA inserts, or clones 
containing genomic DNA sequence. For Fractions 1 (0.2-1.7 kb), 2 (1.7-3 kb) and 3 (3-5 kb), 
82-92% of clones contained inserts of the anticipated size for each fraction. For Fraction 4, 
only 17% of clones contained inserts of the anticipated size (>5 kb). Sequencing revealed that 
Fractions 2 and 3 contained the highest proportions of full-length cDNA clones (50% and 
64% respectively), whereas Fractions 1 and 4 contained relatively few full-length clones 
(17% and 25% respectively). The majority of clones which did not contain full-length cDNA 
were truncated at the 5` end (up to 67% 5`-truncated clones – Fraction 1), with relatively few 
truncated at the 3` end (up to 17% 3`-truncated clones – Fraction 1). 
The data obtained from digestion and sequencing of selected clones was extrapolated to 
estimate the composition of the M1 library (Figure 3.5A). A total number of 3.4x10
6 clones 
were obtained, 41% of which are estimated to be full-length cDNA (1.4x10
6), over a size 
range of 0.2 to >5 kb. To assess the overall composition of each fraction of the library, an 
aliquot of plasmid DNA from each fraction was digested with Sfi1 and analysed by gel 
electrophoresis (Figure 3.5B). This confirmed the predicted size range of cDNA inserts as 
0.2-1.7 kb (Fraction 1), 1.7-3 kb (Fraction 2) and 3-5 kb (Fraction 3). A smear of the 
anticipated size was not visible for Fraction 4 due to the linearised MIG-Sfi1 vector being a 
similar size (6.5 kb). However, sequencing revealed approximately 17% of clones in Fraction 
4 contained inserts of >5 kb. The total number of clones in each fraction ranged from 5x10
5
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Number of clones assessed  12 12 11 12 
Clones with 1 cDNA insert
*  10 (83%)  11 (92%)  10 (91%)  9 (75%) 
Other
*  2 (17%)  1 (8%)  1 (9%)  3 (25%) 
Predicted size range (kb)  0.2-1.7  1.7-3  3-5  >5 
Actual insert size range (kb)  0.25-0.85  1.8-3.0  0.15-4.5  0.2->5
**
Clones within predicted size range  10 (83%)  11 (92%)  9 (82%)  2 (17%) 
Full-length clones
†  2  (17%) 6  (50%) 7  (64%) 3  (25%) 
5`-truncated clones
††  8  (67%) 4  (33%) 3  (27%) 6  (50%) 
3`-truncated clones
††  2 (17%)  1 (8%)  1 (9%)  0 (0%) 
Table 3.1: Summary of selected clones from each fraction of the M1 library. 12 representative clones 
(see Figure 3.4) were sequenced from each fraction of the M1 cDNA library. *One clone in Fraction 3 did 
not grow when cultured overnight. The approximate insert size range of selected clones following Sfi1 
digestion is indicated for each fraction. **Fraction 4 contains 17% (2/12 clones) with inserts >5 kb in 
length. †Sequences were interrogated using the NCBI Basic Local Alignment Search Tool (BLAST)355
and relative completeness of each clone was assessed by alignment with the accession numbers shown in 
Appendix A. ††Note that some clones were truncated at both 5` and 3` ends. ‘Other’ indicates vector alone 
(uncut vector, linearized vector, original vector with eGFP stuffer), clones with multiple inserts, clones 
with genomic DNA inserts, or clones for which sequence was not able to be obtained.
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Size range  0.2 to >5 kb 
Total clones  3.4x10
6
Clones with 1 cDNA insert  2.9x10
6 (86%) 
Full-length clones  1.4x10
6 (41%) 
5`-truncated clones  1.5x10
6 (44%) 








FRACTION 1  0.2-1.7 kb  1x10
6 1.7x10
5
FRACTION 2  1.7-3 kb  1x10
6 5.0x10
5
FRACTION 3  3-5 kb  9x10
5 5.8x10
5




Figure 3.5: Composition of the M1 cDNA library. A. Overall composition of the M1 library. Estimates were 
based on total clone numbers in each fraction and data shown in Figure 3.4 and Table 3.1. B. The four fractions 
of the M1 library. Plasmid DNA from individual fractions was digested with Sfi1 and separated by gel 
electorphoresis. Filled arrow indicates the linearised vector backbone (MIG-Sfi1 = 6.5kb). M = DNA size 
marker (1 Kb Plus). The size of selected bands is indicated to the left of the gel photograph. Characteristics of 
each fraction are summarised in the adjacent table.  ‘Size range’ indicates the size of cDNA inserts in each 
fraction estimated using gel electrophoresis (except for Fraction 4 which contains 17% large inserts (>5 kb) as 
determined by sequencing selected clones). The number of full-length clones in each fraction was estimated by 
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6 (Fractions 1 and 2), and the number of full-length clones in each fraction 
ranged from 1.3x10
5 (Fraction 4) to 5.8x10
5 (Fraction 3). 
3.2.3 Assessment of the FDB1 cell line as a target population for retroviral 
expression screening 
We wished to establish the suitability of the FDB1 cell line for use as a target population in 
functional screening for oncogenes which confer factor-independent growth or a block in 
differentiation. It has been previously shown that FDB1 cells display factor-independent 
proliferation in response to expression of oncogenes such as the V449E mutant form of 
hEc
128, or the ITD mutant form of the FLT3 receptor (FLT3-ITD)
326. However identification 
of such oncogenes using a functional expression cloning screen requires clonal outgrowth 
from a single cell in conditions without growth factor, and on a background of dead or dying 
untransformed cells. To test the efficiency of clonal FDB1 outgrowth in these conditions, we 
used FACS to seed one FDB1 cell expressing FLT3-ITD (FDB1-ITD) on a background of 
1x10
4 parental FDB1 cells per well in medium without growth factor (100 Pl /well, one 96-
well plate). Both parental FDB1 cells and FDB1-ITD cells were washed three times in 1x 
PBS to remove growth factor prior to sorting. Following one week of culture, we observed 
factor-independent outgrowth in 9/96 (approximately 10%) of wells seeded with a single 
FDB1-ITD cell. FDB1-ITD cells lose approximately 10-20% viability overnight following 
removal from growth factor, which may account for some wells seeded with a single FDB1-
ITD cell not displaying any growth (M. Perugini and D. Salerno, personal communication). 
The observation that we detected growth in approximately 10% of wells seeded suggests that 
FDB1 cells are not adept at clonal growth from single cells, but rather, they may require 
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a suitable system for screening of genes conferring factor-independent growth. 
We were also interested to utilise the FDB1 cell line system to screen for genes which would 
block differentiation in GM-CSF. Preliminary studies have shown that this system is suitable 
for detection of such oncogenes, with suppression of FDB1 differentiation achieved through 
expression of oncogenic MYB
1. We hypothesised that as parental cells remain viable in GM-
CSF, this would support the outgrowth of a single cell with a blocked-differentiation 
phenotype. To this end, we carried out a negative control test screen to assess background 
outgrowth of parental FDB1 cells in GM-CSF. FDB1 cells were washed three times in 1x 
PBS to remove IL-3, then seeded at 1x10
4 cells per well in medium containing 500 BMU/ml 
GM-CSF (100 Pl per well, one 96-well plate). Wells were scored weekly for possible 
outgrowth, and at week 4 we observed growth in 13/96 wells (13.5%). Of these, 4 wells gave 
rise to continuous culture in GM-CSF (4.2%). To completely screen the M1 library in 
duplicate, this would require seeding 6.8x10
6 cells in GM-CSF in a total of 680 wells. This 
would be predicted to give a high rate of background growth, making FDB1 system an 
unsuitable cell line for identification of genes conferring a differentiation block in GM-CSF.  
3.2.4 Utilising the FDC-P1 cell line as a target population for retroviral 
expression screening 
As the FDB1 cell line proved unsuitable for the proposed functional screening experiments, 
we instead turned to the FDC-P1 cell line to screen the M1 library. Similarly to FDB1 cells, 
the FDC-P1 cell line is an immature myeloid cell line, although it was initially derived from 
murine bone marrow cultures as opposed to foetal liver cells
356. FDC-P1 cells can be 
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cells, FDC-P1 cells cannot be induced to differentiate with the addition of cytokines. The 
FDC-P1 cell line has successfully been used in a previous study to identify genes conferring 
factor-independent growth from a haemopoietic retroviral cDNA library
335. In addition, we 
have previously observed clonal outgrowth of FDC-P1 cells expressing the FIǻ mutant form 
of hEc in conditions without growth factor, making this a suitable cell line for screening of 
oncogenes which confer factor-independent growth in the M1 library
357.
Before screening we wished to optimise recovery of integrated retroviral sequences from 
transduced FDC-P1 clones using PCR. Primers for recovery of the integrated MIG-Sfi1 
retroviral construct were designed as shown in Figure 3.6A. To test these primers on genomic 
DNA, FDC-P1 cells were transduced with the MIG-Sfi1 construct containing human CD4
cDNA cloned into the Sfi1 restriction sites (CD4 = 1.3 kb). FACS was utilised to obtain a 
stable population expressing GFP. Genomic DNA was prepared from FDC-P1 cells 
transduced with MIG-Sfi1-CD4 and also from untransduced FDC-P1 cells as a negative 
control. PCR was performed using the Qiagen LongRange PCR kit according to the 
manufacturer’s protocols with the following parameters: 2 Pl genomic DNA template, primer 
annealing temperature of 60qC, and 30 amplification cycles. 4 Pl of each PCR reaction was 
separated and visualised using gel electrophoresis. Using these conditions, the recovery 
primers efficiently amplified a product of 1.4 kb in length from FDC-P1 cells transduced with 
MIG-Sfi1-CD4 but not from untransduced cells, as shown in Figure 3.6B. 





















































Figure 3.6: PCR recovery of integrated MIG-Sfi1 retroviral construct. A. Location of primers for PCR 
recovery of integrated MIG-Sfi1 retroviral construct. The DNA sequence of the MIG-Sfi1 multiple cloning 
site is shown. Restriction sites for EcoRI and Xho1 are indicated in blue text, and for Sfi1A/B are indicated in 
red text. The position of recovery primers is highlighted in green. B. Optimisation of PCR recovery of the 
integrated MIG-Sfi1 construct from genomic DNA. Genomic DNA was harvest from untransduced FDC-P1 
cells or FDC-P1 cells transduced with MIG-Sfi1-CD4, and PCR performed using recovery primers shown in 
part ‘A’. A PCR product of 1.4 kb was detected indicating the presence of integrated MIG-Sfi1-CD4 in
transduced FDC-P1 cells.
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growth in FDC-P1 cells 
We initially sought to assess the number of retroviral integrations per FDC-P1 clone 
following transduction with the M1 library. FDC-P1 cells were transduced with DNA from 
each of the four fractions of the M1 library. 24 hrs post-infection, FACS was utilised to sort a 
single GFP positive (GFP
+) FDC-P1 cell per well in medium containing 80 BMU/ml GM-
CSF (100Pl per well, one 96-well plate per fraction). After 1 week of culture, we selected 12 
wells from each fraction which showed clonal outgrowth and removed half of the cells in 
each well for production of genomic DNA. PCR was performed as described above using 2 ȝl
of genomic DNA template per reaction and 30 amplification cycles. Extension was carried out 
for 10 mins in each cycle to ensure amplification of long cDNA inserts (sufficient for 
amplification of products up to 10 kb). 4 ȝl of each PCR reaction was then separated and 
visualised using gel electrophoresis as shown in Figure 3.7. Under these reaction conditions, 
we obtained a PCR product indicating integrated retroviral constructs in 83% of clones 
assessed. For the remaining 17% of clones, it is possible that an untransduced clone had been 
seeded using FACS for single-cell sorting. Alternatively, it is possible that the PCR reaction 
was not successful using these parameters due to the location of the integration or the 
length/composition of the cDNA insert. We observed that 53% of clones showed one 
integration as judged by the presence of a single dominant band in the gel photograph. 25% 
showed two integrations, and the remaining 22% showed three or more integration products 
detected by PCR (see Figure 3.7). 
For functional screening of the M1 library, DNA from each of the four size fractions of the 
M1 library was used to transduce FDC-P1 cells. 24 hrs post-infection, cells positive for the 
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FRACTION 1  4 (40%)  1 (10%)  5 (50%)  2 (17%) 
FRACTION 2  7 (78%)  2 (22%)  0 (0%)  3 (25%) 
FRACTION 3  5 (50%)  5 (50%)  0 (0%)  2 (17%) 
FRACTION 4  5 (46%)  2 (18%)  4 (36%)  1 (8%) 
TOTAL  21 (53%)  10 (25%)  9 (22%)  8 (17%) 
A.
B.
Figure 3.7: Analysis of retroviral integrations in selected FDC-P1 clones transduced with the M1 
library. FDC-P1 cells were transduced with each fraction of the M1 library then FACS was utilised to seed 
one GFP+ cell per well the following day. These were cultured for 1 week in the presence of GM-CSF then 
12 representative FDC-P1 clonal populations from each fraction were lysed and genomic DNA extracted. 
PCR was performed to amplify the retroviral integrations in each clonal population. A. PCR products from 
amplification of retroviral integrations in FDC-P1 clonal populations were separated on an agarose gel. M = 
DNA size marker (1Kb plus). The size of selected bands is indicated to the left of each agarose gel 
photograph. B. Summary of the number of retroviral integrations in FDC-P1 clones transduced with the M1 
library. Note that the PCR reaction did not generate a product in all clones under these reaction conditions. 
For the clones from which a PCR product was obtained, the percentage of clones containing 1, 2 or 3
integrations (detected as dominant bands in gel photographs in part ‘A’) per clone is indicated.
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clones in each fraction to ensure adequate representation of the library in our screens. Sorted 
cells were recovered overnight, then washed three times in 1x PBS to remove growth factor. 
Cells were resuspended at 1x10
4 cells per well in medium without growth factor (100 Pl per 
well, 96-well plates). Note that untransduced FDC-P1 cells were also seeded in medium 
without growth factor at 1x10
4 cells per well as a negative control (100 Pl per well, one 96-
well plate). Cells were cultured for a total of 5 weeks, however we saw no outgrowth in wells 
containing M1 library-transduced cells.
3.3 Discussion 
3.3.1 Construction of the M1 retroviral cDNA library 
This chapter describes the successful modification of existing methods for generation of full-
length cDNA libraries. We utilised a combination of the SMART system and size 
fractionation to generate a retroviral cDNA library in the MIG-Sfi1 vector. This library was 
cloned from expressed sequences in the murine leukaemia cell line M1, which has not 
previously been utilised as a source in retroviral expression cloning studies. The M1 library 
contained a total of 1.4x10
6 full-length cDNA clones ranging in size from approximately 200 
bp to over 5 kb. Although studies have estimated that the mammalian transcriptome contains 
approximately 20,000 protein coding genes, the full complexity of the transcriptome has not 
yet been wholly elucidated
358. Traditionally, a cDNA library complexity of >1x10
6 individual 
clones is considered an adequate representation of the mouse or human transcriptome
359, and 
hence the M1 library contained sufficient full-length cDNAs to represent the mouse 
transcriptome. Despite the use of the SMART (Switching mechanism at 5` end of RNA 
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352,353) protocol for enrichment of full-length transcripts at the 5` end, we found that 
44% of clones contained cDNA which was truncated at the 5` terminus. This is likely due to 
hybridisation of the poly-G-modified 5` SMART IV primer at C-rich sequences within cDNA 
transcripts during second strand cDNA production. It is possible that other methods may be 
employed to improve cloning of the 5` end of transcripts, such as the CAP-trapper or oligo-
capping methods which involve modification of the 5` cap structure as part of the library 
construction protocol
360,361.
3.3.2 Screening the M1 retroviral cDNA library 
Assessment of the FDB1 cell line showed that these cells do not represent a suitable 
experimental system for the identification of genes conferring factor-independent growth or 
blocking differentiation in functional screening assays, due to inefficient clonal growth in 
growth factor-free conditions, and a high background of clonal growth in GM-CSF. The M1 
library was subsequently screened for genes conferring factor-independent growth in the 
FDC-P1 cell line. However no factor-independent growth was observed, suggesting that the 
M1 library may not contain an oncogene which, on its own, is sufficient to transform FDC-P1 
cells to factor-independent growth. It may be possible to modify the screen to identify genes 
that confer growth of FDC-P1 cells in sub-optimal concentrations of growth-factor. 
Alternatively, it is possible that oncogenes conferring factor-independent growth may be 
under-represented in the M1 library. It may therefore be of benefit to employ a cDNA 
normalisation method such as duplex-specific normalisation to remove abundant cDNAs in 
the M1 library
362.
Other target cell systems could potentially be utilised to continue screening the M1 library, 
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cell lines have previously been used in a number of retroviral expression screening 
studies
126,335,337,345. It is important to consider also that our experimental approach will only 
detect single oncogenes which are sufficient to induce the particular leukaemic properties of 
interest, however it is now generally accepted that cooperation of multiple genetic lesions is 
required for the development of AML
24,55. Thus it may be useful to consider modifying our 
screens to look for genes which might cooperate with known leukaemia oncogenes. This 
approach has been successfully used to identify genes cooperating with the RAS pathway in 
leukaemia, for example, Passioura, et al. detected IRF2 as a putative oncogene which 
overcomes NRAS-induced growth suppression of U937 leukaemia cells
363. Scholl, et al. used 
a similar approach to screen an RNAi library to identify genes which are necessary for the 
oncogenic properties of KRAS
364. This ‘synthetic lethality’ screen identified the 
serine/threonine kinase STK33 as one such gene, and the authors demonstrated that 
suppression of STK33 in KRAS-positive cells inhibited proliferation and induced cell death. 
3.3.3 Retroviral expression screening for the detection of oncogenes in human 
disease
Although most of the studies mentioned previously have utilised various haemopoietic cell 
lines for library construction, there are fewer examples of screens where libraries have been 
constructed using primary samples from patients with haemopoietic disorders.  The two 
homeobox genes PRH and HLX, although previously known to be involved in embryonic 
development, were isolated from a retroviral cDNA library screen of patients with MPD, 
suggesting a hitherto unknown role for these genes in haemopoiesis with potential 
involvement in HSC development
365. A study utilising a retroviral cDNA library from an 
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AML patient revealed a deletion mutation in a nerve growth factor-receptor gene previously 
suspected to play a role in glioma formation
366. In theory, with appropriate screening methods 
it should be possible to identify disease-causing genes or mutations for almost any disorder, 
which makes retroviral expression cloning an attractive application once optimised. As we 
have successfully optimised methods for construction of cDNA libraries, it will be interesting 
to apply these methods further to screening libraries constructed from primary AML samples. 
The PCR step in the Clontech SMART Library Construction kit allows construction from 
limited amounts of starting material, which is particularly relevant to the construction of 
libraries from patient samples. 
The primary advantage of expression cloning over other methods of oncogene identification is 
that genes are identified based directly on their function
341. However, a number of groups 
have now performed expression cloning screens to identify leukaemia-associated genes, and 
thus it is likely that subsequent screens may identify oncogenes which are already known. 
One such example is the oncogenic RAS activator, RASGRP4, which was isolated in two 
independent studies screening libraries from patients with MDS or cytogenetically normal 
AML
126,367. It is likely that oncogenic lesions could potentially be more readily detected using 
genome-wide approaches such as exon capture and whole genome sequencing. However, 
these approaches are not based on functional screening and a high level of validation is 
required to show a causal association of any change with disease. Continued research utilising 
a combination of these technologies will be essential in elucidating oncogenes and related 
pathways contributing to the development of AML. Due to technical limitations and time 
constraints, these retroviral expression cloning studies were discontinued and characterisation 
of the putative AML tumour suppressor KLF5 was alternatively undertaken. Chapter 4 – KLF5 expression and function in 
myeloid differentiation. 
4.1 Introduction 
The expression patterns of transcription factors often reflect their function in determining cell 
fate or promoting differentiation, whether it be a role in proliferation and self-renewal, or 
induction of growth arrest and activation of cell-type-specific gene expression programs
368.
KLF5 is highly expressed in proliferating cells of a number of different tissues, for example, 
in proliferating intestinal epithelial cells, VSMCs, and ESCs (see Chapter 1, Section 1.3.7.1). 
Accordingly it has been demonstrated that KLF5 has a pro-proliferative function in these 
tissues with additional effects on suppression of differentiation. Conversely, KLF5 expression 
is increased during hormone-induced adipogenesis, and it has been demonstrated that over-
expression of KLF5 in this tissue is sufficient to induce adipocyte differentiation, whereas 
haploinsufficiency of Klf5 in mouse models impairs adipogenesis
156. In an extensive series of 
microarrays performed to elucidate mechanisms of myeloid differentiation, Klf5 was 
identified as a gene for which mRNA expression increased during granulocyte-macrophage 
differentiation of the murine myeloid cell line FDB1 in response to expression of a 
constitutively activated cytokine receptor, FI' hEc
1 (see Chapter 1, Section 1.2.3). We have 
thus hypothesised that KLF5 plays a key role in induction of myeloid differentiation. 
In the myeloid system, there are a number of transcription factors which have been identified 
as important for determination of granulocyte-macrophage lineage differentiation
369. For 
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but not in the granulocyte lineage. Consistent with this observation, functional studies have 
shown that over-expression of IRF8 directs macrophage differentiation of bipotential myeloid 
progenitors
370,371, and that Irf8 knock-out mouse models develop myeloproliferative-like 
disorders characterised by an increased proportion of granulocytes in the peripheral blood
372.
In contrast, C/EBPH expression is restricted to the granulocyte lineage
373, and functional 
studies have confirmed that it acts in determination of granulocyte commitment
374,375.
Previous unpublished microarray studies performed by our research group demonstrated that 
Klf5 expression was specifically associated with the granulocyte lineage in the FDB1 cell 
system (see Chapter 1, Section 1.2.3.1). In particular, Klf5 expression was associated with that 
of a number of C/EBPD target genes
1. C/EBPD is a transcription factor known to have an 
essential regulatory role in granulocyte development
131. Interestingly, KLF5 has been shown 
to directly activate expression of the neutrophil-specific secondary granule gene 
Lactotransferrin ( LTF) in endometrial carcinoma cells
201, which is up-regulated by both 
C/EBPD and C/EBPH in granulocyte differentiation
376,377. Given these observations, we 
predicted that KLF5 may have a function in differentiation of the granulocyte lineage.  
In this Chapter we wished to characterise Klf5 expression during granulocyte-macrophage 
differentiation of the FDB1 cell line in response to GM-CSF. We also sought to characterise 
KLF5 expression specifically in granulocyte and monocyte lineages using an alternative cell 
line model and primary haemopoietic cell systems, and to compare expression of KLF5 with 
expression profiles of the granulocytic transcription factors CEBPA and CEBPE. To gain 
insights into the function of KLF5 in haemopoiesis, we utilised both retroviral over-
expression and gene knock-down approaches to modulate KLF5 expression in murine cell 
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differentiation.
4.2 Results 
4.2.1 KLF5 mRNA expression increases during myeloid differentiation and is 
predominantly associated with granulocyte differentiation
4.2.1.1 GM-CSF-induced granulocyte-macrophage differentiation of the FDB1 
cell line 
Klf5 expression increases during granulocyte-macrophage differentiation of the FDB1 cell 
line in response to enforced expression of the activated receptor FI' h Ec, and we hence 
sought to determine if expression similarly increases in this system during granulocyte-
macrophage differentiation in response to cytokine induction. FDB1 cells were cultured in 
GM-CSF (500 BMU/ml) for a period of 5 Days. On Day 0 (cells in IL-3 (500 BMU/ml)), 
FDB1 cells displayed an immature myeloblastic cell morphology, with the majority of cells 
exhibiting rounded nuclei, dark-staining cytoplasms, and a low cytosplam-to-nucleus volume 
ratio (Figure 4.1A). By Day 5 in GM-CSF, the majority of cells underwent morphological 
differentiation to granulocytes and macrophages. Mature granulocytes were characterised by 
polylobular nuclei (often presenting in a ring shape), diminished size, and light-staining, 
granular cytoplasms. Mature macrophages displayed a large cytoplasm-to-nucleus volume 
ratio, light-staining granular cytoplasms, small rounded nuclei, and ruffled cellular edges. 
Analysis of cell surface marker expression correlated with the observed morphological 
appearance of differentiated FDB1 cells, with an increase in expression of both the 













































Figure 4.1: Granulocyte-macrophage differentiation of FDB1 cells in GM-CSF. A. Representative 
photomicrographs showing Wright-Giemsa stained cytospin preparation of FDB1 cells cultured in IL-3 (Day 
0) or GM-CSF (Day 5). Gran = granulocyte, Mac = macrophage. Original magnification = 200x B. Flow 
cytometric detection of c-Fms and Gr-1 expression on FDB1 cells in IL-3 (Day 0) or in GM-CSF (Day 5). 
Representative results from a typical experiment are shown. Empty peak = isotype control, grey peak = 
marker expression. MFI = mean fluorescence intensity. C. Expansion of FDB1 cells in IL-3 or GM-CSF 
relative to Day 0. Live cell numbers were determined at each time-point using Trypan Blue staining and cell 
counts. n=2, *p<0.05. D.  Viability of FDB1 cells in IL-3 or GM-CSF. Percentage of live cells were 
determined at each time-point using Trypan Blue exclusion. n=2, *p<0.05.
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Chapter 4: KLF5 expression and function in myeloid differentiation – Page 110 macrophage-specific marker c-Fms, and the granulocyte-associated marker Gr-1 by Day 5 in 
GM-CSF (Figure 4.1B). Differentiation of FDB1 cells was accompanied by a 10-fold 
reduction in cell expansion compared to cells cultured in IL-3 (Figure 4.1C), and cell viability 
was reduced from 91% in IL-3 to 66% by Day 5 in GM-CSF (Figure 4.1D). 
RNA was prepared from cells harvested at Days 1, 2, 3 and 5 post-induction with GM-CSF, 
as well as on Day 0. Q-PCR analysis demonstrated that Klf5 expression increased over the 
first two days following addition of GM-CSF (Figure 4.2A), which is consistent with the 
increased Klf5 expression observed during granulocyte-macrophage differentiation of FDB1 
cells in response to the activated receptor FI' hEc (see Chapter 1, Figure 1.3). Interestingly, 
we found that Klf5 expression reached a maximum level at Day 2 in GM-CSF then by Day 5 
had decreased to levels below that found in IL-3. Thus Klf5 expression peaks early before 
morphological differentiation of FDB1 cells, consistent with a potential role in granulocyte or 
macrophage differentiation. Q-PCR was also performed to detect expression of Cebpa and 
Cebpe during FDB1 cell differentiation. The pattern of Cebpe expression showed a similar 
trend to that of Klf5, with a peak occurring at Day 2 in GM-CSF (Figure 4.2B). In contrast, 
Cebpa expression decreased rapidly during differentiation (Figure 4.2C).
4.2.1.2 G-CSF-induced granulocyte differentiation of the 32D cell line 
The 32D murine myeloid cell line was selected as a model of granulocytic differentiation in 
response to G-CSF stimulus
378. 32D cells were maintained in IL-3 (500 BMU/ml), where they 
showed continuous proliferation with a myeloblastic morphology (Figure 4.3A). Cells were 
induced to differentiate using G-CSF (50 ng/ml), and by Day 7 in G-CSF the majority of cells 
showed morphologic differentiation along the granulocyte lineage. Mature granulocytes were 




























































































Figure 4.2: Expression of Klf5 and Cebp family members during GM-CSF-
induced FDB1 cell differentiation. FDB1 cells were induced to differentiate over 5 
days in GM-CSF. Q-PCR was performed to determine: A. Klf5 mRNA expression, 
B. Cebpe mRNA expression, and C. Cebpa mRNA expression. Expression is 
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Figure 4.3 (A-C): Granulocyte differentiation of 32D cells in G-CSF. A. Representative photomicrograph 
showing Wright-Giemsa stained cytospin preparation of 32D cells in IL-3 (Day 0) or in G-CSF (Day 7). 
Original magnification = 200x. Gran = granulocyte, BC = band cell. B. Flow cytometric detection of Gr-1 and 
Mac-1expression on 32D cells in IL-3 (Day 0) or in G-CSF (Day 7). Representative results from a typical 
experiment are shown. Empty peak = isotype control, grey peak = cell surface marker expression. MFI = mean 
fluorescence intensity. C. Q-PCR detection of Csf3 mRNA expression in 32D cells differentiated over 7 days 
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Figure 4.3 (D-F): Granulocyte differentiation of 32D cells in G-CSF. D. Representative 
photomicrographs showing MPO activity of 32D cells cultured in IL-3 (Day 0) or in G-CSF (Day 7). 
Original magnification = 200x. MPO activity was detected using the Hanker-Yates method. Examples of 
cells positive for MPO are indicated (MPO+) E. Q-PCR detection of Ltf mRNA expression in 32D cells 
differentiated over 7 days in G-CSF. Expression was plotted relative to Day 0 (cells in IL-3). n=3. F.
Expansion of 32D cells in IL-3 or G-CSF relative to Day 0. Live cell numbers were determined at each
time-point using Trypan Blue staining and cell counts. n=3, **p<0.01. G. Viability of 32D cells in IL-3 or 
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cells were also visible, and could be distinguished from their mature counterparts by their 
thicker, ringed nuclei.
Marker staining was utilised to confirm induction of granulocyte differentiation on Day 7 
(Figure 4.3B). There was a negligible change in expression of the granulocyte-associated 
marker Gr-1 in response to G-CSF, which is in contrast to previous studies which have 
reported that Gr-1 expression is strongly up-regulated during granulocyte differentiation of 
32D cells (see for example Vradii, et al.
379). Although 32D cells cultured in IL-3 were already 
positive for expression of the myeloid marker Mac-1, we observed a peak shift corresponding 
to increased expression on induction with G-CSF (mean fluorescence intensity of 27.2 and 
69.5 in IL-3 and G-CSF respectively). This agrees with previous reports which have 
demonstrated increased Mac-1 expression on 32D cells when differentiated in G-CSF
379,380.
Antibodies to detect expression of the murine G-CSF receptor (CSF3) were not available, 
however Q-PCR performed on Day 0 (cells in IL-3) and Days 3 and 7 post-induction (G-CSF) 
revealed that Csf3 mRNA expression increased over the course of this assay (Figure 4.3C). 
Increased expression of Mac-1 (a marker expressed on both granulocytes and macrophages), 
and of Csf3, is consistent with the observed morphological differentiation of 32D cells to 
granulocytes.
Granulocyte differentiation is also characterised by the expression of specific proteins which 
localise to different subsets of neutrophilic granules
381. Myeloperoxidase (MPO) is a marker 
of primary neutrophilic granules, which is first detectable at the myeloblast or promyelocyte 
stages of granulocyte differentiation
382. Using the Hanker-Yates method
328, 32D cells cultured 
in IL-3 were found to be negative for active MPO enzyme (Figure 4.3D). When cultured in G-
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detected by the presence of brown/black granules. LTF is a marker of secondary neutrophilic 
granules, which is first detectable at the myelocyte or metamyelocyte stages of 
differentiation
382. Q-PCR performed on Days 0, 3 and 7 post-induction showed that Ltf
mRNA expression increased as 32D cells were cultured in G-CSF (Figure 4.3E). Collectively, 
these observations are consistent with 32D cells differentiating along the granulocyte lineage 
when cultured in G-CSF over 7 days. Differentiation of 32D cells was accompanied by a 
dramatic reduction in cell expansion compared to cells cultured in IL-3 (Figure 4.3F), and cell 
viability was reduced from 92% in IL-3 to 48% by Day 7 in G-CSF (Figure 4.3G). 
For detection of Klf5 expression, 32D cells were harvested on Days 1, 2, 3, 5 and 7 following 
addition of G-CSF, as well as on Day 0. Q-PCR analysis showed that Klf5 mRNA expression 
increased during granulocytic differentiation in response to G-CSF, reaching a maximum 
level at Day 5 and remaining high thereafter (Figure 4.4A). A similar trend was observed for 
Cebpe (Figure 4.4B), however the fold induction of Cebpe expression was higher than that of 
Klf5 (30-fold induction of Cebpe compared with 2-fold induction of Klf5). The observed up-
regulation of Cebpe mRNA during G-CSF-induced differentiation of 32D cells is consistent 
with previously published reports
383. Cebpa expression peaked early at 24 hours in G-CSF, 
then decreased to almost basal levels by Day 3 post-induction (Figure 4.4C), which is 
consistent with data published previously by Scott, et al.
384.


























































































Figure 4.4: Expression of Klf5 and Cebp family members during G-CSF-
induced 32D cell differentiation. 32D cells were induced to differentiate over 7 
days in G-CSF. Q-PCR was performed to detect: A. Klf5 mRNA expression, B.
Cebpe mRNA expression, and C. Cebpa mRNA expression. Expression is plotted 
relative to Day 0 (IL-3). n=4.
Chapter 4: KLF5 expression and function in myeloid differentiation – Page 1174.2.1.3 M-CSF-induced macrophage differentiation of murine bone marrow 
progenitors
We utilised primary murine bone marrow progenitors to assess Klf5 mRNA expression during 
cytokine-induced macrophage differentiation. Bone marrow cells were freshly isolated from 
C57BL/6 mice treated with 5-fluorouracil to enrich for haemopoietic progenitors
385, then 
differentiated for 7 Days in M-CSF (100 ng/ml). Morphologically, cells treated with M-CSF 
differentiated almost exclusively to mature macrophages by Day 7 in culture (Figure 4.5A). 
Analysis of cell surface marker expression correlated with the observed morphological 
appearance of differentiated macrophages, with the majority of cells positive for the 
macrophage marker c-Fms (66%) on Day 7 in M-CSF, and relatively few cells positive for 
expression of the granulocyte-associated marker Gr-1 (12.3%) (Figure 4.5B). RNA was 
isolated from cells prior to addition of M-CSF (Day 0), and on Days 3 and 7 following 
addition of M-CSF. Q-PCR analysis showed a dramatic drop in Klf5 expression, with 
undetectable levels remaining by Day 7 when cells had completely matured (Figure 4.5C). To 
confirm that Klf5 expression did not increase at an earlier time-point in this system, Q-PCR 
was also performed on cells at Days 0, 1, 2 and 3 in M-CSF. This revealed an immediate 
decrease in Klf5 expression by Day 1, and levels remained low thereafter (Figure 4.5D). 
4.2.1.4 mRNA expression of KLF family members in primary haemopoietic cell 
populations
We utilised published microarray data to further analyse expression of KLF5 and other KLF
family members in haemopoietic lineages from primary murine and human tissues. 
Chambers, et al. performed extensive microarray analyses to identify unique genetic 
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Figure 4.5: Macrophage differentiation of primary mouse bone marrow progenitors  in M-
CSF. A. Representative photomicrograph showing Wright-Giemsa stained cytospin preparation of 
mouse bone marrow progenitor cells differentiated for 7 days in M-CSF. Original magnification = 
200x. B. Flow cytometric detection of Gr-1 and c-Fms expression on bone marrow cells in M-CSF 
(Day 7). Representative results from a typical experiment are shown. Empty peak = isotype 
control, grey peak = cell surface marker expression. C-D. Q-PCR was performed to detect mRNA 
expression levels of Klf5 during M-CSF induced differentiation of mouse bone marrow 
progenitors. Expression is plotted relative to Day 0 (bone marrow harvest). Q-PCR was initially 
performed on Days 3 and 7 (part ‘C’, n=2) then performed at earlier time-points which included 


















































































Chapter 4: KLF5 expression and function in myeloid differentiation – Page 119fingerprints for mouse haemopoietic stem cells and their various myeloid and lymphoid 
progeny
386. Bone marrow and peripheral blood cells were isolated from C57BL/6 mice and 
lineage-restricted populations obtained using a combination of surface expression markers. 
Purified cell populations were analysed for global gene expression differences using 
Affymetrix microarray chips. We extracted raw data from supplementary information 
provided for 15 Klf family members and plotted expression in monocytic, granulocytic, 
erythroid, and various lymphoid subpopulations relative to haemopoietic stem cells. This data 
is presented as a heat map in Figure 4.6A. Unsupervised hierarchical cluster analysis was 
performed to generate evolutionary gene trees using MultiExperiment Viewer v4.5.1. 
We were also able to obtain expression data for myeloid and erythroid lineages derived from 
human CD34
+ haemopoietic progenitors. In a study by Tonks, et al., human CD34
+ cells from 
cord blood samples were cultured in IL-3, SCF and G/GM-CSF for 6 days then sorted to 
obtain various lineages using a combination of surface expression markers
387. Purified cell 
populations were analysed for global gene expression differences using Affymetrix 
microarray chips. We extracted raw data for 14 KLF family members from supplementary 
information and plotted expression in monocytic, granulocytic and erythroid lineages relative 
to control CD34
+ progenitors. Data is presented as a heat map in Figure 4.6B. Unsupervised 
hierarchical cluster analysis was performed to generate evolutionary gene trees as described 
above.
The results of this expression profiling analysis were consistent with the reported expression 
profiles and functions of selected KLF family members. For example, KLF1 (or Erythroid
Krüppel-Like Factor) was strongly up-regulated in erythroid populations in both mouse and 
human data sets, consistent with studies demonstrating a role for this gene in development of 
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Figure 4.6: Expression of KLF family members in myeloid lineages (primary cells). Heat maps showing 
expression of KLF5 (starred) and other family members in mouse and human haemopoietic lineages. Data 
was extracted from the microarray studies described below by C. Kok. Unsupervised heirarchical cluster 
analysis was performed to generate the evolutionary gene trees shown above (Euclidean distance metric 
selection and average linkage clustering). A. Expression of Klf family members in primary mouse 
haemopoietic lineages. Data was extracted from a study by Chambers, et al. in which mature haemopoietic 
cell populations and haemopoietic stem cells were freshly harvested from bone marrow or peripheral 
blood386. Gene expression for each population was analysed by microarray. Heat map colours represent fold 
change relative to haemopoietic stem cells as indicated by the colour scale (log2). B. Expression of KLF
members in primary human haemopoietic lineages. Data was extracted from a study performed by Tonks, et 
al. where human CD34+ cells were cultured in IL-3, SCF and G/GM-CSF for 6 days prior to isolation of 
mature cell populations387. Microarray analysis was performed to analyse gene expression levels in each 
mature population and in CD34+ progenitor cells. Heat map colours represent fold change relative to CD34+





































































































































































Chapter 4: KLF5 expression and function in myeloid differentiation – Page 121the erythroid lineage
138,139. Klf2 was shown to be expressed in naïve murine T-cell 
populations, where studies have shown that it functions in the maintenance of progenitor T-
cell populations
142. KLF4 expression was found to be up-regulated in the monocyte lineage in 
both human and mouse data-sets, which is consistent with studies demonstrating that KLF4 is 
an essential regulator of monocyte formation and activation
388,389.
In both the human and mouse data-sets, KLF5 was found to be up-regulated in the 
granulocyte population. Interestingly, Klf5 expression was also increased in the murine 
monocyte lineage, although this change was markedly less than that seen in the granulocyte 
compartment. There was no change in KLF5 expression in the human monocyte lineage when 
compared to CD34
+ progenitors. 
Cluster analysis of Klf family members in mouse haemopoietic lineages demonstrated that 
expression of Klf5 most closely correlated with that of Klf6, Klf10 and Klf12. These genes all 
showed decreased expression in B-cell and T-cell populations compared to haemopoietic stem 
cells, suggesting that down-regulation of these factors is required in development of lymphoid 
lineages. However, of these 4 genes, only Klf5 was up-regulated in the granulocyte lineage. In 
the human data-set, KLF5 expression clustered with KLF8, KLF12 and KLF15. These four 
genes were not regulated in the monocyte or erythroid lineages, and of the four genes only 
KLF5 was up-regulated in the granulocyte lineage. Of all the KLF family members presented 
in these analyses, KLF5 was the only gene which displayed maximum up-regulation of 
expression in the granulocyte lineage compared to primitive populations, supporting a specific 
role for this KLF member in granulocyte development. 
Chapter 4: KLF5 expression and function in myeloid differentiation – Page 122 4.2.2 Retroviral expression of KLF5 induces macrophage differentiation, cell 
cycle arrest and cell death
4.2.2.1 Enforced expression in the FDB1 cell line model 
To examine the effect of enforced expression of KLF5 on myeloid cell growth and 
differentiation, murine Klf5 was constitutively expressed from the MIG retroviral vector
320 in 
FDB1 cells. FDB1 cells were transduced with the murine MIG-Klf5 construct or the empty 
MIG vector as a control. Twenty-four hours after infection, GFP
+ cells were isolated using 
FACS and recovered overnight in growth medium containing IL-3 (500 BMU/ml). Sorted 
populations were seeded at 1x10
5 cells/ml on Day 2 post-transduction in medium containing 
IL-3 (sorted populations were >90% positive for expression of GFP). Assays for effects on 
cell viability, expansion, growth arrest and differentiation were performed on Days 2 and 4 
post-transduction.
FDB1 cells transduced with Klf5 displayed significantly reduced GFP
+ cell expansion, as 
shown in Figure 4.7A. Analysis of total cell viability showed that this may be partly due to 
induction of cell death, as Klf5-transduced cells exhibited a 40% average reduction in viable 
cell number on Day 4 compared to control cells (Figure 4.7B). This result did not reach 
significance, however, as the effect on cell death was variable between independent assays 
(n=3, p=0.080). Propidium iodide staining on Day 2 post-transduction revealed a significant 
accumulation of cells in G0/G1 phase (82% of cells transduced with Klf5 compared to 68% of 
control cells), with half as many Klf5-transduced cells entering the S and G2/M phases 
compared to control cells (Figure 4.7C). By Day 4 post-transduction, cells transduced with 
Klf5 had the appearance of mature macrophages (Figure 4.7D). These were larger than control 



























































Figure 4.7 (A-D): Enforced expression of murine KLF5 in the FDB1 cell line model. A. GFP+ cell
expansion. The total number of live cells was determined at Day 4 by Trypan Blue staining and cell counts, and 
the percentage of GFP+ cells determined by flow cytometry. The number of GFP+ cells was hence determined 
and expansion calculated relative to seeding on Day 2. n=3, *p<0.05. B. Total cell viability was assessed by 
Trypan Blue staining and cell counts on Day 4 post-transduction. n=3, p=0.080. C. Day 2 flow cytometric 
assessment of cell cycle by propidium iodide staining. Representative results from a typical experiment are 
shown. n=3, p=0.002, 0.010 and 0.022 for G0/G1, S and G2/M phases respectively. D. Representative 
photomicrographs showing Wright-Giemsa stained cytospin preparations of FDB1 cells transduced with Klf5 or
the empty vector control in IL-3 (Day 4). Original magnification = 200x. Note that cells were >90% positive for 
































































































































Figure 4.7 (E-F): Enforced expression of murine KLF5 in the FDB1 cell line model. E. Two-colour flow 
cytometric detection of c-Fms and Gr-1 expression on FDB1 cells transduced with Klf5 or the empty vector 
control. Expression was detected using PE-conjugated antibodies on GFP+ cells. Profiles show representative 
results from a typical experiment on Day 2 post-transduction (empty peak = isotype control, grey peak = cell 
surface marker expression). F. Average percentage expression and mean fluorescence intensity (MFI) of c-




MFI 1.5 MFI 6.2
MFI 15.5 MFI 38.4
Chapter 4: KLF5 expression and function in myeloid differentiation – Page 125cells, and were characterised by light-staining, granular cytoplasms, small rounded nuclei, and 
ruffled cellular edges. Analysis of cell surface marker expression on GFP
+ cells also 
confirmed differentiation of Klf5-transduced FDB1 cells (Figure 4.7E). We observed a 
significant increase in the proportion of cells positive for the monocyte-specific marker c-Fms 
in Klf5-transduced populations on Day 2 post-transduction (Figure 4.7F), which is consistent 
with the macrophage morphology of these cells. There was also a significant increase in the 
level of Gr-1 expression on Day 2 post-transduction (see Figure 4.7F). Gr-1 is primarily 
expressed on mature granulocytes, but is also expressed transiently on a subset of monocytes 
during differentiation along the monocyte-macrophage lineage
390. We have previously 
observed that Gr-1 is highly expressed on mature macrophages in the FDB1 cell line model 
(A. Brown, unpublished data), which is consistent with the macrophage morphology observed 
on transduction with Klf5 (see Figure 4.7D). Collectively, these results show that KLF5 is 
capable of inducing macrophage differentiation and growth arrest of FDB1 cells in the 
presence of IL-3. 
4.2.2.2 Enforced expression in primary murine bone marrow progenitors 
We next wished to study the effect of enforced KLF5 expression in a primary biological 
system, and thus used retroviral transduction to infect murine bone marrow progenitor cells 
for analysis. Bone marrow cells were freshly isolated from C57BL/6 mice treated with 5-
fluorouracil to enrich for haemopoietic progenitors
385. These were cultured for 3 days in 
growth medium containing IL-3 (500 BMU/ml), IL-6 (10 ng/ml) and SCF (50 ng/ml), then 
transduced with either the murine MIG-Klf5 construct or empty MIG vector. Forty-eight 
hours post-transduction cells were sorted for GFP expression, then recovered overnight. 
Functional assays were established from Day 3 post-transduction, with populations that 
contained >90% GFP
+ cells. For liquid culture experiments, all cells were seeded in a 
Chapter 4: KLF5 expression and function in myeloid differentiation – Page 126 cytokine cocktail of IL-3 (500 BMU/ml), IL-6 (10 ng/ml) and SCF (50 ng/ml). c-Kit 
expression and cell cycle status were assessed on Day 3, and cell expansion, viability and 
morphology were assessed on Days 3, 5 and 7. For colony assays, cells were seeded on Day 3 
post-transduction in methylcellulose medium containing either the IL-3/IL-6/SCF cytokine 
cocktail (as above), or G-CSF (100 ng/ml) or M-CSF (100 ng/ml) as the sole cytokine. 
Colonies of 40 cells were scored after 7 days in culture, and individual colonies cultured in 
G-CSF or M-CSF were picked for morphological analysis. 
As with FDB1 cells, transduction of murine haemopoietic progenitors with Klf5 dramatically 
inhibited cell expansion in liquid culture (Figure 4.8A). This was again accompanied by 
reduced cell viability (Figure 4.8B), and an accumulation of cells in G0/G1 phase (Figure 
4.8C). On Day 3 post-transduction, cells transduced with Klf5 displayed decreased expression 
of c-Kit (Figure 4.8D), a marker which is highly expressed on haemopoietic stem cells and 
myeloid progenitors but decreases during differentiation
391. Morphologically, the appearance 
of mature macrophages was detected much sooner than in cells carrying the empty vector 
(Figure 4.8E). Differential cell counts revealed that transduction with Klf5 significantly 
increased the proportion of macrophages when compared to control cells on Days 3 and 5 
post-transduction (Figure 4.8F). This was accompanied by a comparable decrease in the 
proportion of immature cells on these days, which is consistent with the observed reduction in 
c-Kit expression on Day 3 (see Figure 4.8D). We did not detect substantial differences in the 
proportion of granulocytes, although a small decrease (approximately 5%) was observed in 
cells transduced with Klf5 on Day 5 of the assay.
Bone marrow progenitors transduced with Klf5 or the empty vector were seeded in 
methylcellulose supplemented with the IL-3/IL-6/SCF cytokine cocktail, allowing formation 
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Figure 4.8 (A-D): Enforced expression of murine KLF5 in primary mouse bone marrow progenitors. 
Bone marrow cells transduced with Klf5 or empty vector control were seeded in liquid culture medium 
containing IL-3, IL-6 and SCF (populations were >90% GFP+ on day of seeding). A. The total number of live 
cells was determined at each time-point by Trypan Blue staining and cell counts, and cell expansion determined 
relative to Day 3. n=2, *p<0.05. B. Total cell viability was assessed by Trypan Blue staining and cell counts. 
n=2, *p<0.05. C. Day 3 flow cytometric assessment of cell cycle by propidium iodide staining. Representative 
results from a typical experiment are shown. n=2, p=0.045, 0.019 and 0.071 for G0/G1, S and G2/M phases 
respectively. D. Flow cytometric detection of c-Kit on GFP+ bone marrow cells transduced with Klf5 or the 
empty vector control. Expression was detected on Day 3 post-transduction using cells grown in liquid culture 
medium supplemented with IL-3, IL-6 and SCF. Profiles show representative results from a typical experiment 
































Chapter 4: KLF5 expression and function in myeloid differentiation – Page 128Figure 4.8 (E): Enforced expression of murine KLF5 in primary mouse bone 
marrow progenitors. E. Representative photomicrographs showing Wright-Giemsa 
stained cytospin preparations of bone marrow cells transduced with Klf5 or the 
empty vector control. Cells were seeded in liquid culture medium supplemented with 
IL-3, IL-6 and SCF and samples taken for analysis at Days 3, 5 and 7 as indicated 
(populations were >90% GFP+ on day of seeding). Original magnification = 200x.




























































































Figure 4.8 (F): Enforced expression of murine KLF5 in primary mouse bone 
marrow progenitors. F. Proportion of immature cells, macrophages and 
granulocytes in bone marrow populations transduced with Klf5 or the empty vector 
control. Cells were seeded in liquid culture medium supplemented with IL-3, IL-6 
and SCF, and cell counts performed using cytospin preparations taken at Days 3, 5 
and 7 post-transduction (populations were >90% GFP+ on day of seeding). * p<0.05, 
n=2.
F.

































































































































Figure 4.8 (G-H): Enforced expression of murine KLF5 in primary mouse bone marrow progenitors. 
G. Bone marrow cells expressing the empty vector control were seeded on Day 3 post-transduction in 
methylcellulose medium containing G-CSF or M-CSF alone for formation of granulocytic and monocytic 
colonies respectively. Two examples colonies are shown from each condition. The top panel shows colony 
morphology in agar (original magnification = 100x), and the bottom panel shows the morphology of cells in 
the colonies pictured above (original magnification = 400x). Individual colonies were harvested then 
centrifuged onto slides prior to Wright-Giemsa staining. H. Bone marrow cells transduced with Klf5 or the 
empty vector control were seeded on Day 3 post-transduction in methylcellulose medium containing IL-3, 
IL-6 and SCF (CFU-G, CFU-M and CFU-GM), G-CSF alone (CFU-G) or M-CSF alone (CFU-M). 





Chapter 4: KLF5 expression and function in myeloid differentiation – Page 131of CFU-G, CFU-M and CFU-GM; or with G-CSF or M-CSF alone, which supported the 
exclusive formation of granulocyte or macrophage colonies respectively as shown in Figure 
4.8G. Klf5 transduction had a significant effect on the colony forming potential of murine 
bone marrow progenitors in all three conditions (Figure 4.8H). A 5.4-fold reduction in colony 
number was detected due to transduction with Klf5 when cells were seeded in methylcellulose 
supplemented with the IL-3/IL-6/SCF cytokine cocktail, which is consistent with results from 
liquid culture experiments where transduction with Klf5 inhibited cell expansion. As Klf5
transduction severely reduced colony formation in this condition, we were unable to 
determine if there was a significant effect on lineage specification through colony typing. 
Interestingly, transduction with Klf5 also decreased colony formation in both G-CSF and M-
CSF (see Figure 4.8H). Collectively these results suggest that enforced expression of KLF5 
acts on early myeloid progenitors to inhibit growth and survival, and promote differentiation. 
4.2.3 RNAi-mediated knock-down of Klf5 induces effects consistent with 
reduced granulocyte differentiation 
4.2.3.1 Knock-down in the 32D cell line model of G-CSF-induced granulocyte 
differentiation
As Klf5 mRNA levels were found to increase during 32D cell differentiation in response to G-
CSF (Section 4.2.1.2), we were interested to see if knock-down of Klf5 in this system would 
suppress granulocyte differentiation. We utilised 9 independent shRNA sequences predicted 
to target Klf5 in an attempt to knock-down Klf5 expression in 32D cells by RNAi. Three Klf5
shRNA constructs were purchased from the Open Biosystems shRNAmir library collection in 
the p-SHAG MAGIC 2 vector (pSM2c)
323. shRNAmirs are designed to mimic natural 
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to produce more effective knock-down . Two control shRNAs were also assessed in this 
vector system (one non-targeting shRNA (pSM2c-NT) and one targeting eGFP (pSM2c-
GFP)). The remaining 6 shRNA constructs had been previously designed and cloned into the 
retroviral 
392
pMSCV-'LTR-H1 vector (pM'H), which is based on the pRETRO-SUPER siRNA 
vector
322. In this construct, transcription is under the control of a constitutive Histone H1 
RNA polymerase III promoter which is coupled to precise termination of transcription at a run 
of four or more ‘T’ nucleotides at the end of the siRNA sequence
393. Two control shRNAs 
were also assessed in this vector system (one non-targeting shRNA (pM'H-NT), and one 
targeting eGFP (pM'H-GFP)). For details of all shRNA constructs, see Chapter 2, Section 
2.2.4.
32D cells were transduced with each of the shRNA constructs then cultured in medium 
containing puromycin for 7 days to develop stable populations. Transduction and selection of 
cells was undertaken in medium supplemented with IL-3. Stable populations cultured in IL-3 
(500 BMU/ml) were assessed for Klf5 mRNA expression using Q-PCR. From the 9 shRNA 
constructs predicted to target Klf5, one shRNA in the pM'H vector (pM'H-K1) substantially 
reduced Klf5 expression compared to the relevant non-targeting control (61% knock-down, 
Figure 4.9A). This pM'H-K1 population was further characterised to determine the 
functional effects of reduced Klf5 expression in the 32D model of granulocyte differentiation. 
Expression of the remaining shRNA constructs did not substantially reduce the level of Klf5
mRNA and were hence not characterised further. 
Stable 32D cell populations transduced with pM'H-K1 or the pM'H-NT control construct 
were assayed in G-CSF (50 ng/ml) to test for cell expansion, viability and differentiation over  
Chapter 4: KLF5 expression and function in myeloid differentiation – Page 133 Klf5-targeting shRNA Control shRNA















































































































































Figure 4.9 (A-D): shRNA knock-down of Klf5 in the 32D cell line model. A. Q-PCR detection of Klf5
mRNA levels in 32D cells expressing shRNA sequences in the pSM2c or pM'H vector. Light grey bars 
indicate control shRNAs (non-targeting = NT, targeting GFP = GFP). Dark grey bars indicate shRNAs 
predicted to target Klf5. Klf5 expression was detected in cells cultured in IL-3 and expression was plotted 
relative to the NT control in each case. Striped bars indicate pM'H-K1 which showed >60% knock-down 
compared to the pM'H-NT control. n=2. B. Q-PCR detection of Klf5 mRNA levels in 32D cells transduced 
with pM'H-K1 as a percentage of expression detected in the pM'H-NT control. Expression was detected at 
Day 0 (cells in IL-3) and at Days 3 and 7 in G-CSF. The percentage knock-down at each time-point is 
indicated (KD). n=3. C-D. Cell expansion and viability of 32D cells transduced with pM'H-K1 or the pM'H-
NT control shRNA. Cells were differentiated in G-CSF over 7 days. Viable cell counts were determined using 





















































Figure 4.9 (E-G): shRNA knock-down of Klf5 in the 32D cell line model. E. Representative 
photomicrographs showing Wright-Giemsa stained cytospin preparations of 32D cells expressing the non-
targeting pM'H-NT shRNA control or the Klf5-targeting pM'H-K1 in G-CSF (Day 7). Original 
magnification = 200x. Gran = mature granuloycte, My = myelocyte. F. Flow cytometric detection of Mac-1 
expression on 32D cells transduced with pM'H-NT or pM'H-K1 on Day 7 in G-CSF. Representative results 
from a typical experiment are shown. Empty peak = isotype control, grey peak = cell surface marker 
expression. Expression was detected using PE-conjugated antibodies, and the average mean fluorescence 
intensity (MFI) is shown. n=3, *p<0.05. G. mRNA expression level of Csf3 (relative to the control Beta-actin 
















































































































Figure 4.9 (H-J): shRNA knock-down of Klf5 in the 32D cell line model. H. Representative 
photomicrographs showing MPO activity of 32D cells expressing the pM'H-NT shRNA control or the 
Klf5-targeting pM'H-K1 in G-CSF (Day 7). Original magnification = 200x. MPO activity was detected 
using the Hanker-Yates method. A total of 200 cells were counted per sample and the average percentage 
of cells positive for MPO is shown. n=3, ***p<0.001. I-J. mRNA expression levels of Ltf and Cebpe 
(relative to the control Beta-actin gene) were assessed by Q-PCR in 32D cells transduced with pM'H-NT 
or pM'H-K1 on Day 7 in G-CSF. n=3, *p<0.05.
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on Days 3 and 7 in G-CSF (Figure 4.9B). Functional analysis demonstrated that decreased 
Klf5 expression was associated with improved expansion of pM'H-K1 cells compared to the 
pM'H-NT control population (Figure 4.9C) but did not affect cell viability (Figure 4.9D). 
Morphologically, pM'H-NT control cells differentiated over 7 days in G-CSF to mature 
granulocytes characterised by polylobulated or ringed nuclei, as well as granulocyte 
intermediates (metamyelocytes and band cells) characterised by indented or ‘C’-shaped nuclei 
(Figure 4.9E). pM'H-K1 cells produced some mature granulocytes by Day 7 in G-CSF, 
however the majority of cells were granulocyte intermediates. These included 
metamyelocytes and band cells, and also a proportion of cells with larger and less-indented 
nuclei characteristic of more immature myelocytes. These observations suggest that pM'H-
K1 cells did not differentiate to the same extent as control cells. 
To confirm attenuated granulocyte differentiation associated with reduced Klf5 expression, 
pM'H-K1 cells were further assessed for characteristics of granulocyte differentiation on Day 
7 in G-CSF. We previously demonstrated increased expression of the differentiation markers 
Mac-1 (by flow cytometry) and Csf3 (by Q-PCR) during G-CSF-induced granulocyte 
differentiation of the 32D cell line (see Section 4.2.1.2). Flow cytometry revealed 
significantly reduced expression of Mac-1 on pM'H-K1 cells compared to the pM'H-NT 
control on Day 7 in G-CSF, consistent with reduced differentiation (Figure 4.9F). mRNA 
expression of the murine G-CSF receptor Csf3 was not significantly affected due to decreased 
Klf5 expression (Figure 4.9G). Assays to detect markers of neutrophilic granule formation 
revealed that the pM'H-K1 population had significantly fewer cells positive for MPO activity 
compared to the control population on Day 7 (Figure 4.9H), and Ltf mRNA expression was 
also significantly decreased as detected by Q-PCR (Figure 4.9I). Reduced Ltf expression is 
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201. Finally, Q-
PCR analysis also revealed significantly lower expression of the granulocytic transcription 
factor Cebpe in pM'H-K1 cells compared to the control pM'H-NT population (Figure 4.9J), 
which we and others have demonstrated increases during granulocyte differentiation of 32D 
cells (see Section 4.2.1.2 and Scott, et al. for example
384). Collectively, these observations are 
consistent with reduced granulocyte differentiation of 32D cells in response to G-CSF 
associated with reduced expression of Klf5.
4.3 Discussion 
4.3.1 Increased expression of KLF5 mRNA is predominantly associated with 
granulocyte differentiation 
The results presented in this chapter demonstrated up-regulation of Klf5 expression during 
GM-CSF-induced granulocyte-macrophage differentiation of the FDB1 cell line. Analysis of 
KLF5 expression in an alternative cell line and in primary cell systems showed that increased 
KLF5 expression is predominantly associated with the granulocyte lineage. Expression of 
Klf5 was up-regulated during G-CSF-induced granulocyte differentiation of murine 32D cells. 
Conversely, Klf5 expression was down-regulated during M-CSF-induced macrophage 
differentiation of mouse bone marrow progenitors. Bioinformatic analysis of published 
microarray data showed that KLF5 was up-regulated to a greater extent relative to primitive 
haemopoietic cells in primary granulocyte populations than in monocyte or erythroid 
populations, and conversely demonstrated that Klf5 expression was down-regulated in cells of 
lymphoid lineages. Collectively, these observations are consistent with a potential role for  
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levels of KLF5 in these systems to confirm that this also correlates with granulocyte 
differentiation, as recent analyses have demonstrated that mRNA expression is not always 
indicative of protein expression due to parameters such as translation efficiency and protein 
turnover (correlation coefficients (r) ranging from 0.36-0.76 depending on the organism 
evaluated and study design)
394.
4.3.2 Enforced expression of KLF5 is sufficient to induce macrophage 
differentiation of FDB1 cells and primary murine bone marrow progenitors 
In accordance with KLF5 expression patterns, the functional studies presented in this chapter 
provide evidence supporting a role for KLF5 in myeloid differentiation. We demonstrated that 
retroviral expression of KLF5 was sufficient to promote macrophage differentiation of murine 
haemopoietic progenitor cells. In the FDB1 cell line system, transduction with Klf5 overcame 
the IL-3 induced differentiation block to induce macrophage differentiation, and in primary 
mouse haemopoietic progenitors, enforced expression of KLF5 promoted macrophage 
differentiation at the expense of immature cells. KLF5-induced differentiation was 
accompanied by an accumulation of cells in G0/G1 phase and by cell death, both processes 
which are tightly linked to terminal cell maturation
395,396. With regard to cell survival, studies 
have demonstrated a pro-apoptotic role for KLF5 expression in the TE2 esophageal cancer 
cell line
284. From the results presented in this chapter we were not able to conclude if the 
reduced cell viability observed due to Klf5 transduction in haemopoietic cells is a 
consequence of terminal differentiation, or whether KLF5 may also be acting to specifically 
induce apoptosis.
Chapter 4: KLF5 expression and function in myeloid differentiation – Page 139 Given that Klf5 expression is predominantly associated with granulocyte differentiation, it is 
interesting that we observed macrophage formation due to enforced expression of KLF5 in 
both FDB1 cells and primary murine bone marrow progenitors. It is possible that we were 
unable to detect granulocytes using these approaches as they have a shorter lifespan than 
macrophages
397, which could lead to selective loss of granulocytes in liquid culture. 
Alternatively it is possible that the observed macrophage differentiation is a consequence of 
inappropriate KLF5 expression. In Figures 4.2 and 4.4, we showed that Klf5 mRNA levels 
increased approximately 2-fold during differentiation of both FDB1 and 32D cells, suggesting 
that small changes in expression of this gene may be sufficient to promote differentiation. 
These physiological levels are greatly exceeded through MSCV promoter-driven expression, 
potentially causing inappropriate activation of target-genes by KLF5. For example, as KLF 
family members bind to similar DNA sequences to activate target genes
195,196, it is possible 
that high levels of KLF5 may also be activating KLF4 target genes to direct macrophage 
differentiation
388. Importantly, KLF5 has been shown to activate expression of the 
transcription factor EGR1 in VSMCs
234, which in the haemopoietic system drives macrophage 
differentiation
398,399. Therefore, inappropriate activation of Egr1 by KLF5 over-expression 
could be another potential mechanism to account for macrophage differentiation in FDB1 
cells and in murine haemopoietic progenitors.
The expression profiles of KLF5 during granulocyte-macrophage differentiation suggest that 
spatial and temporal control of KLF5 expression may be important for KLF5 function. In the 
approach described in this chapter, KLF5 was constitutively expressed in all progenitor types 
rather than being restricted to a stage of committed granulocyte progenitors. Interestingly, a 
study performed by Sasmono, et al. suggested that macrophage differentiation acts as the 
‘default’ pathway in myelopoiesis, and that additional signals are required to specify 
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314. Thus, we could speculate that in some myeloid progenitors KLF5 
induces growth arrest which then couples to this default pathway. This could be resolved by 
introducing KLF5 retrovirally into purified populations of granulocyte-macrophage 
progenitors or common myeloid progenitors. It may also be of benefit to utilise inducible 
over-expression experiments, which have proven to be successful in elucidating the function 
of transcription factors such as C/EBPD in myeloid systems
400,401. In this way it may be 
possible to control timing of KLF5 induction and also the level of expression. 
4.3.3 Reduced expression of Klf5 produces functional effects consistent with 
reduced granulocyte differentiation in the 32D cell line model 
We next wished to determine if Klf5 expression was necessary for G-CSF-induced 
granulocyte differentiation of 32D cells using a series of RNAi knock-down experiments. A 
single shRNA trigger (pM'H-K1) consistently reduced Klf5 mRNA expression by >60% 
compared to the relevant control construct when cells were cultured in IL-3 or on Days 3 and 
7 in G-CSF. Reduced Klf5 expression in this population was associated with increased cell 
expansion compared to the non-targeting control population in G-CSF, consistent with 
reduced differentiation. Correspondingly, morphological analysis revealed that cells with 
reduced Klf5 mRNA expression displayed a reduced level of granulocyte differentiation, as 
seen by the presence of immature cells of the granulocyte series on Day 7 in G-CSF. 
Attenuated granulocyte differentiation due to reduced Klf5 expression was associated with 
decreased expression of the myeloid marker Mac-1, the primary granule protein MPO, and 
the granulocyte genes Ltf and Cebpe. An independent means of reducing KLF5 function, such 
as independent siRNA triggers or a dominant-negative form of KLF5, will be necessary to 
confirm these results. 
Chapter 4: KLF5 expression and function in myeloid differentiation – Page 141 Although reduced Klf5 expression in 32D cells resulted in functional effects which were 
consistent with inhibition of granulocyte differentiation, it is clear that granulocyte 
differentiation was not completely blocked in this system. It is possible that the 60% 
reduction in Klf5 expression was not sufficient to prevent normal function in G-CSF-induced 
granulocyte formation. Studies assessing the role of KLF5 in ESCs have demonstrated that as 
little as 10-20% of normal Klf5 mRNA expression is sufficient to maintain KLF5 function in 
this system
160,245. In light of these considerations, we are constructing a transgenic mouse 
model where Klf5 will be targeted for deletion specifically in the haemopoietic compartment 
using a Cre-Lox system. This will enable complete eradication of KLF5 expression in vivo for 
analysis of KLF5 function in a relevant biological system. 
4.3.4 Evidence for a regulatory pathway involving KLF5 and members of the 
C/EBP family in G-CSF and GM-CSF-induced differentiation 
As KLF5 expression was up-regulated during G-CSF induced granulocyte differentiation and 
in primary granulocyte populations, we were interested to compare the expression profile of 
KLF5 with that of the two granulocytic transcription factors CEBPA and CEBPE in our cell 
line models of differentiation. We demonstrated that regulation of Klf5 mRNA expression is 
concordant with that of Cebpe during G-CSF-induced differentiation of 32D cells, and during 
GM-CSF-induced differentiation of FDB1 cells. Studies have demonstrated that CEBPE
mRNA expression is induced during differentiation of primary human CD34
+ cells to 
granulocytes but not macrophages
373. Accordingly, it has been shown that C/EBPH functions 
in terminal granulocyte differentiation and activation, with knock-out mouse models failing to 
produce mature neutrophils
375. The highly concordant expression patterns of Klf5 and Cebpe
Chapter 4: KLF5 expression and function in myeloid differentiation – Page 142 during cytokine-induced differentiation further support a similar role for KLF5 in granulocyte 
differentiation.
During G-CSF-induced differentiation of 32D cells, we detected an early peak in Cebpa
expression, which was followed by a steady increase in mRNA levels of both Cebpe and Klf5.
CEBPE is a direct downstream target gene activated upon binding of C/EBPD
402. KLF5 has 
been previously implicated as a direct target gene of C/EBPD, as expression increased in 
response to enforced C/EBPD expression in human CD34
+ haemopoietic progenitor cells 
cultured in the presence of the protein synthesis inhibitor cyclohexamide
132. Collectively, 
these observations suggest a regulatory cascade during G-CSF-induced differentiation 
whereby C/EBPD up-regulates transcription of Cebpe and Klf5 which mediate terminal 
granulocyte differentiation. It will be necessary to show binding of C/EBPD to KLF5
promoter sequences using ChIP assays to confirm direct regulation in granulopoiesis. 
In models of granulocyte differentiation, it has been shown that G-CSF activates C/EBPD
through G-CSF receptor (CSF3) signalling, and in turn C/EBPD induces expression of 
CEBPE and the primary granule gene MPO
402-405. C/EBPD can also stimulate expression of 
CSF3 through a positive-feedback loop
404,406. Studies have shown that C/EBPH acts further 
downstream of C/EBPD by activation of the secondary granule gene LTF, however it does not 
affect expression of MPO or CSF3
375,377,407. In 32D cells with reduced Klf5 expression (see 
Section 4.2.3), we detected decreased expression of active MPO enzyme, and decreased 
mRNA expression of Ltf and Cebpe, but not of Csf3. These results, combined with our 
expression profiling studies (discussed above), suggest that KLF5 may act downstream of 
C/EBPD during granulocyte differentiation, as knock-down in 32D cells did not affect Csf3
expression. Our analysis also suggests that KLF5 may act upstream of C/EBPH, as reduced 
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Klf5 expression was associated not only with decreased Ltf expression, but also with reduced 
expression of the primary granule protein MPO and of Cebpe itself. 
Despite the up-regulation of Klf5, Cebpe, and other C/EBPD target genes (e.g. Mmp8, Per2,
Slfn2
1) during FDB1 differentiation, we showed that expression of Cebpa mRNA expression 
decreased during GM-CSF-induced differentiation of FDB1 cells. It is therefore possible that 
GM-CSF-induced differentiation of FDB1 cells occurs independently of C/EBPD, and that 
other proteins such as alternative members of the C/EBP family are responsible for the 
observed activation of C/EBPD target genes in this system. For example, there is evidence to 
suggest that granulopoiesis can occur independently of C/EBPD via C/EBPE and C/EBPG in 
murine cell line and animal models
408-411, and these two proteins have been shown to regulate 
Klf5 expression in adipose tissue
156. Alternatively, it is possible that C/EBPD activity in FDB1 
cells may be predominantly under post-transcriptional or post-translational control in response 
to GM-CSF. It is well known that C/EBPD is regulated by a variety of post-translational 
mechanisms which alter functional activity, such as phosphorylation and sumoylation
412-414.
C/EBPD activity can also be modulated by the relative expression ratio of it’s two protein 
isoforms, p42 and p30, which demonstrate distinct transactivational activities
37,415. To explore 
these possibilities further it will be necessary to detect modified C/EBPD protein using anti-
phospho-C/EBPD antibodies or anti-SUMO immunoprecipitation techniques, and also to 
quantitate the relative expression of C/EBPD protein isoforms during GM-CSF-induced 
FDB1 differentiation.Chapter 5 – Deregulation of KLF5 in human Acute 
Myeloid Leukaemia. 
5.1 Introduction 
In AML, many transcription factors found to be important for normal haemopoiesis are 
affected by mutation or chromosomal translocation, resulting in enhanced growth and survival 
or a block in differentiation
38,416. In particular, reduced biological activity of transcription 
factors with tumour suppressor function (e.g. p53, RB, C/EBPD) is an important feature in the 
development of AML
417. Conventional tumour suppressor genes normally act in biological 
processes such as cell cycle arrest, apopotosis, or cellular differentiation
418. The data 
presented in Chapter 4 is consistent with KLF5 acting as an inducer of growth arrest and 
myeloid differentiation, suggesting a potential role for KLF5 as a novel tumour suppressor in 
AML.
Tumour suppressor genes can be affected by inactivating mutations in haemopoietic 
malignanices, however, in the absence of mutation, the expression levels of these genes are 
often decreased due to deletion or other mechanisms
417. Studies have shown that reduced 
mRNA expression can be a marker for identification of novel tumour suppressor genes in 
AML, such as TRIB2 and NOTCH1
419,420. Methylation is a frequent mechanism associated 
with silencing of tumour suppressor genes in AML, for example, the SOCS1 gene was found 
to be hypermethylated in 60% of AML
421, and the pro-apoptotic DAPK1 gene was reported to 
be hypermethylated in 47% of therapy-related AML
422. KLF5 has been previously implicated 
Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 145 as a tumour suppressor in breast and prostate cancer, with studies demonstrating decreased 
expression due to hemi- or homozygous deletion or excessive protein degradation in disease 
tissue
224,295,297,300,301. Importantly, deletion of the 13q21-22 chromosomal region containing 
KLF5 has been described in various lymphoid and myeloid malignancies
305,306, and loss of 
hetereozygosity has also been detected for this region in AML patient samples
307,308. CpG 
methylation of KLF5 has been reported in MPN, MDS and in AML, though not thoroughly 
investigated
111,309. Methyl-binding protein ChIP analysis has demonstrated methylation of 
KLF5 in the AML cell lines KG-1 and U937, and in peripheral blasts from 2/9 AML 
patients
111. This finding has been further corroborated by a study showing that KLF5 was 
hypermethylated in 2/17 patients with secondary AML transformed from MDS
309.
We initially sought to determine if KLF5 mRNA expression is decreased in AML samples 
compared to primitive haemopoietic cells from normal controls. Given that KLF5 expression 
is associated with C/EBP regulatory pathways (Chapter 4, Section 4.3.4), we were also 
interested to see if KLF5 expression levels correlated with any particular subtype or 
mutational category of AML. For these studies, we performed Q-PCR to detect KLF5
expression in a local cohort of diagnostic bone marrow biopsies from AML patients and 
normal bone marrow controls, and interrogated a larger publicly-available microarray dataset 
for further analysis
329. We sought to further examine CpG methylation of the KLF5 gene as a 
potential mechanism for its deregulated expression in AML. Methylation of KLF5 was 
examined in a panel of leukaemia cell lines and in our cohort of primary AML patient 
samples, and we investigated potential correlation of KLF5 CpG methylation with specific 
genetic lesions or subtypes of AML. To assess whether methylation of KLF5 functionally 
represses transcription, we treated leukaemia cell lines showing hypermethylation of KLF5
with methyltransferase inhibitors to detect reactivation of expression. Leukaemia samples 
Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 146 were compared with normal bone marrow controls to define the genomic region of 
differential CpG methylation, providing some insight as to how methylation could interfere 
with regulation of KLF5 expression. Finally, the tumour suppressor activity of KLF5 was 
investigated by retroviral expression of KLF5 in a leukaemia cell line displaying low KLF5
expression.
5.2 Results 
5.2.1 KLF5 mRNA expression is reduced in AML 
5.2.1.1 Expression in a local cohort of primary AML samples and correlation 
with AML subtype 
KLF5 mRNA expression levels were assessed in a cohort of 30 AML patients (Queen 
Elizabeth Hospital/IMVS cohort - details regarding collection, processing and genotyping are 
provided in Chapter 2, Section 2.4.1). Samples consisted of BMMNC preparations taken from 
patients at diagnosis (characteristics shown in Table 5.1). We included 5 bone marrow CD34
+
progenitor samples from healthy volunteers as normal controls. cDNA templates were 
prepared and replicate Q-PCR reactions were performed for each sample. KLF5 expression 
levels were also examined in a range of human myeloid leukaemia cell lines (characteristics 
described in Table 5.2). Independent mRNA preparations were used to prepare cDNAs from 
each cell line (refer to Figure 5.1 for replicate numbers), and Q-PCR performed on each 
cDNA preparation. KLF5 expression was determined using the average of Q-PCR results 
from independent cDNA templates for each cell line. AML4 was included in each Q-PCR 
Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 147 Table 5.1: Characteristics of human AML samples. AML BMMNC samples were taken at diagnosis. FAB 
classification, karyotype, and percentage of blasts and CD34+ cells were determined at this time. Diagnostic 
samples were obtained from the Queen Elizabeth Hospital and the IMVS. Genomic DNA was prepared from 
each and assessed for CEBPA, FLT3 and NPM1 mutations. ‘Mut.’ in the CEBPA column indicates a CEBPA
coding region mutation (Mut.* indicates the mutation is potentially a TAD2C polymorphism423). ‘4bp ins.’ in 
the NPM1 column indicates a 4 bp insertion in the NPM1 gene. A dash in the CEBPA, FLT3 and NPM1
columns indicates the patient has wildtype copies of these genes. **AML2  had 63% promyelocytes.  ‘N/A’
indicates value is unknown.
SAMPLE AGE/GENDER  FAB  KARYOTYPE  CEBPA STATUS  FLT3 STATUS  NPM1 STATUS  % BLASTS  % CD34
+
AML 1  80/M  M1  Monosomy 7  -  -  -  83  98 
AML 2  32/F  M3  t(15;17)  -  -  -  23**  1 
AML 3  66/M  M8  Complex (incl. t(9;22))  -  -  -  95  97 
AML 4  19/F  M4  Normal  -  FLT3-ITD  - 64  72 
AML 5  73/M  M2  Normal  -  -  -  97  1 
AML 6  70/F  M1  Complex (incl. monosomy 7, del(5))  -  -  -  60  97 
AML 7  73/M  M2  Normal  -  -  4bp ins.  97  1 
AML 8  65/M  M4  Complex (incl. inv(16), trisomy 8)  -  -  -  40  89 
AML 9  78/M  N/A  Normal  Mut.*  -  -  24  86 
AML 10  73/F  M1  Complex  -  -  -  98  100 
AML 11  49/F  M2  Trisomy 14  -  -  -  45  99 
AML 12  77/M  M4  Normal  -  FLT3-ITD  - 29  74 
AML 13  63/M  M3  Trisomy 8, t(15;17)  Mut.  FLT3-ITD  - 40  12 
AML 14  80/M  M1  Normal  -  -  -  90  94 
AML 15  38/M  M1  Normal  -  FLT3-ITD 4bp  ins.  100  <1
AML 16  51/F  M2  Monosomy 7, del(7q)  -  -  -  83  93 
AML 17  71/F  M1  Del(5q)  -  FLT3-TKD  - 90  96 
AML 18  79/M  M6  Normal  -  -  -  25  82 
AML 19  37/M  M4  Inv(16)  -  FLT3-TKD  - 70  85 
AML 20  71/F  M2  Normal  Mut.  -  -  24  83 
AML 21  89/M  M5  Trisomy 5 & 8, del(5q)  -  -  4bp ins  92  <1
AML 22  83/M  M2  Trisomy 8  Mut.*  -  -  38  52 
AML 23  18/M  M2  Normal  -  -  4bp ins  52  <1
AML 24  72/M  M4  Inv(16)  -  -  -  69  93 
AML 25  80/M  M4  t(13;14)  Mut.*  -  -  21  18 
AML 26  74/M  M3  t(15,17)  -  FLT3-ITD  - 76  34 
AML 27  74/M  M5  Trisomy 8, t(1:17)  Mut.*  FLT3-TKD  4bp ins  71  <1
AML 28  69/M  N/A  Normal  Mut.  -  -  26  88 
AML 29  23/M  M5  11q23 (t(10;11))  -  -  -  95  <1
AML 30  51/M  M1  Complex (incl. +11q23)  -  FLT3-TKD  - 91  <1








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 149reaction, and KLF5 expression levels for both primary samples and cell lines were plotted 
relative to the AML4 reference sample. 
Relative KLF5 expression for individual samples is shown in Figure 5.1A. The majority of 
AML samples displayed low KLF5 expression compared to normal CD34
+ controls. One 
notable exception was AML7, which showed 36-fold higher KLF5 expression than the 
average of other AML samples, and 16-fold higher expression than the average of CD34
+
controls. AML7 was hence excluded from the following analyses as an outlier. Statistical 
analysis of KLF5 expression (Figure 5.1B) demonstrated that average KLF5 expression was 
significantly lower in AML samples than in normal CD34
+ controls, with a mean relative 
expression of 1.14 compared with 2.59. The seven leukaemia cell lines tested also showed 
low levels of KLF5 expression compared to controls, with an average relative expression of 
0.72.
KLF5 mRNA expression was subsequently assessed according to FAB subtype, main 
cytogenetic abnormality, or molecular abnormality including mutations in CEBPA, FLT3 and 
NPM1.  Expression was significantly reduced in FAB subtypes M1, M3 and M4 compared to 
normal CD34
+ controls (Figure 5.2A), and also in samples exhibiting FLT3-ITD mutations 
(Figure 5.2B). There were no significant differences in subgroups according to main 
cytogenetic abnormality, possibly due to the limited sample number in each group (Figure 
5.2C).








































































































































































































































































































Figure 5.1: KLF5 mRNA expression in human AML samples, normal bone marrow controls and human 
leukaemia cell lines as detected by Q-PCR. A. KLF5 mRNA levels in primary human AML BMMNC 
samples at diagnosis (grey bars) leukaemia cell lines (white bars) and normal bone marrow CD34+ controls 
(black bars). KLF5 levels are shown relative to AML4 reference sample. Note that sufficient RNA was not 
obtained for AML16 and AML18 for Q-PCR. Control and AML samples n=2 (from one cDNA preparation), 
cell lines n=2 (MOLM-13), n=3 (K562, MV4;11), n=8 (HL-60, KG-1, THP-1, U937) from independent cDNA 
preparations.  B. Summary of KLF5 expression levels determined by Q-PCR for primary human AML 
BMMNC samples at diagnosis, leukaemia cell lines, and normal bone marrow CD34+ controls (described in 









































































































































Figure 5.2: Differences in KLF5 mRNA expression in human AML samples according to AML 
subtype. KLF5 mRNA expression detected relative to reference sample AML4 by Q-PCR (see Figure 
5.1). Samples were grouped according to: A. FAB subtype, B. molecular abnormality including 
mutations in CEBPA, FLT3 and NPM1, and C. cytogenetic abnormality. Note that NK = normal 
karyotype, and ‘None’ in part ‘C’ indicates no mutations detected in CEBPA, FLT3 or NPM1. Subgroups 




Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 1525.2.1.2 Expression in an expanded cohort of primary AML samples and 
correlation with AML subtype 
We wished to validate our analysis using a larger sample set, and in order to achieve this we 
accessed KLF5 expression data for a large number of AML samples from a land-mark gene 
expression profiling study performed by Valk, et al.
329. In this study, mononuclear cells 
(MNC) were isolated from bone marrow or peripheral blood of 285 AML patient samples and 
8 healthy volunteers as controls (5 MNC and 3 CD34
+ samples), and gene expression analysis 
was performed using Affymetrix arrays. We utilised a normalised data-set for analysis of 
KLF5 expression
435. In support of our observations in Section 5.2.1.1, this analysis showed 
that average KLF5 expression in AML samples was significantly lower than that of the MNC 
controls (log2 RMA normalised expression of 5.6 compared to 7.0) (Figure 5.3A). KLF5
expression in AML samples was not significantly lower than in CD34
+ controls, although this 
may be related to the small number of samples in this control group (CD34
+ n=3). 
In Figures 5.3B-D we present the relative levels of KLF5 mRNA in AML patient samples 
using the normalised Valk data-set according to FAB subtype, molecular abnormality, or 
main cytogenetic abnormality. Statistical analysis demonstrated significantly reduced KLF5
expression in each subgroup examined when compared with the normal MNC control group. 
There were no significant differences in expression between FAB subtypes (Figure 5.3B), or 
between samples grouped by molecular abnormality (Figure 5.3C). There was however some 
variation between AML subgroups according to cytogenetic abnormality; samples exhibiting 
the inv(16) lesion showed significantly lower KLF5 expression than those with trisomy 8 or a 
normal karyotype (Figure 5.3D). This agrees with the Q-PCR results from our local cohort of 
AML patients as presented in Figure 5.2C, which showed that the mean relative KLF5


























































































































































































Figure 5.3: KLF5 expression levels in the Valk cohort. A. Analysis of KLF5 mRNA levels as detected by 
microarray in Valk, et al.329. Samples include normal controls (5 MNC and 3 CD34+ samples) and AML 
MNC (n=274). ***p<0.001. B-D. Analysis of KLF5 mRNA levels as detected by microarray using data from 
Valk, et al.329 grouped by: B. FAB subtype, C. molecular abnormality (mutation in CEBPA, FLT3 or RAS,
over-expression of EVI1), or D. cytogenetic abnormality (NK=normal karyotype). All subgroups show 
significantly reduced KLF5 expression compared to normal controls (blue triangles) using One way ANOVA 




Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 154expression for samples with inv(16) was lower than the mean expression for samples with 
trisomy 8 or a normal karyotype, although these differences did not reach significance. 
5.2.2 Analysis of the KLF5 5` proximal promoter and intron 1 CpG 
methylation in AML 
5.2.2.1 Experimental design 
Methylation analysis of the KLF5 gene was initially performed on the first 15 samples from 
our local AML cohort detailed in Table 5.1. The 7 leukaemia cell lines were also assessed 
(Table 5.2), as well as 3 normal CD34
+ bone marrow controls from Section 5.2.1 for which 
sufficient genomic DNA was available (C3-5 CD34
+). In addition, genomic DNA was 
isolated from 4 normal BMMNC samples which were included in the following analysis. 
Genomic DNA was sent to the AGRF for quantitative methylation analysis using the 
Sequenom EpiTYPER system. The method for detection of methylation is depicted in Figure 
5.4 and described briefly as follows: Genomic DNA is bisulfite-modified, converting 
unmethylated cytosine residues to uracil. Oligonucleotides are designed to amplify regions of 
converted DNA from approximately 100-500 bp in length, and PCR produces amplicons 
where unmethylated cytosine residues are detected as thymidine residues. These amplicons 
are in vitro transcribed and treated with Ribonuclease A for uracil-specific cleavage into small 
fragments. The fragments are assessed by mass spectrometry to determine differences in 
mass. A fragment initially containing a single unmethylated CpG residue (where the original 
cytosine is now detected as an adenosine residue) will be 16 Da lighter in mass than that same 
fragment with a methylated CpG residue (where the original cytosine is now detected as a 
Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 155 Figure 5.4: Overview of Sequenom EpiTYPER system for quantitative methylation analysis. A.
Procedure for quantitative methylation analysis using  amplification and transcription of bisulfite-converted 
DNA combined with MALDI-TOF mass spectrometry analysis. B. Interpretation of mass spectrum to 
quantitate percentage methylation. Figure was adapted from the Sequenom website 
(http://www.sequenom.com).
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                                          NOTE:   
   This figure is included on page 156 of the print copy of  
     the thesis held in the University of Adelaide Library.guanosine residue). Thus one fragment initially containing a single CpG residue can be 
detected by mass spectrometry as two peaks separated by 16 Da, and the ratio of these two 
peaks is used to calculate the percentage of DNA showing methylation at that particular CpG 
residue within each sample. 
We analysed a region of the KLF5 locus stretching from the proximal promoter to the end of 
exon 2 (Figure 5.5). This region was selected as it was predicted to contain a CpG island by 
two independent prediction programs (UCSC Genome Browser and Sequenom EpiDesigner 
program). The region analysed contains a total of 222 CpG dinucleotide residues over 4424 
bp. Fifteen PCR amplicons were designed with the aid of Sequenom EpiDesigner Software to 
cover all but 4 of the 222 total CpG residues (see Figure 5.5). Analysis of methylation using 
the EpiTYPER system is limited by the size of individual cleaved fragments – methylation 
cannot be assessed by mass spectrometry if the fragment is too small or too large, or if there 
are multiple fragments of the same size within any given amplicon. From the 222 total CpG 
residues, we were able to quantitatively assess the methylation status of 150, which are 
indicated in red in Figure 5.5. CpG residues which were not informative in this analysis are 
indicated in green. 
5.2.2.2 Identification of regions which are differentially methylated between AML 
samples and normal controls 
The methylation status of the 150 informative CpG residues in 29 samples (AML samples, 
leukaemia cell lines and normal controls) is represented using a heat map in Figure 5.6 (note 
that CpG residues are numbered according to their total CpG number from the 222 analysed). 
Normal controls are shown in the top 7 rows of Figure 5.6. These displayed little CpG 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 159methylation associated with the proximal promoter, through exon 1, and into intron 1 of 
KLF5. However a higher degree of methylation was observed between CpG residues 189-195, 
which lie approximately midway through intron 1. In exon 2 (CpG residues 213-219) all CpG 
residues were highly methylated in both control and AML samples. This is not surprising, as 
CpG residues which are not part of CpG islands in the genome of normal tissues are usually 
methylated
436. However, when compared to controls, selected primary AML and leukaemia 
cell line samples showed a higher degree of methylation in two distinct areas across the KLF5
region analysed, as indicated in Figure 5.6. The first of these, termed Differentially-
methylated Region 1 (DMR-1), lies at the very 5` end of the region assessed, in the KLF5
proximal promoter. DMR-1 consists of 5 informative CpG residues numbered CpG 3-8. The 
second differentially-methylated region, DMR-2, lies in the first half of KLF5 intron 1, and 
consists of 41 informative CpG residues numbered CpG 141-195. 
We expanded our analysis to include the remaining 15 AML patient samples from our local 
AML cohort (details in Table 5.1), using amplicons selected to cover DMR-1 and DMR-2. 
Amplicon number 1 was selected for analysis of the 5 CpG residues in DMR-1, and amplicon 
numbers 6, 7, 8 and 9 were selected for analysis of 40/41 CpG residues (CpG 141-193) from 
DMR-2 (see Figure 5.5). The methylation results across DMR-1 and DMR-2 for all 30 AML 
samples together with leukaemia cell lines and normal controls are depicted in a heat map in 
Figure 5.7. 
To define a smaller region representative of methylation in KLF5 DMR-2 for further 
quantitative analysis we performed unsupervised hierarchical cluster analysis (Figure 5.8A). 
This revealed a subset of six AML patient samples which clustered independently due to high 
methylation specifically at three CpG residues at the 5` end of DMR-2 (CpG 141-143). These 




























































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.8 (A-B): Defining the differentially-methylated regions of KLF5. A. Unsupervised hierarchical 
clustering of AML samples (n=30) by methylation of KLF5 CpG residues 141-193 (DMR-2). Parameters 
used were Euclidean distance metric selection and average linkage clustering, and the evolutionary gene tree 
is depicted. Heat map shows percentage methylation of individual CpG residues according to the scale 
shown. The AML samples with highest methylation as determined by clustering are indicated. A group of six 
AML samples clustered independently due to high methylation specifically at CpGs 141-143 as shown. The 
two regions chosen for further analysis (CpG 141-143 and CpG 173-181) are boxed in blue. Note that for 
CpG residues 141-143, sample AML30 did not provide informative methylation results and was excluded 
from further analysis. B. The average percentage methylation at CpG residues 141-193 for the group of 
highly-methylated AML samples (identified in part ‘A’) is shown relative to the average percentage 
methylation at these same residues for normal bone marrow CD34+ control samples. The two regions chosen 
for further analysis (CpG 141-143 and CpG 173-181) are boxed in blue.



















































Figure 5.8 (C-D): Defining the differentially-methylated regions of KLF5. C. The average percentage 
methylation of DMR-2 CpG residues 173-181 correlates well with the average percentage methylation 
across the whole of DMR-2 (excluding CpG residues 141-143) as determined using linear regression 
analysis of methylation in AML samples (n=30). Blue line shows linear regression, R and R2 values are 
indicated. D. The location of DMR-1 (CpG residues 3-8) and DMR-2 (CpG residues 141-193) relative to 
the KLF5 genomic region assessed. The location of CpG residues 141-143 and 173-181 chosen for further 
analysis of DMR-2 are shown (termed DMR-2a and DMR-2b respectively). Differentially-methylated 
regions identified in previous studies are also indicated. Potapova, et al.309 identified KLF5 methylation in 
MDS and related disorders. Gebhard, et al.111 identified KLF5 methylation in leukaemia cell lines and 
peripheral blood from AML patients. Note that Gebhard, et al. utilised a methyl-ChIP technique to identify 
methylation, hence the extent of the methylated region is unclear (indicated by dotted arrow). The solid part 
of the arrow indicates the region used for Q-PCR in this ChIP analysis. 
Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 163three CpG residues, termed DMR-2a, were hence selected for further analysis. A group of 
seven AML samples formed a second cluster associated with high methylation across the 3` 
portion of DMR-2. The average methylation in these seven methylated samples was 30% 
higher than the average methylation in normal bone marrow CD34
+ controls from CpG 
residues 173-193 (excluding CpG 176), as shown in Figure 5.8B. From this region of greatest 
differential methylation, we selected CpG residues 173-181 for further quantitative analysis. 
The average percentage methylation of these nine CpG residues, termed DMR-2b, was found 
to be highly representative of the average percentage methylation across the whole of DMR-2 
(excluding CpG residues 141-143, DMR-2a), using results from AML samples as shown in 
Figure 5.8C (R=+0.936, R
2=0.876 using linear regression analysis). The nine CpG residues in 
DMR-2b can be assessed for methylation using a single amplicon, which will facilitate 
analysis of additional AML samples in the future.  
The locations of DMR-1 and DMR-2 relative to the KLF5 genomic region are depicted in 
Figure 5.8D. DMR-1 encompasses a 212 bp region in the proximal promoter, and DMR-2 
encompasses a 1114 bp region in intron 1. The location of CpG residues selected for further 
analysis of methylation in DMR-2 (DMR-2a and DMR-2b) are also shown in Figure 5.8D. 
The location of DMR-2 (particularly DMR-2b) coincides with the region of differential 
methylation identified by Gebhard, et al. in AML
111. There have been no previous reports of 
KLF5 being differentially methylated in DMR-1 in AML. We did not detect any methylation 
in the region reported to be methylated in AML by Potapova, et al.
309.
We sought to determine if methylation of the KLF5 proximal promoter correlated with 
methylation of intron 1 in AML. Using linear regression analysis, we observed that there were 
no significant correlations of methylation in DMR-1 with either DMR-2a or DMR-2b 
Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 164 (Appendix B1-2). A weak negative correlation was detected between methylation of DMR-2a 
and DMR-2b (Appendix B3). All further analyses were therefore performed independently on 
DMR-1, DMR-2a and DMR-2b. 
5.2.2.3 Methylation of KLF5 DMR-1, DMR-2a and DMR-2b in de novo AML 
AML samples were classified as aberrantly methylated if the average percentage methylation 
within a particular DMR was greater than two times the standard deviation above the average 
methylation of BMMNC controls in the same region (Avg BMMNC + 2x STDEV). This 
calculation is a commonly accepted limit to define aberrant methylation (see references for 
example
437-439). For DMR-1, 33% of AML samples assessed were aberrantly methylated 
compared to normal BMMNC controls (Figure 5.9). We were interested to determine any 
potential correlations of a high level of KLF5 methylation with characteristics of AML 
samples at diagnosis, including FAB subtype, cytogenetic abnormality, or mutation. 
Interestingly, all three AML samples displaying monosomy 7/del(7q) from our cohort of 30 
displayed aberrant methylation of DMR-1. Statistical analysis revealed that average DMR-1 
methylation in the monosomy 7/del(7q) subgroup was significantly higher than that seen in 
both the BMMNC and CD34
+ normal controls (Figure 5.10A). It was also significantly higher 
than average DMR-1 methylation in a number of other cytogenetic subgroups including the 
normal karyotype, trisomy 8, 11q23 and t(15;17) groups (Figure 5.10A). Collectively, DMR-1 
methylation was significantly greater in the monosomy 7/del(7q) subgroup than in patients 
negative for this abnormality (Figure 5.10B). There were no significant differences in DMR-1 
methylation between different FAB subtypes and mutational categories, although there were 
non-significant trends observed for increased methylation in FAB M1 and in samples negative 
for mutations in CEBPA, FLT3 and NPM-1 (Figures 5.10C-D). We also assessed overall 
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Figure 5.9: AML samples with aberrant methylation of KLF5 DMR-1. Average percentage methylation of 
DMR-1 in normal bone marrow controls (2x CD34+ and 4x BMMNC) and in primary human AML BMMNC 
samples (n=27). The blue dotted line represents twice the standard deviation above the mean of BMMNC 
controls. AML samples which showed average methylation above this level were classified as aberrantly 
methylated (**p<0.01). The relative genomic location of DMR-1 is indicated. Characteristics of AML 
samples with aberrant methylation of DMR-1 are shown including FAB subtype, cytogenetic abnormality 
(‘Normal’ indicates normal karyotype), and molecular abnormality including mutations in CEBPA, FLT3 or 
NPM1 (‘None’ indicates no mutation in CEBPA, FLT3 or NPM1). Characteristics which are over-represented 
in this group are indicated in purple text. 
Sample FAB Cytogenetic abnormality Molecular abnormality
AML1 M1 Monosomy 7 None
AML6 M1 Complex (incl. monosomy 7, del(5q)) None
AML10 M1 Complex None
AML14 M1 Normal None
AML15 M1 Normal FLT3-ITD, NPM1
AML16 M2 Monosomy 7, del(7q) None
AML23 M2 Normal NPM1
AML24 M4 Inv(16) None
AML28 N/A Normal CEBPA
Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 166 Figure 5.10: AML characteristics associated with high methylation of KLF5 DMR-1. Average percentage 
methylation of KLF5 DMR-1 in AML samples (n=27) grouped according to: A-B. Cytogenetic abnormality, 
C. FAB subtype, or D. mutation status of CEBPA, FLT3 and NPM1. Normal bone marrow controls (2x CD34+
and 4x BMMNC) are included for comparison (blue triangles). ‘NK’ in part ‘A’ indicates normal karyotype. 
‘None’ in part ‘D’ indicates that these samples are negative for mutations in CEBPA, FLT3 and NPM1 but 
have not been screened for other point mutations common in AML. Red arrows show subgroups demonstrating 
trends for high methylation of DMR-1. Statistical analysis was performed using One way ANOVA with Tukey 
post-test comparison. *p<0.05, **p<0.01, ***p<0.001. E. Kaplan-Meier estimates of overall survival for 
patients with aberrant or normal methylation of DMR-1 (determined in Figure 5.9). Excludes FAB subtype M3 
















































































































































































































Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 167survival of patients with high versus low methylation of DMR-1, excluding patients with FAB 
subtype M3 and those which had not received treatment. No differences in overall survival 
were observed, although it will be of interest to extend this analysis to a larger patient cohort 
(Figure 5.10E). 
For DMR-2a, 24% of AML samples assessed were aberrantly methylated compared to normal 
BMMNC controls (Figure 5.11). Analysis of average DMR-2a methylation did not reveal a 
trend for increased methylation in any particular cytogenetic subgroup, although the majority 
of samples with high methylation of DMR-2a displayed an abnormal karyotype (Figure 
5.12A). However, the difference in average DMR-2a methylation between samples presenting 
with a normal versus abnormal karyotype was not statistically significant (p=0.111) (Figure 
5.12B). DMR-2a methylation did not correspond with any particular FAB subtype or 
mutational subgroup (Figures 5.12C-D). There were too few patients displaying 
hypermethylation of DMR-2a (excluding FAB M3 and untreated patients) to comment on any 
association with overall survival (n=3, Figure 5.12E). 
We observed aberrant methylation of DMR-2b in 47% of AML samples (Figure 5.13). 
Quantitative analysis of average DMR-2b methylation revealed a trend for increased 
methylation in the normal karyotype group compared with normal controls and also with 
selected other cytogenetic subgroups (Figure 5.14A). Collectively, mean DMR-2b 
methylation was significantly higher in samples with normal karyotype than in those 
displaying abnormal cytogenetics (Figure 5.14B). There was no significant association of 
methylation in DMR-2b with FAB subtype or with molecular abnormality (Figure 5.14C-D). 
Analysis of survival revealed a trend for worse overall survival in patients displaying aberrant 
methylation of DMR-2b (Figure 5.14E), although this comparison did not reach significance 
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Figure 5.11: AML samples with aberrant methylation of KLF5 DMR-2a. Average percentage methylation 
of DMR-2a in normal bone marrow controls (3x CD34+ and 4x BMMNC) and in primary human AML 
BMMNC samples (n=29). The blue dotted line represents twice the standard deviation above the mean of 
BMMNC controls. AML samples which showed average methylation above this level were classified as 
aberrantly methylated (***p<0.001). The relative genomic location of DMR-2a is indicated. Characteristics of 
AML samples with aberrant methylation of DMR-2a are shown including FAB subtype, cytogenetic 
abnormality (‘Normal’ indicates normal karyotype), and molecular abnormality including mutations in CEBPA,





Sample FAB Cytogenetic abnormality Molecular abnormality
AML5 M2 Normal None
AML11 M2 Trisomy 14 None
AML21 M5 Trisomy 5 & 8, del(5q) NPM1
AML22 M2 Trisomy 8 CEBPA
AML24 M4 Inv(16) None
AML25 M4 t(13;14) CEBPA
AML29 M5 t(10;11) None
A
Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 169 Figure 5.12: AML characteristics associated with high methylation of KLF5 DMR-2a. Average percentage 
methylation of KLF5 DMR-2a in AML samples (n=29) grouped according to: A-B. Cytogenetic abnormality, 
C. FAB subtype, or D. mutation status of CEBPA, FLT3 and NPM1. Normal bone marrow controls (3x CD34+
and 4x BMMNC) are included for comparison (blue triangles). ‘NK’ in part ‘A’ indicates normal karyotype. 
‘None’ in part ‘D’ indicates that these samples are negative for mutations in CEBPA, FLT3 and NPM1 but have 
not been screened for other point mutations common in AML. Statistical analysis was performed using One 
way ANOVA with Tukey post-test comparison. E. Kaplan-Meier estimates of overall survival for patients with 
aberrant or normal methylation of DMR-2a (determined in Figure 5.11). Excludes FAB subtype M3 and 
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Sample FAB Cytogenetic abnormality Molecular abnormality
AML1 M1 Monosomy 7 None
AML2 M3 t(15;17) None
AML3 M8 Complex (incl. t(9;22)) None
AML4 M4 Normal FLT3-ITD
AML6 M1 Complex (incl. monosomy 7, del(5q)) None
AML8 M4 Complex (incl. inv(16), trisomy 8) None
AML9 N/A Normal CEBPA
AML10 M1 Complex None
AML14 M1 Normal None
AML15 M1 Normal FLT3-ITD, NPM1
AML17 M1 Del(5q) FLT3-TKD
AML18 M6 Normal None
AML23 M2 Normal NPM1
AML28 N/A Normal CEBPA
Figure 5.13: AML samples with aberrant methylation of KLF5 DMR-2b.  Average percentage 
methylation of DMR-2b in normal bone marrow controls (3x CD34+ and 4x BMMNC) and in primary human 
AML BMMNC samples (n=30). The blue dotted line represents twice the standard deviation above the mean 
of BMMNC controls. AML samples which showed average methylation above this level were classified as 
aberrantly methylated (*p<0.05). The relative genomic location of DMR-2b is indicated. Characteristics of 
AML samples with aberrant methylation of DMR-2b are shown including FAB subtype, cytogenetic 
abnormality (‘Normal’ indicates normal karyotype), and molecular abnormality including mutations in 
CEBPA, FLT3 or NPM1 (‘None’ indicates no mutation in CEBPA, FLT3 or NPM1). Characteristics which are 
over-represented in this group are indicated in purple text. 
Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 171Figure 5.14: AML characteristics associated with high methylation of KLF5 DMR-2b.  Average 
percentage methylation of KLF5 DMR-2b in AML samples (n=30) grouped according to: A-B. Cytogenetic 
abnormality, C. FAB subtype, or D. mutation status of CEBPA, FLT3 and NPM1. Normal bone marrow 
controls (3x CD34+ and 4x BMMNC) are included for comparison (blue triangles). ‘NK’ in part ‘A’ indicates 
normal karyotype. ‘None’ in part ‘D’ indicates that these samples are negative for mutations in CEBPA, FLT3
and NPM1 but have not been screened for other point mutations common in AML. Red arrows show 
subgroups demonstrating trends for high methylation of DMR-2b. Statistical analysis was performed using 
One way ANOVA with Tukey post-test comparison. *p<0.05. E. Kaplan-Meier estimates of overall survival 
for patients with aberrant or normal methylation of DMR-2a (determined in Figure 5.13). Excludes FAB 


























































































































































































Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 172(p=0.257). It will be necessary to further investigate comparisons of KLF5 methylation in 
each of the DMRs with AML characteristics and overall survival due to the limited number of 
AML samples in the current analysis. 
5.2.2.4 Correlation of KLF5 methylation with relative mRNA expression 
We next sought to determine whether methylation of KLF5 in any of the DMRs correlated 
with relative KLF5 expression as detected by Q-PCR in Section 5.2.1.1. Linear regression 
analysis and Fisher’s exact test did not detect a significant correlation of aberrant methylation 
in any DMR with reduced KLF5 mRNA expression (Appendix C). We did, however, observe 
a non-significant trend for decreased average KLF5 expression in AML samples with aberrant 
methylation of DMR-1 or DMR-2b compared with unmethylated samples (Figure 5.15). This 
trend was not observed for DMR-2a. Aberrant methylation of either DMR-1 or DMR-2b was 
not detected in any samples displaying a high level of KLF5 mRNA expression (relative 
expression level of >2.0), which is consistent with hypermethylation of these two regions 
acting to repress KLF5 transcription. Note that AML7 was excluded from these analyses as an 
outlier, as it displayed abnormally high levels of KLF5 expression (see Section 5.2.1.1). 
However, consistent with this observation, we observed little methylation of AML7 in DMR-
1 or DMR-2 (see Figure 5.7). Analysis of additional samples may improve the significance of 
the correlation between hypermethylation of DMR-1/DMR-2b and reduced mRNA 
expression.

























































































Figure 5.15: Correlation of relative KLF5 mRNA expression with average methylation of 
KLF5 DMR-1, DMR-2a and DMR-2b. KLF5 mRNA expression as detected by Q-PCR (relative 
to AML4 – see Figure 5.1) in AML samples according to methylation status of DMR-1, DMR-2a 
or DMR-2b. Aberrantly methylated samples were determined in Figures 5.9, 5.11 and 5.13 for 
DMR-1, DMR-2a and DMR-2b respectively. Note that AML7 was excluded as an outlier (see 
Figure 5.1). 
Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 1745.2.2.5 Treatment with demethylating agents activates KLF5 transcription 
We selected four leukaemia cell lines for functional analysis of KLF5 methylation including 
THP-1, HL-60, KG-1 and U937 cells (characteristics shown in Table 5.2). These cell lines 
exhibited a range of KLF5 expression levels, as shown in Figure 5.16A, and of KLF5
methylation in DMR-1 and DMR-2, shown in Figure 5.16B. The cell lines were treated with 
methyltransferase inhibitors (4 ȝM 5-azacytidine or 5 ȝM 5-aza-2-deoxycytidine) for 48 
hours to induce global DNA demethylation. RNA was isolated from treated and untreated 
cells at this time-point, and Q-PCR performed to quantitate KLF5 expression. For each cell 
line, KLF5 expression was determined relative to untreated cells. 
U937 cells, which displayed the lowest KLF5 expression and highest methylation, showed a 
3.0-fold reactivation of KLF5 expression on treatment with 5-azacytidine and a 7.8-fold 
reactivation on treatment with 5-aza-2-deoxycytidine (Figure 5.16C). THP-1 cells, which 
conversely displayed the highest KLF5 expression and lowest methylation, did not show 
reactivation of KLF5 expression on treatment with 5-azacytidine. We did however observe a 
modest induction of KLF5 expression in THP-1 cells treated with 5-aza-2-deoxycytidine (2.6-
fold). We observed a greater induction of KLF5 expression in KG-1 cells than in HL-60 cells 
on treatment with the demethylating agents. This was particularly evident on treatment with 
5-aza-2-deoxycytidine, where KG-1 cells showed a similar level of reactivation to U937 cells 
(7.4 and 7.8-fold respectively), while HL-60 cells showed less reactivation than THP-1 cells 
(2.2 and 2.6-fold respectively). Taken together with the observation that HL-60 cells 
displayed higher methylation than KG-1 cells in DMR-2, and less methylation in DMR-1, this 
suggests that methylation at DMR-1 may be involved in functional repression of KLF5
transcription.


































































































































Figure 5.16: Reactivation of KLF5 mRNA expression on treatment with demethylating agents. A. KLF5
mRNA expression of selected human leukaemia cell lines relative to AML4 (see Figure 5.1, n=8). B.
Percentage methylation of CpG residues in KLF5 DMR-1 and DMR-2 in selected human leukaemia cell lines 
(determined in Section 5.2.2.2). DMR-1 = 5 CpG residues, DMR-2 = 40 CpG residues. The location of 
residues used for analysis of DMR-2a and DMR-2b are shown in purple. C. Induction of KLF5 expression in 
selected human leukaemia cell lines in response to treatment with 5-azacytidine (n=3) or 5-aza-2-
deoxycytidine (n=3). Cells were treated for 48 hours with the demethylating agents at the concentrations 



















































































































Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 1765.2.2.6 Potential significance of differentially-methylated regions for the 
transcriptional regulation of KLF5
We were interested to investigate how methylation of DMR-1 and DMR-2 could potentially 
affect KLF5 transcription. Figure 5.17 shows features of the KLF5 genomic region analysed 
and alignment with the differentially-methylated regions identified in this study. The degree 
of interspecies conservation across the KLF5 region analysed is also depicted (44 vertebrate 
species, UCSC Genome Browser). There are two regions of highly-conserved homology in 
intron 1 of KLF5, termed Homology regions 1 and 2 (HR-1 and HR-2). Figure 5.17 also 
shows known transcription factor binding sites, as well as interspecies conserved binding sites 
predicted using the UCSC Genome Browser. 
DMR-1 lies in the proximal promoter of KLF5 (-529 to -318 bp from initiation of 
transcription). It encompasses a relatively highly conserved region of DNA which includes a 
known CEBPE/G binding site
156. This binding site also corresponds with the consensus 
sequence for binding of C/EBPD, which is consistent with observations suggesting that 
C/EBPD may be an upstream activator of KLF5 expression in haemopoiesis (discussed in 
Chapter 4, Section 4.3.4). Hence it is conceivable that KLF5 expression may be deregulated 
due to methylation across this C/EBP binding site in AML. 
DMR-2 lies in the 5` portion of intron 1 (+744 to +1855 bp from initiation of transcription). 
CpG residues 141-143 in DMR-2 (DMR-2a, +744 to +755 bp from initiation of transcription) 
are specifically methylated in a subset of AML samples as shown in Figure 5.8A. These do 
not lie in a region of high interspecies conserved homology (Appendix D1). Using a 
transcription factor binding site prediction program from the Technical University of 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 178Catalonia
440,441, we found predicted binding sites for human ENKTF1, E2F1, p53, PAX5 and 
FOXP3 in the DNA sequence encompassing CpG residues 141-143 (+5 nucleotide residues 
upstream of CpG 141, and +5 nucleotide residues downstream of CpG 143) (Appendix D2). 
However there have been no reports of KLF5 transcriptional regulation by these proteins to 
date.
Interestingly, the 3` half of DMR-2 encompasses the first of the two highly conserved regions 
in intron 1 of KLF5 (HR-1) (see Figure 5.17). This high degree of homology suggests an 
evolutionarily conserved regulatory function for this DNA sequence in control of KLF5
expression. Using the UCSC Genome Browser, we identified two predicted MYB binding 
sites within DMR-2, raising the possibility that the oncogenic MYB protein may have a role 
in regulating KLF5 expression, and that this may be altered by methylation in AML. The CpG 
residues in DMR-2b (CpG 173-181, +1284 to +1446 bp from initiation of transcription) 
encompass the second predicted MYB binding site, and CpG residues 177-179 lie within this 
predicted binding sequence.
Further investigation of this region using the UCSC Genome Browser identified a previously 
undescribed alternative exon within KLF5 intron 1, which also lies in the highly conserved 
HR-1 and within DMR-2b (see Figure 5.17). We identified an EST (accession number 
BG717510) cloned from a testis cDNA library (NIH_MGC_97) which contains the 
alternative exon (termed exon 1a) spliced to exon 2 of KLF5. Sequencing of the clone 
revealed that the cDNA sequence begins at this alternative exon 1a rather than the previously 
annotated exon 1 (Figure 5.18A), suggesting an alternative transcription start site for KLF5.
As exon 1a lies adjacent to the predicted MYB binding sites, this led us to speculate that these 
Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 179 binding sites form part of an alternative promoter region for initiation of transcription at exon 
1a.
To verify that this variant isoform of KLF5 is expressed, oligonucleotide primers were 
designed to specifically detect splicing from exon 1a to exon 2 (BG717510 primer set) using 
reverse-transcription PCR. The primer set used for Q-PCR analysis of KLF5 expression, 
which detects both the BG717510 and the primary NM_001730 KLF5 transcripts (splicing 
from exon 2 to exon 3), was also utilised as a control. The location of these oligonucleotide 
primers relative to each transcript is depicted in Figure 5.18A. mRNA was isolated and cDNA 
produced from a range of templates including a non-haemopoietic, non-tumorous cell line 
(HEK-293T - fibroblast), a non-haemopoietic, cancerous cell line (MCF7 – breast cancer), 
seven human leukaemia cell lines with varying degrees of KLF5 expression and methylation 
(HL-60, K562, KG-1, MOLM-13, MV4;11, THP-1 and U937), and a primary normal human 
BMMNC control sample (C8 BMMNC). 
PCR using the BG717510 primer set on the cDNA templates listed above produced a product 
at approximately 300 bp in the MCF7 breast cancer cell line, and in the HL-60 and K562 
leukaemia cell lines, which is consistent with the expected product size of 298 bp (Figure 
5.18B). These products were excised and isolated from the agarose gel and sequenced to 
verify amplification of the correct product. Sequencing confirmed splicing of exon 1a to exon 
2 as detected in the initial EST clone BG717510 (Figure 5.18C). The complete BG717510 
EST clone consists of exons 1a, 2, 3 and 4 of KLF5. Translation of this EST from the ATG 
start codon in exon 2 would produce a truncated KLF5 protein lacking the N-terminal 91 
amino acids (Figures 5.18D-E). This truncated protein would still retain the KLF5 nuclear 
export signal, and the transactivation and DNA-binding domains.  




















































































Figure 5.18 (A-C): KLF5 EST BG717510. A. Structure of transcripts for KLF5 NM_001730 and BG717510.  
Transcription for NM_001730 begins at exon 1 (blue) and is spliced to exon 2. Transcription for BG717510 is 
predicted to begin at exon 1a (green) and is spliced to exon 2. The location of oligonucleotide primers for 
specific detection of the BG717510 transcript are depicted with green arrows, and the control oligonucleotide 
primers which detect both transcripts are depicted with red arrows. B. Top panel: PCR was performed on 
cDNA from a range of cell types using primers to specifically detect the BG717510 KLF5 transcript. The 
green box indicates the expected product size for this PCR (298 bp). Bottom panel: PCR was performed on the 
same cDNA using control primers which detect both BG717510 and NM_001730 KLF5 transcripts. The 
expected product size for this PCR is 275 bp (boxed in red). C. Chromatogram sequence of the PCR product 
from primers used to detect the KLF5 BG717510 transcript. The chromatogram shows 50 bp of the 298 bp
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Figure 5.18 (D-E): KLF5 EST BG717510. D. In-frame translation of EST BG717510. Potential initiating 
methionines are shown in red, stop codons are shown with *. Initiation at the first methionine would result in 
an untranslated KLF5 mRNA; initiation at the second methionine would produce a protein containing most of 
exon 2, and all of exons 3 and 4. E. Full length KLF5 protein (NP_001721) and predicted protein resulting 
from translation of BG717510 at the second initiating methionine. NES = nuclear export signal, TAD = 
transactivation domain, DBD = zinc-finger DNA-binding domain.
FulllengthKLF5 protein(NP_001721)–4 5 7 aminoacids
PredictedproteinforBG717510– 366aminoacids
Exon3E x o n 4
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differentiation
5.2.3.1 KLF5 induces expression of the myeloid marker CD11B in U937 
leukaemia cells 
Of the four leukaemia cell lines assessed in Section 5.2.2.5, the U937 cell line displayed the 
lowest relative level of KLF5 mRNA expression and highest methylation of the KLF5
proximal promoter and intron 1 (see Figures 5.16A-B). In order to assess the potential tumour 
suppressor activity of KLF5, we expressed KLF5 in the U937 cell line and analysed 
functional effects on growth, survival and differentiation. For these experiments, human 
KLF5 was constitutively expressed from the MIG retroviral vector. Cells were retrovirally 
transduced with the empty MIG vector or MIG-KLF5, and sorted for GFP expression 48 
hours later. Purified GFP
+ populations were allowed to recover overnight then seeded in 
assays for functional assessment (Day 3 post-transduction). Note that the percentage of cells 
positive for GFP in each population was 85% at all time points of the assay. 
Growth and viability were assessed by determining GFP
+ cell number and total cell viability 
over 2 weeks following transduction. Transduction with KLF5 did not affect expansion 
(Figure 5.19A) or viability (Figure 5.19B) of U937 cells when compared to cells transduced 
with the empty vector control. Stable populations were further assessed for effects on 
differentiation using morphological analysis and staining for expression of the cell surface 
markers CD11B and CD14. Two-colour flow cytometry demonstrated that transduction with 
KLF5 significantly increased the MFI of CD11B expression on GFP
+ cells compared with 
controls (Figures 5.19C-D). There was no effect on expression of the monocytic marker 
















































































Figure 5.19: Enforced expression of KLF5 in the U937 leukaemia cell line model. A. GFP+ cell expansion. 
The total number of live cells was determined at each time-point by Trypan Blue staining and cell counts, and 
the percentage of GFP+ cells determined by flow cytometry. The number of GFP+ cells was hence determined 
and expansion calculated relative to seeding on Day 3. n=2. B. Total cell viability was assessed by Trypan Blue 
staining and cell counts at each time-point. n=2. C. Two-colour flow cytometric detection of CD11B and CD14 
expression on U937 cells transduced with KLF5 or the empty vector control. Expression was detected using PE-
conjugated antibodies on GFP+ cells. Profiles show representative results from a typical experiment on Day 21 
post-transduction (stable cell populations). Empty peak = isotype control, grey peak = cell surface marker 
expression. D. Average MFI of CD11B and CD14 on U937 cells transduced with KLF5 or the empty vector on 
Day 21 post-transduction (n=3). *p<0.05. E. Representative photomicrographs showing Wright-Giemsa stained 
cytospin preparations of U937 cells transduced with KLF5 or the empty vector control (Day  21). Original 
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U937 cells transduced with KLF5, although these cells displayed increased formation of 
cytoplasmic protrusions compared to control cells (Figure 5.19E). 
5.2.3.2 KLF5 enhances the response of the U937 cell line to differentiation-
inducing agents 
Stable U937 cell populations transduced with KLF5 or the empty vector control (from Section 
5.2.3.1) were treated with chemical inducers of myeloid differentiation to determine if 
enforced expression of KLF5 cooperates to enhance differentiation in these conditions. U937 
is a myelomonocytic leukaemia cell line (see Table 5.2) which undergoes monocyte-
macrophage differentiation in response to a number of reagents including PMA, Vitamin D3
and Interferon-gamma
442-444. In response to ATRA, U937 cells exhibit some characteristics of 
granulocyte differentiation, such as increased CD11B expression but not CD14, and lobulated 
nuclei
445,446, however studies have also shown up-regulation of several genes related to a more 
monocyte-macrophage phenotype in this system
447-452. U937 cells transduced with KLF5 or 
the empty MIG vector were treated with 0.3 PM ATRA or 5 nM PMA to determine if 
enforced expression of KLF5 enhanced granulocyte and/or monocyte differentiation in these 
conditions. Populations were seeded at 1x10
5 cells/ml and assayed over 5 days for effects on 
cell viability, expansion, and differentiation. Note that the percentage of cells positive for 
GFP in each population was 85% at all time points of these assays. 
Transduction with KLF5 did not affect expansion of GFP
+ cells (Figure 5.20A) or total cell 
viability (Figure 5.20B) of U937 cells cultured in ATRA when compared to empty vector-
transduced control cells. Two-colour flow cytometry was utilised to detect expression of the 
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Figure 5.20: ATRA treatment of KLF5-transduced U937 cells. A. GFP+ cell expansion in ATRA. The total 
number of live cells was determined at each time-point by Trypan Blue staining and cell counts, and the 
percentage of GFP+ cells determined by flow cytometry. The number of GFP+ cells was hence determined and 
expansion calculated relative to seeding on Day 0. n=3. B. Total cell viability was assessed by Trypan Blue 
staining and cell counts at each time-point following ATRA treatment. n=3. C. Two-colour flow cytometric 
detection of CD11B and CD14 expression on ATRA-treated U937 cells transduced with KLF5 or the empty 
vector control. Expression was detected using PE-conjugated antibodies on GFP+ cells. Figures show average 
MFI on Days 0, 3 and 5 post-treatment (n=3). ***p<0.001. D.  Representative photomicrographs showing 
Wright-Giemsa stained cytospin preparations of U937 cells transduced with KLF5 or the empty vector control 
at Day 5 post-ATRA treatment. Meta = metamyelocytes, Gran = segmented or lobulated mature granulocyte. 
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+ U937 cells transduced 
with KLF5 or the empty vector control (Figure 5.20C). The MFI of CD11B expression on 
control cells increased over 5 days of ATRA treatment, consistent with myeloid 
differentiation, however this increase was significantly greater in cells transduced with KLF5
indicating enhanced differentiation. No changes in CD14 expression were observed in either 
control cells or KLF5-transduced cells, which is consistent with the development of a 
granulocytic phenotype in response to ATRA treatment rather than a monocytic phenotype. 
Morphologically, control cells developed cytoplasmic protrusions by Day 5 of ATRA 
treatment, and a proportion of cells exhibited indented nuclei which are characteristic of 
metamyelocytes (Figure 5.20D). KLF5-transduced cells treated with ATRA for 5 days also 
differentiated to metamyelocytes, however a proportion of cells displayed lobulated or 
segmented nuclei which are characteristic of more mature cells of the granulocyte series. 
These observations are consistent with enhanced granulocyte differentiation of U937 cells in 
ATRA due to transduction with KLF5.
When cultured in PMA, KLF5-transduced cells exhibited reduced GFP
+ cell expansion 
compared to cells carrying the empty vector (Figure 5.21A). The reduced expansion was not a 
consequence of decreased cell viability (Figure 5.21B). Flow cytometric analysis 
demonstrated that expression of both the myeloid marker CD11B and the monocytic marker 
CD14 increased on PMA treatment of control cells (Figure 5.21C). However this increase was 
significantly higher in cells transduced with KLF5 compared to cells carrying the empty 
vector on Day 5 of treatment. Morphologically, control U937 cells showed evidence of 
macrophage differentiation when treated with PMA, with mature macrophages observed on 
Day 5 of treatment characterised by a large cytoplasm-to-nucleus volume ratio, light-staining 
granular cytoplasms, small rounded nuclei, and ruffled cellular edges (Figure 5.21D). No 
















































































Figure 5.21: PMA treatment of KLF5-transduced U937 cells. A. GFP+ cell expansion in PMA. The total 
number of live cells was determined at each time-point by Trypan Blue staining and cell counts, and the 
percentage of GFP+ cells determined by flow cytometry. The number of GFP+ cells was hence determined and 
expansion calculated relative to seeding on Day 0. n=3. B. Total cell viability was assessed by Trypan Blue 
staining and cell counts at each time-point following PMA treatment. n=3. C. Two-colour flow cytometric 
detection of CD11B and CD14 expression on PMA-treated U937 cells transduced with KLF5 or the empty 
vector control. Expression was detected using PE-conjugated antibodies on GFP+ cells. Figures show average 
MFI on Days 0, 3 and 5 post-treatment (n=3). *p<0.05. D. Representative photomicrographs showing Wright-
Giemsa stained cytospin preparations of U937 cells transduced with KLF5 or the empty vector control at Day 
5 post-PMA treatment. Mac = macrophages. Original magnification = 200x. Note that cells were 85% GFP+
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These observations are consistent with enhanced macrophage differentiation of U937 cells in 
PMA due to transduction with KLF5.
5.3 Discussion 
5.3.1 Reduced KLF5 expression potentially contributes to the disease 
pathogenesis of AML 
The results presented in this chapter demonstrate that KLF5 mRNA expression is decreased in 
human AML BMMNC compared to normal controls; Q-PCR analysis of our local AML 
cohort showed that expression levels of KLF5 were reduced by 2.3-fold on average in AML 
BMMNC samples when compared with control bone marrow CD34
+ cells. KLF5 expression 
levels were also decreased in human leukaemia cell lines by an average of 3.6-fold compared 
to CD34
+ control samples. The findings for leukaemia cell lines are comparable to those 
reported by Chen, et al. for both breast and prostate cancer cell lines (3.7-fold and 3.8-fold 
reduction of KLF5 expression compared to relevant controls assessed by Q-PCR)
295,301. We 
validated our Q-PCR results using bioinformatic analysis of a larger, publicly-available 
microarray data-set, which demonstrated that KLF5 expression was significantly reduced in 
human AML MNC samples compared to normal MNC controls. As KLF5 expression 
increases during myeloid differentiation (see Chapter 4, Section 4.2.1), it is possible that 
decreased expression in AML may be a consequence of blocked differentiation in this disease. 
However, our evidence that average KLF5 expression is reduced in comparison to that in 
primitive CD34
+ haemopoietic progenitor cells is consistent with deregulation of KLF5 being 
a pathological feature of AML development. This is further supported by the observation that 
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haemopoietic stem cells (mean RMA normalised expression of 27 and 128 respectively, 
p<0.0001. C. Kok, unpublished analysis of microarray data from Majeti, et al.
453). It will be of 
benefit to determine whether KLF5 expression is also reduced at the protein level in 
leukaemic samples, as mRNA and protein expression are not always correlated (as discussed 
in Section 4.3.1). As KLF5 is a differentiation-associated gene in the myeloid system (Chapter 
4), reduced KLF5 expression may act as a Class II abnormality by contributing to the 
differentiation block which is central to the AML disease process. 
5.3.2 Deregulation of KLF5 expression by common genetic lesions in AML. 
Our bioinformatics analysis revealed that KLF5 expression was significantly reduced in all 
AML subtypes assessed when compared to normal MNC controls (see Figure 5.3). Q-PCR 
analysis correspondingly revealed significantly reduced KLF5 expression in selected 
subgroups relative to bone marrow CD34
+ control cells (see Figure 5.2). In particular, KLF5
expression was significantly lower in the FAB subtypes M1, M3 and M4. M1 represents a 
minimally-differentiated AML subtype and comprises approximately 15% of adult AML. It is 
not specifically associated with a common cytogenetic abnormality, although point mutations 
in RUNX1 and CEBPA have been shown to occur at a high frequency in this subtype
454,455.
Reduced KLF5 expression in this subtype may provide a novel insight into the biology of 
AML M1. The pre-granulocytic M3 subtype comprises a distinct phenotypic form of AML, 
APL, which is characterised by the t(15;17) translocation. The oncogenic PML-RARĮ fusion 
protein produced by the t(15;17) translocation can inhibit myeloid differentiation by 
repressing the expression of proteins necessary for granulocyte differentiation, such as p21, 
C/EBPȕ and PU.1
456,457. The observation that KLF5 expression is significantly reduced in the 
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PML-RARD fusion protein, contributing to the block in granulocyte differentiation 
characteristic to APL. 
KLF5 expression was also significantly reduced in the monocytic M4 FAB subtype of AML. 
The inv(16) chromosomal abnormality is frequently detected in the M4 subtype
458,459, and 
accordingly half of the patients in our M4 subgroup displayed the inv(16) lesion (3/6). Our 
bioinformatic analysis of the Valk data-set demonstrated that mean KLF5 expression in the 
inv(16) subgroup was not only significantly lower than that seen in normal MNC controls, but 
it was also significantly reduced compared to other subtypes of AML (including the trisomy 8 
and normal karyotype subgroups). These observations suggest that KLF5 may be repressed in 
AML down-stream of the CBFȕ-MYH11 fusion protein produced by the inv(16) abnormality. 
The CBFȕ-MYH11 fusion protein contributes to leukaemogenesis by interfering with 
activation of RUNX1 (AML1) target genes
460, which is consistent with the observation that 
transcription of the rat Klf5 gene can be directly activated by RUNX proteins
209.
Our Q-PCR expression analysis also demonstrated that KLF5 expression was significantly 
reduced in AML samples positive for the FLT3-ITD mutation (see Figure 5.2). The FLT3
gene encodes a receptor tyrosine kinase which is activated upon binding of the FLT ligand 
and induces down-stream signalling pathways which modulate cell proliferation, growth, and 
differentiation in normal haemopoiesis
461. Internal tandem duplication (ITD) of a section of 
the FLT3 receptor within the juxtamembrane domain occurs in approximately 25% of AML, 
and results in constitutive activation of signalling pathways which contribute to ligand-
independent cellular proliferation
461. Aberrant signalling from the FLT3-ITD receptor can 
down-regulate expression of tumour suppressor genes such as GADD45A
326. Our results 
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receptor. It is possible that this may occur through abnormal activation of pathways such as 
the MEK/ERK, AKT and STAT pathways, which have been shown to regulate expression of 
KLF5 in other tissues (see Chapter 1, Section 1.3.7.2). 
In Chapter 4, Section 4.3.4, we discussed evidence for KLF5 being a target of activation by 
C/EBPĮ, which is commonly mutated or hypermethylated in AML
462. Our analyses 
demonstrated that reduced KLF5 expression was not selectively associated with the CEBPA
mutational subgroup, and we were not able to detect significantly reduced expression in the 
CEBPA subgroup relative to bone marrow CD34
+ controls using Q-PCR (see Figures 5.2-5.3). 
These observations suggest that while mutation of CEBPA may contribute to reduced KLF5
expression in selected AML samples, there are most likely additional mechanisms which 
contribute to down-regulation of KLF5 mRNA levels in AML. 
5.3.3 DNA methylation of KLF5 as a potential mechanism for down-
regulation in AML 
CpG methylation was subsequently investigated as a potential mechanism for the observed 
reduction of KLF5 mRNA expression in AML. We identified two discrete regions of the 
KLF5 gene locus which were aberrantly methylated in a subset of AML patient samples and 
leukaemia cell lines compared to normal BMMNC and CD34
+ controls. These were termed 
Differentially-methylated regions (DMR) 1 (in the KLF5 5` proximal promoter) and DMR-2 
(in KLF5 intron 1). The location of DMR-2 is consistent with the region previously found to 
be methylated in AML by Gebhard, et al.
111, and accordingly we confirmed that this region is 
hypermethylated in U937 and KG-1 cells, but not in THP-1 cells (see Figure 5.7). We did not 
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et al. 
309, however this may be due to the fact that Potapova assessed secondary AML patients 
transformed from MDS, whereas in the current study we have assessed de novo AML 
samples. In our cohort of AML samples, KLF5 was found to be specifically methylated in two 
independent regions of DMR-2, which were subsequently named DMR-2a and DMR-2b. The 
incidence of aberrant methylation of KLF5 in AML was 33% in DMR-1, and 24% and 47% in 
DMR-2a and DMR-2b respectively. Aberrant methylation was not strongly correlated with 
reduced KLF5 expression in any of the DMRs, however, we determined in Section 5.2.2.6 
that the Q-PCR primers used to measure KLF5 mRNA levels in this study can detect 
expression of multiple isoforms of KLF5. Hence, it will now be necessary to quantitate 
expression of these different isoforms to determine any specific correlation with methylation 
status at each DMR. The observation that overall KLF5 mRNA levels were relatively low 
even in samples which did not display aberrant methylation also suggests that multiple 
mechanisms may account for down-regulation of KLF5 expression in AML, as discussed in 
Section 5.3.2. Demethylation treatment of leukaemia cell lines displaying aberrant 
methylation of KLF5 induced KLF5 mRNA expression, which is consistent with methylation 
acting to functionally repress KLF5 transcription. 
5.3.4 Aberrant methylation of KLF5 is associated with selected cytogenetic 
subgroups in AML 
In the present study, we observed significant association of KLF5 methylation (DMR-1) with 
monosomy 7/del(7q) in patients with de novo AML. Deletion of part or all of chromosome 7 
is a common cytogenetic feature in both de novo and therapy-related MDS and AML
463,464.
Several genes on the long arm of chromosome 7 have been proposed as putative tumour 
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malignancy remain unclear. It has been suggested that monosomy 7 may act as a Class I 
aberration, as bone marrow cells from MDS patients with monosomy 7 demonstrate abnormal 
activation of STAT1 and STAT5 signalling pathways
465. Studies have demonstrated a strong 
association of monosomy 7/del(7q) in therapy-related MDS/AML with inactivating point 
mutations or chromosomal translocations involving RUNX1
466, and with hypermethylation of 
the tumour suppressor gene CDKN2B (p15)
38. Our results are consistent with aberrant 
methylation of KLF5 acting as a Class II mutation which cooperates with the Class I-acting 
monosomy 7/del(7q) in the pathogenesis of AML. However it will be necessary to expand the 
patient cohort size to further confirm the significance of this association, and additional 
studies will be required to determine the mechanisms by which these two abnormalities may 
cooperate in the development of myeloid leukaemia. 
Aberrant methylation of the 3` portion of DMR-2 (DMR-2b) was significantly associated with 
normal karyotype AML samples. Up to half of all newly-diagnosed AML patients do not have 
karyotypic abnormalities detectable by Fluorescence in-situ hybridisation (FISH) 
techniques
2,106,107. Studies have demonstrated that these patients can exhibit recurring 
mutations in individual genes (e.g. FLT3, NPM1), aberrant expression of molecular markers 
(e.g. MN1, ERG), small copy number changes not detectable by FISH (both duplications and 
deletions), and copy-neutral LOH
467,468. Although global methylation is not associated with 
karyotype in AML
469, Griffiths, et al. demonstrated significantly higher methylation of 
tumour suppressor genes such as CEBPA, CTNNA1, ER1, and FHIT in normal karyotype 
AML compared to those patients displaying karyotypic abnormalities
470. Our results suggest 
that deregulation of KLF5 expression by methylation in DMR-2b (intron 1) may also 
contribute to the pathogenesis of AML in patients with normal karyotype. 
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AML
The observation that the KLF5 gene is differentially methylated across distinct regions in 
AML may provide insights into mechanisms leading to deregulation of expression. DMR-1 
lies in the proximal promoter of KLF5 and encompasses a highly-conserved C/EBP binding 
site (see Oishi, et al.
156 and Figure 5.17). This raises the possibility that methylation of DMR-
1 may prevent activation of KLF5 expression by C/EBPĮ, or other members of the C/EBP 
family, facilitating the differentiation block characteristic of this disease. It will be necessary 
to demonstrate direct regulation of KLF5 by C/EBPĮ using ChIP analysis and reporter assays. 
Interestingly, demethylation of leukaemia cell lines displaying highly methylated DMR-1 
resulted in the greatest reactivation of KLF5 expression, suggesting that methylation of this 
region may be particularly important in repression of KLF5 transcription. 
The second differentially-methylated region, DMR-2, lies within intron 1 of the KLF5 gene. 
DMR-2b encompasses two interspecies-conserved predicted MYB transcription factor 
binding sites. MYB is a proto-oncogene highly expressed or amplified in AML
471-473, and 
studies have demonstrated that enforced expression of MYB can transform haemopoietic 
cells
474,475. The transcriptional regulation of target genes by MYB is complex, depending on 
the relative expression of different isoforms, various coregulator interactions, MYB protein 
modifications, and methylation of target binding sequences
476-479. Most MYB target genes 
exhibit groups of at least two MYB binding sites
476, which is consistent with the configuration 
observed in intron 1 of KLF5. Although precise mechanisms of target gene activation by 
MYB remain elusive, it is conceivable that methylation of KLF5 intron 1 could alter binding 
Chapter 5: Deregulation of KLF5 in human Acute Myeloid Leukaemia – Page 195 affinities of different isoforms of MYB or coregulators at these two binding sites to influence 
KLF5 expression in AML. It will be necessary to demonstrate direct binding of MYB to 
intron 1 of KLF5 using ChIP. The effect of MYB on transcription of KLF5 may be 
investigated through MYB over-expression or knock-down and subsequent examination of 
KLF5 mRNA expression.
An alternative possibility is raised by the identification of a putative alternative initiating exon 
adjacent to the predicted MYB binding sites in KLF5 intron 1. The KLF5 EST BG717510 
contains this alternative exon (exon 1a) spliced to exon 2 of KLF5. Accordingly, we utilised 
reverse-transcription PCR to demonstrate that exon 1a is transcribed in selected leukaemia 
cell lines and spliced to exon 2. Although the BG717510 EST was constructed using a CAP-
trapper cDNA synthesis protocol for enrichment of full-length cDNAs at the 5` end
480, it will 
be necessary to perform Rapid amplification of 5` cDNA ends (5` RACE) to validate that 
exon 1a represents a true alternative transcription start site for KLF5. It is possible that MYB 
or other factors may be acting to regulate transcription of this alternative isoform of KLF5.
Translation of this isoform is predicted to produce a N-terminal-truncated KLF5 protein 
which lacks the first 99 amino acids (from a total of 457). The function of the KLF5 N-
terminus has not yet been fully elucidated. Chen, et al. demonstrated that the N-terminal 19 
amino acids were necessary for ubiquitin-independent degradation of KLF5
227, however it is 
conceivable that loss of this N-terminal region could also interfere with other functional 
aspects of the KLF5 protein such as target gene specificity. Alternatively, it is possible that N-
terminal truncation of the KLF5 protein may not significantly affect normal activity, and that 
the function of these alternative start sites is instead to drive different tissue-specific 
expression patterns. GATA1 is an example of a gene where tissue-specific expression is 
achieved through the use of alternative promoter regions which control transcription initiation 
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different regulatory elements recruit specific transcriptional regulators which allow expression 
of GATA1 in the testis or in the erythrocyte/megakaryocyte lineages at appropriate stages of 
development
481. It will now be of interest to investigate regulation of the alternative KLF5
isoform by MYB or other transcription factors in normal haemopoiesis and in 
leukaemogenesis, and to determine how the biological function of the protein produced from 
the BG717510 isoform may differ from the primary KLF5 protein. 
5.3.6 Tumour suppressor function of KLF5 in human leukaemia cells 
Finally, we assessed potential tumour suppressor activity of KLF5 using retroviral 
transduction of the U937 leukaemia cell line, which displayed a high degree of KLF5
methylation and correspondingly low KLF5 gene expression. Expression of KLF5 in U937 
cells induced expression of the myeloid marker CD11B. KLF5-transduced cells also showed 
increased cytoplasmic protrusions, which were similar to those seen in ATRA-treated control 
U937 cells. These observations are consistent with induction of granulocyte differentiation in 
this cell line. However, there were no corresponding effects observed on cell expansion or 
viability due to transduction with KLF5. It is possible that expression of KLF5 alone was not 
sufficient to completely overcome the leukaemic differentiation block, and that activation or 
repression of additional genes may be necessary for cooperative reversal of the leukaemic 
phenotype. Alternatively, it is likely that KLF5 is targeted at the protein level for rapid 
degradation in U937 cells. It may be possible to construct a stabilised form of KLF5 to use in 
these studies, by introducing mutations which are known to enhance KLF5 protein stability 
(e.g. mutations which prevent interaction with ubiquitin ligases, and deletion of the N-
terminal region to prevent ubiquitin-independent degradation – see Chapter 1, Section 1.3.4). 
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Transduction with KLF5 enhanced differentiation of U937 cells towards the granulocyte 
lineage in ATRA, and towards the macrophage lineage in PMA, suggesting that activation of 
KLF5 facilitates differentiation of leukaemia cells in response to differentiation-inducing 
agents (discussed further in Chapter 6, Section 6.2.8). These data are consistent with KLF5 
having tumour suppressor function, and suggest that reactivation of KLF5 may be of 
particular relevance in the treatment of AML, especially in the development of combination 
therapies.  Chapter 6 – Discussion 
The overarching aim of this thesis was to identify and characterise genes important for 
regulation of haemopoietic growth and differentiation with potential roles as myeloid 
oncogenes or tumour suppressors. In Chapter 3 of this thesis, an expression cloning approach 
was undertaken to identify putative oncogenes contributing to the development of AML. This 
Chapter describes optimisation of methods for construction of high-quality retroviral cDNA 
libraries, and the production and screening of such a library from a murine myeloid leukaemia 
cell line (M1). These methods will be applicable to future research utilising retroviral 
expression cloning to identify oncogenes in AML.
Chapters 4 and 5 of this thesis focus on characterisation of a novel myeloid transcription 
factor acting as a potential transcriptional regulator of granulocyte-macrophage 
differentiation
1. Transcription factors play a vital role in the maintenance of the haemopoietic 
system, and disrupted function can contribute to the pathogenesis of AML (see Chapter 1, 
Section 1.1.2). In particular, the differentiation block which is a hallmark of AML can often 
be attributed to decreased or altered function of transcription factors with roles in normal 
haemopoietic differentiation. A major aim in the field is therefore to identify and characterise 
the functions of these differentiation-associated transcription factors in haemopoiesis, which 
will lead to a greater understanding of how their deregulation contributes to human disease. 
We wished to determine the role of KLF5 as an inducer of myeloid differentiation, and to 
examine its potential function as a tumour suppressor gene which is deregulated in the 
pathogenesis of AML. The key findings from this study are discussed below. 
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6.1.1 Expression of KLF5 during myeloid differentiation 
In Chapter 4 of this thesis, we provide evidence demonstrating that KLF5 acts as a novel 
regulator in the myeloid lineage. Results presented in Section 4.2.1 demonstrated that Klf5
mRNA expression increased during granulocyte-macrophage differentiation of the FDB1 
myeloid cell line, consistent with microarray results published by Brown, et al.
1. Klf5
expression also increased during G-CSF-induced granulocyte differentiation of the 32D 
murine myeloid cell line, and analysis of published microarray studies confirmed that 
expression was higher in primary granulocyte populations than in human cord blood CD34
+
progenitors or in murine bone marrow haemopoietic stem cells
386,387. Conversely, Klf5
expression decreased during M-CSF-induced macrophage differentiation of primary murine 
bone marrow progenitors. This granulocyte-associated expression pattern implies a potential 
role for KLF5 in differentiation of this lineage. In addition, the time-course of Klf5 mRNA 
expression in FDB1 cells undergoing granulocyte-macrophage differentiation and in 32D 
cells undergoing granulocyte differentiation closely mirrored that of the granulocytic 
transcription factor Cebpe, suggesting a similar functional role for these two genes and a 
potential common mechanism of transcriptional regulation (discussed further in Section 
6.2.3).
6.1.2 KLF5 function 
In Section 4.2.3, siRNA knock-down experiments demonstrated that decreased Klf5
expression was associated with reduced granulocyte differentiation of the murine 32D 
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lineage based on expression studies. Reduced Klf5 expression was associated with decreased 
levels of the neutrophil granule markers MPO (active enzyme) and Ltf (mRNA), suggesting 
that KLF5 may function early during granulocyte differentiation at the myeloblast or 
promyelocyte stages, prior to the first appearance of these markers. Although the time-course 
expression profile of Klf5 was similar to that of Cebpe during granulocyte-macrophage 
(FDB1) or granulocyte-only (32D) differentiation (see Section 6.1.1), suggesting a common 
mechanism of regulation, knock-down of Klf5 was associated with reduced Cebpe expression 
in the 32D cell line, which is consistent with KLF5 acting upstream of Cebpe to regulate 
granulocyte differentiation. 
Consistent with results from Klf5 knock-down experiments, results presented in Section 4.2.2 
demonstrated that enforced expression of Klf5 from a retroviral promoter was sufficient to 
induce differentiation of the murine myeloid cell line FDB1 and of primary murine bone 
marrow progenitors. This was accompanied by cell cycle arrest and reduced cell viability. 
Although our expression studies and knock-down experiments support a role for Klf5 in 
granulocyte differentiation, enforced expression of Klf5 induced macrophage differentiation 
of FDB1 cells and murine bone marrow progenitors. This may reflect an experimental 
limitation associated with enforced expression (discussed in Section 4.3.2), or alternatively it 
could imply a role for KLF5 in development of the macrophage lineage. There is increasing 
evidence to suggest that key myeloid transcriptional regulators such as PU.1 and C/EBPĮ can 
regulate both granulocyte and macrophage differentiation in different contexts. PU.1 is 
commonly accepted as a critical regulator of macrophage differentiation, however studies 
have also demonstrated a role for this transcription factor in development of the granulocyte 
lineage
482. The concentration of PU.1 is an important factor in determining which lineage is 
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of macrophage and neutrophil specific genes, whereas higher levels of PU.1 activate 
additional transcriptional programs involving repression of granulocyte regulators which 
ultimately leads to macrophage specification
483. For C/EBPĮ, targeted gene disruption in 
mouse models has established an essential role in normal granulocyte development
484.
However, an independent study by Wang and colleagues demonstrated that exogenous 
expression of physiologically relevant levels of C/EBPĮ in primary murine bone marrow 
progenitors can promote macrophage formation
401. It is particularly interesting that in vivo
ablation of the late-acting granulocytic transcription factor Cebpe, whose expression mirrors 
that of Klf5 during myeloid differentiation (see Section 4.2.1), also demonstrated a functional 
role for this gene in differentiation of macrophages
485. Our expression analyses showed that 
although the highest level of KLF5 expression was detected in the granulocyte compartment 
of primary haemopoietic populations, it was also up-regulated to a lesser extent in murine 
macrophages (see Figure 4.6). This further supports a potential role for KLF5 in development 
of the macrophage lineage, and suggests that like PU.1, the relative concentration of KLF5 
may be an important factor in determining whether granulocytes or macrophages are 
produced.
To better establish the role of KLF5 in granulocyte-macrophage lineage specification requires 
targeted disruption of the gene in the haemopoietic system in vivo. Although murine models 
for in vivo deletion of Klf5 have been reported in literature, these have not been utilised for 
analysis of the haemopoietic system. Klf5
-/- mice are embryonic lethal prior to the onset of 
definitive haemopoiesis
157,160. Heterozygous Klf5
+/- mice have a number of defects in 
adipogenesis, cardiovascular remodelling, and intestinal development
156,157, however there 
have been no reports of gross defects in the haemopoietic system of these animals. The 
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our laboratory. Mice carrying floxed Klf5 alleles have been generated and will now be crossed 
with a transgenic strain which produces Cre recombinase from the haemopoietic Vav
promoter
486. This system will enable a detailed in vivo analysis of the effect of Klf5 deletion 
on haemopoiesis, and will further elucidate any specific roles KLF5 may have in granulocyte 
versus macrophage lineage determination. 
6.1.3 KLF family members in the haemopoietic system 
The findings described above are consistent with KLF5 acting as a novel haemopoietic 
transcriptional regulator, adding to the growing number of KLF family members with roles in 
the haemopoietic system
175. In the erythroid system, in vivo mouse models have demonstrated 
essential functional roles for two KLF family members, KLF1 and KLF13. Mice homozygous 
for the null allele of Klf1, or Erythroid Krüppel-like factor, develop a fatal anemia due to 
insufficient haemoglobin production
138,139, whereas mice with homozygous disruption of 
Klf13 display a decreased number of circulating erythrocytes with an increased proportion of 
immature erythroid cells in the liver
184. In the lymphoid lineage, gene targeting experiments 
in mice have demonstrated a role for KLF2 in maintaining the quiescent state of progenitor T-
cell populations
142, and a role for KLF13 in T-cell survival
187.
Relatively few studies have assessed the role of KLF family members in the myeloid lineage. 
Although KLF1 was originally believed to be an erythroid-specific gene, it has been 
demonstrated that KLF1 can regulate transcription of IL12B during monocyte activation
487.
Klf3 knock-out mice develop a chronic myeloproliferative disorder due to increased 
proliferative capacity of myeloid cells, suggesting a role for KLF3 in modulating the 
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488. The most detailed studies 
with regard to KLF family members in myelopoiesis have been undertaken with KLF4. 
Feinberg, et al. demonstrated an essential role for KLF4 in monocyte formation
388. Enforced 
expression of KLF4 in murine common myeloid progenitors (CMP) induced formation of 
predominantly macrophage colonies in semi-solid medium, whereas ablation of KLF4 in 
CMPs induced development of granulocyte colonies at the expense of macrophage colonies. 
KLF4 and KLF5 display similar tissue distribution patterns, and numerous studies have 
shown that they often act in a complementary manner
150. For example, KLF4 is highly 
expressed in mature cells of intestinal villi where it acts to negatively regulate cell growth, 
whereas KLF5 expression is specific to proliferating crypt cells where it functions to enhance 
cell proliferation. In the myeloid system, KLF4 expression is specific to the monocyte lineage 
where it is a direct target of the monocytic transcription factor PU.1
388. In contrast, our studies 
show that Klf5 is expressed predominantly in the granulocyte lineage, and Cammenga, et al. 
identified Klf5 as a target which is activated by C/EBPĮ in human CD34
+ haemopoietic 
progenitor cells
132. As PU.1 and C/EBPĮ have complementary functions in determination of 
granulocyte versus monocyte lineage
489,490, it is interesting to speculate that KLF4 and KLF5 
may also have opposing or antagonistic roles in the myeloid system, possibly acting as key 
downstream mediators of PU.1 and C/EBPĮ.
Our studies have focused on defining the role of KLF5 in the granulocyte and/or macrophage 
lineages, however there is evidence to suggest that KLF5 may also function in other 
haemopoietic cell types. Zhang, et al. demonstrated that KLF5 mRNA expression increases 
during erythroid differentiation of the K562 CML blast crisis cell line, where it binds to and 
activates transcription of the haemoglobin HBG1 gene
237. Our observation that Klf5
expression is reduced in mature T-cell populations relative to murine haemopoietic stem cells 
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levels of KLF5 mRNA and that expression decreases on maturation
204. It was demonstrated 
that KLF5 can activate the T-cell receptor TCR Dȕ1 gene which is necessary for the 
development of T-cells
204.
Taken together, these studies suggest that the KLF family of transcription factors may act at 
many points in the haemopoietic system, with various members such as KLF5 controlling 
distinct aspects of haemopoietic growth and differentiation. 
6.2 Deregulation of KLF5 in AML 
6.2.1 KLF5 mRNA expression in AML 
In Chapter 5 of this thesis, we demonstrated a potential role for KLF5 as a tumour suppressor 
gene in AML. The classical model of tumour suppression involves inactivation of both alleles 
of a tumour suppressor gene, a concept known as Knudson’s ‘two-hit’ hypothesis
491. However 
there is increasing evidence that haploinsufficiency of tumour suppressor genes is sometimes 
sufficient to contribute to tumourigenesis, and studies have shown that gene dosage reduction 
by mechanisms other than mutation or allele loss (e.g. DNA methylation, protein degradation) 
can also be important factors in the development of cancer
492.
The results presented in Section 5.2.1 demonstrated that KLF5 mRNA expression is reduced 
in AML samples relative to normal controls, suggesting that decreased dosage may be 
contributing to the pathogenesis of this disease. We showed by Q-PCR that mean KLF5
expression was significantly lower in AML blasts than in bone marrow CD34
+ control 
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microarray data-set (Valk, et al.
329) which demonstrated significantly reduced KLF5
expression compared to normal MNCs. The observation that KLF5 mRNA expression is 
reduced in AML blasts relative to primitive bone marrow CD34
+ cells, and also in leukaemic 
stem cells compared to normal haemopoietic stem cells, suggests that reduced KLF5
expression is not a consequence of blocked differentiation, but rather that it is functionally 
contributing to the pathogenesis of AML (discussed in Section 5.3.1).
 Analysis of the Valk gene expression profiling study demonstrated that KLF5 expression was 
significantly reduced in all AML subtypes and mutational categories relative to MNC controls 
(see Figure 5.3). Our Q-PCR analysis demonstrated that mean KLF5 expression was also 
significantly reduced in selected subtypes relative to the more primitive CD34+ control bone 
marrow populations (see Figure 5.2). This included the minimally-differentiated M1 subtype 
of AML, and also the pre-granulocytic M3 and monocytic M4 subtypes. FAB M3 is almost 
exclusively associated with the t(15;17) translocation which produces the oncogenic fusion 
protein PML-RARĮ
493, and FAB M4 is commonly associated with aberrations of 
chromosome 16, including inv(16) which produces the CBFȕ-MYH11 fusion protein
458,459.
Targeting oncogenic fusion proteins has proven successful in developing efficient therapeutic 
strategies in the treatment of AML, for example, the use of ATRA for specific targeting of the 
PML-RARĮ protein
43. However, the elucidation of down-stream biological effectors of these 
proteins which may contribute to altered growth and differentiation could potentially suggest 
novel approaches for the development of improved targeted therapies for these AML 
subtypes, particularly for those patients who do not respond to conventional chemotherapy or 
who relapse following initial response to ATRA therapy
494. Q-PCR also showed that KLF5
expression was significantly reduced in AML samples displaying FLT3-ITD mutations, 
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through cooperation with the Class I FLT3-ITD lesion. As the application of FLT3 inhibitors 
has shown limited success in clinical trials to date
495, it is possible that approaches aimed at 
reactivation of KLF5 in FLT3-ITD-positive samples may synergise to improve the efficacy of 
these inhibitors in treatment of this AML subtype. 
6.2.2 Methylation of KLF5 in AML 
Hypermethylation of CpG dinucleotides is a common mechanism for silencing of tumour 
suppressor genes in AML (discussed in Section 5.1). In Section 5.2.2, we demonstrated that 
the KLF5 promoter and intron 1 are hypermethylated in selected leukaemia cell lines and in 
bone marrow MNC samples from a subset of AML patients compared to normal bone marrow 
controls (MNC and CD34
+ cells). Treatment of leukaemia cell lines exhibiting methylation of 
KLF5 with methyltransferase inhibitors induced KLF5 expression, consistent with DNA 
methylation being a significant factor in reduced KLF5 expression (see Figure 5.16). 
Deregulation by hypermethylation has been demonstrated for selected members of the KLF
family in human disease. KLF4 in particular is hypermethylated in gastric cancer, colon 
cancer and in T-cell leukaemia
496-498. Hypermethylation of KLF6 may partly contribute to 
repression in hepatocellular carcinoma
499,500, and KLF11 is reportedly down-regulated by 
methylation in various haematological disorders, particularly in MDS
309. The observation that 
the KLF5 gene is hypermethylated in AML in the proximal promoter and in intron 1 provides 
additional evidence that KLF members may act as tumour suppressors in a variety of 
malignancies, where they are commonly down-regulated by hypermethylation. 
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promoter in AML and potential relevance to CEBPA activity 
We identified two distinct regions of CpG methylation at the KLF5 locus in AML. One third 
of AML patient samples displayed hypermethylation of the first of these regions, which lies in 
the 5` proximal promoter of KLF5. This region encompasses a C/EBP binding site which is 
known to bind CEBPȕ/į
156, and also corresponds with the consensus binding sequence for 
C/EBPĮ (see Figure 5.17). This observation is consistent with previous studies which have 
demonstrated that C/EBPĮ is an upstream activator of KLF5 transcription in human CD34
+
cells
132. Our expression studies in Section 4.2.1 are also consistent with C/EBPĮ activating 
Klf5 transcription during GM-CSF and G-CSF-induced differentiation of the FDB1 and 32D 
myeloid cell lines respectively, as the time-course of Klf5 expression closely correlated with 
that of the known C/EBPĮ target gene Cebpe in both of these model systems. During G-CSF-
induced granulocyte differentiation of the 32D cell line, Cebpa mRNA expression peaked 
early and was followed by a steady increase in the levels of Klf5 and Cebpe, suggesting that 
expression of both may be coordinated by C/EBPD (see Figures 4.2 and 4.4).  Interestingly, 
the greatest increase of KLF5 expression upon treatment with methyltransferase inhibitors 
occurred in cell lines that showed high methylation of the KLF5 5` proximal promoter across 
the C/EBP binding site (see Figure 5.16). These findings are consistent with KLF5 mRNA 
expression being repressed in AML due to methylation of the proximal promoter associated 
with reduced C/EBPĮ binding. 
Although selected AML samples showed relatively high CpG methylation of the KLF5
proximal promoter, there were clearly samples which did not exhibit increased methylation of 
this region yet still displayed relatively low levels of KLF5 expression. This suggests that 
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mechanisms. It is possible that deregulation of C/EBPĮ upstream of KLF5 may also 
contribute to decreased KLF5 expression in AML. Approximately 10% of AML cases have 
mutations in the CEBPA gene, which functional studies have suggested generate dominant-
negative C/EBPĮ isforms
37. CEBPA expression can be reduced in AML through 
hypermethylation of the promoter region
68,75,501-504. Global studies of CpG methylation and 
gene expression in AML have shown that samples with mutated or hypermethylated CEBPA
are associated with distinct expression profiles, which includes down-regulation of tumour 
suppressor genes such as CTNNA1
108,505. Accordingly, we found significantly reduced KLF5
expression in AML samples exhibiting CEBPA mutations compared to normal MNC controls 
(see Figure 5.3). Patients demonstrating hypermethylation of the CEBPA locus also displayed 
reduced KLF5 expression (Figure 6.1). Thus it is likely that deregulation of C/EBPĮ by 
several mechanisms may affect KLF5 expression in AML.
6.2.4 Transcriptional deregulation of KLF5 by methylation of intron 1 in 
AML
For almost half of the AML patient samples assessed we demonstrated hypermethylation of 
KLF5 within intron 1 of the gene locus. This region is highly conserved amongst vertebrate 
species and encompasses a putative alternative promoter region regulating initiation of 
transcription of KLF5 from an alternative exon (exon 1a) (see Figure 5.17). Translation of this 
alternative isoform of KLF5 would produce either an untranslated transcript, or an N-
terminal-truncated form of the KLF5 protein (discussed in Section 5.3.5). Although 
alternative exon usage has been implicated by sequencing of a number of EST clones which 
map to the KLF5 locus, evidence supporting formation of alternative KLF5 isoforms is not 










































Figure 6.1: KLF5 expression levels in AML samples with mutated or hypermethylated 
CEBPA. Analysis of KLF5 mRNA levels as detected by microarray in Valk, et al.329.
Samples include normal controls (5 MNC and 3 CD34+ samples) and AML MNC for patients 
with mutated CEBPA (n=12) or hypermethylated CEBPA (n=4). ***p<0.001, **p<0.01 
(assessed using One way ANOVA with Tukey post-test comparison).
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been detected by northern blotting in the testis
201. Lower molecular weight species have been 
detected by western blotting with various KLF5 antibodies in breast and colorectal epithelial 
cell lines, although it is not known whether these are the result of alternatively spliced 
transcripts or protein cleavage/degradation
201,224,229. Our results presented in Section 5.2.2.6 
provide the first evidence of an alternative mRNA isoform of KLF5 associated with 
transcription and splicing of an alternative exon. It will be important to examine expression of 
this alternative isoform in normal and malignant tissues, and to determine the functional 
significance and regulation of this isoform in normal haemopoiesis and in AML. The 
identification of two highly conserved putative MYB binding sites directly upstream of exon 
1a raises the possibility that the alternative isoform of KLF5 may be regulated by the 
oncogenic MYB protein (discussed in Section 5.3.5). Collectively these studies will help 
define the relevance of KLF5 intron 1 hypermethylation in AML. 
It is well established that aberrant methylation of alternative start sites can contribute to the 
pathogenesis of human disease by altering the normal expression ratio of variant isoforms. 
For example, the growth inhibitor ING1 is transcribed from three different initiating exons, 
which can generate four alternative transcript variants with the use of alternative splicing. 
Two of these isoforms, p24 and p33, show varying degrees of expression in head and neck 
carcinomas, which correlates with hypermethylation at their distinct initiating exons
506. The 
tumour suppressor CDKN2A (p16) can also be transcribed from alternative initiating exons, 
the shorter of which is not translated into protein. In a number of non-small cell lung 
carcinoma cell lines, hypermethylation of the upstream promoter region was detected, leading 
to enhanced transcription of the shorter isoform initiating from alternative exon 1b, and 
consequently reduced protein expression
507. Interestingly, one member of the KLF family also 
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production of at least 4 isoforms, one of which acts as a dominant-negative, oncogenic form 
(KLF6-SV1) which is over-expressed in a number of different cancers
508. Thus it is plausible 
that deregulation of KLF5 isoforms produced by alternative transcription initiation start sites 
may also contribute to altered KLF5 function in disease. 
6.2.5 Biological relevance of KLF5 methylation studies in AML 
In Section 5.2.2.3, we demonstrated that methylation of the KLF5 proximal promoter was 
significantly higher in patients with monosomy 7 or del(7q) than in patients negative for these 
abnormalities. Previous studies have demonstrated that methylation of specific genes may 
cooperate with common mutations in AML, for example, there is evidence to suggest that 
methylation of WNT inhibitor genes is associated with Class II mutations in transcription 
factors such as CEBPA
509. Alvarez, et al. demonstrated that patients who have a FLT3
mutation together with methylation of the cell cycle gene DCB1 have a significantly shorter 
overall survival than patients with only one of these abnormalities
510. It will now be 
interesting to examine the mechanisms by which methylation of KLF5 may cooperate with 
the monosomy 7 or del(7q) abnormalities in the pathogenesis of leukaemia (discussed in 
Section 5.3.4).
The identification of molecular abnormalities in AML, including epigenetic changes such as 
DNA hypermethylation, is particularly important in normal karyotype AML, which displays 
considerable heterogeneity in clinical outcome
511. We identified KLF5 as a gene which 
displayed significantly higher CpG methylation of intron 1 in normal karyotype AML than in 
samples with abnormal cytogenetics. Thus KLF5 may be one of a number of tumour 
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(discussed in Section 5.3.4). Identification of samples with aberrant CpG methylation of these 
tumour suppressor genes may aid in selection of patients with normal karyotype AML who 
could benefit from treatment with demethylating agents in combination with standard AML 
chemotherapeutics. 
6.2.6 Prognostic relevance of methylation studies in AML 
Genome-wide DNA methylation analyses utilising microarray-based methods
512 have 
demonstrated that distinct CpG methylation patterns can identify patient groups which 
correlate highly with prognosis
68,513. This approach was used to identify sets of patients who 
were not otherwise linked by a common abnormality, highlighting how methylation analysis 
may aid in disease classification and prediction of outcome. The effect of CpG methylation on 
prognosis is gene dependent
469. For example, hypermethylation of the ESR1 or HOXA5 genes 
is indicative of a good prognosis
514,515, whereas hypermethylation of genes such as CDH1,
WIF1 and SFRP2/5 genes is associated with a poor outcome
516-518. Our analysis of KLF5
methylation revealed a trend for decreased overall survival in patients displaying 
hypermethylation of KLF5 intron 1 (see Fig 5.14). It will now be of interest to extend our 
methylation analysis of KLF5 to a larger cohort of AML patients to determine if methylation 
of the KLF5 proximal promoter or intron 1 may be a significant independent predictor of 
prognosis.
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Although we have identified methylation of KLF5 as a mechanism potentially associated with 
reduced mRNA levels in AML, it is likely that KLF5 mRNA expression is also decreased by 
other mechanisms in this disease. Transcriptional repression by upstream oncogenic 
pathways, or reduced activation due to mutation or silencing of C/EBPĮ, may represent 
additional mechanisms for reduced KLF5 expression in AML, as discussed in Sections 6.2.1 
and 6.2.3. A single A>G polymorphism (rs3812852) has been reported to be associated with 
reduced KLF5 expression in schizophrenia, and it will be important to establish whether this 
is also prevalent in AML
203. Over-expression of targeting microRNAs is another mechanism 
recently shown to reduce tumour suppressor expression in AML, for example, the oncogenic 
microRNA-155 is over-expressed in selected subgroups of AML where it acts to degrade 
candidate tumour suppressor mRNAs such as SPI1
519-522. MicroRNAs 143, 145 and 448 have 
been shown to regulate KLF5 activity through RNA degradation
214,215. Studies have shown 
that microRNAs 143 and 145 are commonly down-regulated in solid tumours such as 
colorectal cancer, which is consistent with KLF5 acting as a highly expressed oncogene in 
these tissues
523,524. Expression of these microRNAs is also reduced in B-cell leukaemia
525.
However, Volinia, et al. demonstrated that microRNA-143 is highly expressed in Acute 
Myelomonocytic Leukaemia (AMML)
524, consistent with microRNA-143 acting as an 
oncogene which acts to degrade KLF5 mRNA in AML. 
It is possible that KLF5 mRNA may also be reduced due to deletion, as small heterozygous 
chromosomal deletions on chromosome 13 have been reported for myeloid disorders such as 
MPD, MDS and also in some cases of AML
305. These deletions span from 13q12/q14 to 
13q21/q22, which encompasses all or part of the KLF5 gene on chromosome 13q21-q22. The 
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461,526) also 
maps to chromosome 13q12-q13
527. Heterozygous deletion of the FLT3 genomic region may 
reflect loss of the remaining allele of this gene. However, a single AML patient in the study 
described above demonstrated heterozygous deletion spanning from 13q14-q22, which 
encompasses the KLF5 gene but does not affect the FLT3 locus
305. This raises the possibility 
that the pathogenesis of AML associated with deletions of 13q may be attributed to loss of 
KLF5 rather than a FLT3 gene aberration. It will now be of interest to determine if patients 
with heterozygous 13q deletion encompassing the KLF5 genomic region display inactivation 
of the remaining KLF5 allele through hypermethylation or mutation. 
6.2.8 Targeting KLF5 for activation in AML 
The results presented in Section 5.2.3 demonstrate that expression of KLF5 in a leukaemia 
cell line with low basal levels of KLF5 expression can induce changes associated with 
myeloid differentiation. This finding suggests that targeting KLF5 for reactivation may be of 
potential benefit as a therapeutic approach in selected cases of AML. As KLF5 is 
hypermethylated in the proximal promoter and intron 1 in a subset of AML samples, and 
expression is induced in leukaemia cell lines treated with demethylating agents, the use of 
epigenetic modifiers may prove beneficial in treatment for these patients. Clinical trials 
utilising epigenetic modifiers such as DNA methyltransferase inhibitors (e.g. 5-azacytidine) 
and HDAC inhibitors (e.g. SAHA – Vorinostat) have already demonstrated a beneficial 
response in patients with MDS or AML, particularly when used in combination
528-532. As 
larger studies are performed with these agents it may be possible to link response to 
methylation of particular genes, including KLF5.
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samples which do not demonstrate hypermethylation of this gene. The observation that 
enforced KLF5 expression enhanced differentiation of a human leukaemia cell line in 
response to ATRA and PMA suggests that targeting KLF5 may be a viable strategy in 
combinatorial therapy for AML (see Figures 5.21-22). For example, although the use of 
ATRA has significantly improved survival rates in AML patients harbouring the t(15;17) 
translocation (APL), the success of this for treatment of other subtypes has remained 
limited
533. There is evidence to suggest that the limited effect of ATRA on non-APL 
leukaemia cells is due to a deficiency in components of the retinoic acid signalling pathway; 
for example, RARE2 is commonly silenced by hypermethylation in AML
534, and expression of 
RARD is often decreased via methylation-independent mechanisms
535. Chen, et al. 
demonstrated that KLF5 can activate expression of a number of genes associated with the 
retinoic acid signalling pathway (e.g. RAIG1, MN1, TGM2)
251, and hence it is conceivable 
that KLF5 expression may synergise with ATRA by increasing the expression of components 
necessary for efficient ATRA-induced differentiation of non-APL leukaemia cells. 
Alternatively, it has been demonstrated that the KLF5 protein directly interacts with RARD to 
synergistically influence transcription of down-stream target genes in VSMCs
157,264,266. Thus, 
reactivation of KLF5 may improve ATRA-induced differentiation of leukaemic blasts in non-
APL subtypes. 
KLF5 expression can be activated by a number of signalling pathways depending on cell type 
including the MEK/ERK, p38 MAPK and STAT3 pathways (see Section 1.3.7.2). 
Interestingly, a study performed by Bialkowska, et al. identified 6 small molecule activators 
of KLF5 transcription
294. These included PMA, a known inducer of leukaemia cell 
differentiation, and interestingly Piceatannol, an inhibitor of the non-receptor tyrosine kinases 
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294. Hahn and colleagues recently identified SYK as an important modulator of 
myeloid cell proliferation, and demonstrated that it was highly expressed and constitutively 
activated in the majority of AML samples assessed
536. Inhibition of SYK by siRNA or the 
application of SYK inhibitors decreased proliferation and cell viability and induced 
differentiation in a range of myeloid leukaemia cell lines and also in primary AML blasts. 
Chemical inhibition of SYK also reduced tumourigenicity in a xenograft model of human 
AML. The SYK inhibitors R406 and R788 are currently being utilised in Phase I clinical trials 
for rheumatoid arthritis, lymphoma, and Chronic Lymphocytic Leukaemia (CLL)
537,538. It will 
be interesting to evaluate the efficacy of these inhibitors in AML clinical trials, and to 
determine whether activation of KLF5 downstream of these chemicals plays a role in their 
differentiation-inducing effect on AML cells. 
6.3 Summary and concluding remarks 
In summary, we have demonstrated that the transcription factor KLF5 acts as a novel inducer 
of myeloid differentiation. KLF5 mRNA expression is reduced in primary human AML, 
consistent with tumour suppressor function in the myeloid lineage. Methylation of KLF5
partly contributes to this repression, however it is likely that alternative mechanisms also 
contribute to aberrant regulation in AML. Finally, we demonstrated that expression of KLF5 
may be of potential benefit in treatment of this disease. The findings presented in this thesis 
contribute to a more complete understanding of the transcriptional control of normal 
haemopoiesis, and how this may be deregulated to facilitate the development of AML. Future 
work including the use of tissue-specific targeted Klf5 ablation in murine models will further 
elucidate the role of KLF5 in normal haemopoiesis, and the role that it plays in specification 
of granulocyte versus monocyte lineage determination. It will be of interest to determine if 
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ablation of Klf5 in these models contributes to AML development, either as a single genetic 
aberration or in cooperation with known Class I mutations such as the FLT3-ITD activated 
receptor. Our studies evaluating KLF5 expression and methylation in primary human AML 
suggest that further investigation into how KLF5 may be deregulated in the pathogenesis of 
AML is warranted. It will be necessary to expand cohort size to determine any correlation of 
these factors with outcome. Determining the regulation and functional significance of 
alternative KLF5 isoforms will be of particular interest in the future given the importance of 
alternative isoforms of other genes in normal haemopoiesis and in AML. Evaluation of KLF5 
expression in clinical trials of epigenetic agents and chemical activators of KLF5 expression 
(e.g. SYK inhibitors) will provide insights into the role of KLF5 as a tumour suppressor in 
AML. Ultimately, a comprehensive knowledge of the function of KLF5 in AML may aid in 
the development of more efficient targeted therapies for this disease. Appendices
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Correlation of methylation in KLF5 DMR-1, DMR-2a and DMR2b. Average percentage methylation of 
1. DMR-2a plotted relative to DMR-1 (n=27), 2. DMR-2b plotted relative to DMR-1 (n=27), and 3. DMR-2b 
plotted relative to DMR-2a (n=29) in AML samples described in Chapter 5, Section 5.2.2.2. The blue line 





Appendices – Page 222Correlation of relative KLF5 mRNA expression with methylation of KLF5 DMR-1, DMR-2a 
and DMR-2b using linear regression and Fisher’s exact test. Statistics for the correlation of 
relative KLF5 mRNA expression (Q-PCR) with methylation of DMR-1, DMR-2a or DMR-2b using 
linear regression analysis and Fisher’s exact test. Multiple linear regression analysis was also 
performed to determine the combined influence of methylation at DMR-1 and both regions of DMR-
2 on relative KLF5 mRNA expression. For Fisher’s exact test, the high methylation groups consist of 
samples classified as aberrantly methylated in Chapter 5, Figures 5.9, 5.11 and 5.13 for DMR-1, 
DMR-2a and DMR-2b respectively. Note that AML7 was excluded as an outlier (see Chapter 5, 
Figure 5.1). Samples were defined as having high KLF5 expression if the relative expression was 
>1.5.
R value R2 value P value P value
DMR-1 -0.255 0.065 0.230 0.629
DMR-2a +0.161 0.026 0.432 0.293
DMR-2b -0.135 0.018 0.502 0.077
Multiple 0.291 0.085 0.632 N/A
Linear regression Fisher
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Features of KLF5 DMR-2a. 1. Homology of DNA region containing KLF5  CpG 141-143 (DMR-2a) 
amongst selected vertebrate species (UCSC Genome Browser). Histogram shows relative conservation 
amongst 44 vertebrate species. Highly homologous sequences between species are given positive scores, 
indicating that they have evolved more slowly than would have been predicted. Divergent sequences are 
given a negative score, as they have evolved more quickly. For a detailed explanation of the homology 
scoring system see UCSC Genome Browser, Vertebrate Multiz Alignment and Conservation feature. 
Alignment for 11 vertebrate species is shown below the histogram. Human CpG residues 141-143 are boxed 
in blue. Note that a horizontal dash shows nucleotides missing in this alignment, and a vertical dash shows 
the position of extra nucleotides in this alignment. 2. Predicted transcription factor binding sites (human) for 
the DNA sequence containing CpG residues 141-143 (boxed in blue). Transcription factor binding sites were 
predicted using the Technical University of Catalonia ALGGEN-PROMO web-based program440,441.
2. Predicted transcription factor binding sites in DMR-2a
1. DNA homology of region containing CpG residues 141-143 (DMR-2a)
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